

# International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors

FLORENCE NOBLE, STEPHEN A. WANK, JACQUELINE N. CRAWLEY, JACQUES BRADWEJN, KIM B. SEROOGY,  
MICHEL HAMON, AND BERNARD P. ROQUES<sup>1</sup>

*Institut National de la Santé et de la Recherche Médicale U266, Centre National de la Recherche Scientifique UMR 8600, Université René Descartes, Paris, France (B.P.R., F.N.); Royal Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada (J.B.); Section on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, Bethesda, Maryland (J.N.C.); National Institutes of Health, Digestive Diseases Branch, Bethesda, Maryland (S.A.W.); Department of Anatomy and Neurobiology, Chandler Medical Center, University of Kentucky, Lexington, Kentucky (K.B.S.); and Institut National de la Santé et de la Recherche Médicale U288, Faculté de Médecine Pitié-Salpêtrière, Paris, France (M.H.)*

This paper is available online at <http://www.pharmrev.org>

I. Introduction . . . . .	746
II. Characterization of cholecystokinin (CCK) receptors . . . . .	747
A. CCK <sub>1</sub> (CCK-A) receptors . . . . .	747
1. CCK <sub>1</sub> receptor clones . . . . .	747
2. Antagonists of CCK <sub>1</sub> receptors . . . . .	747
3. Agonists of CCK <sub>1</sub> receptors . . . . .	751
B. CCK <sub>2</sub> (CCK-B) receptors . . . . .	752
1. CCK <sub>2</sub> receptor clones . . . . .	752
2. Gastrin receptors are CCK <sub>2</sub> receptors . . . . .	752
3. Antagonists of CCK <sub>2</sub> receptors . . . . .	752
4. Agonists of CCK <sub>2</sub> receptors . . . . .	755
III. Molecular biology of CCK receptors . . . . .	756
A. CCK receptor gene structure . . . . .	756
B. Chromosomal localization of CCK receptor genes . . . . .	758
C. Animal models without detectable levels of CCK receptors . . . . .	758
IV. Receptor structure/function studies . . . . .	758
A. Signal transduction . . . . .	758
1. CCK <sub>1</sub> receptors . . . . .	759
2. CCK <sub>2</sub> receptors . . . . .	760
B. Ligand-receptor interaction . . . . .	760
1. Agonists . . . . .	760
2. Antagonists . . . . .	760
C. Receptor regulation . . . . .	761
V. Radioligands and Binding Assays: Heterogeneity of CCK <sub>1</sub> and CCK <sub>2</sub> Receptors . . . . .	761
A. Radioligands at CCK <sub>1</sub> receptors . . . . .	761
B. Radioligands at CCK <sub>2</sub> receptors . . . . .	761
C. Heterogeneity of CCK <sub>2</sub> receptor-binding sites . . . . .	762
VI. Distribution of CCK receptors . . . . .	762
A. Distribution in central nervous system . . . . .	762
1. CCK <sub>1</sub> receptors . . . . .	763
2. CCK <sub>2</sub> receptors . . . . .	764
3. Regulation of CCK receptors . . . . .	765
B. Distribution in gastrointestinal and other systems . . . . .	765
VII. Physiological implications of CCK receptors . . . . .	766
A. Peripheral functions . . . . .	766
B. Central functions . . . . .	766

<sup>1</sup> Address for correspondence: Prof. Bernard P. Roques, INSERM U266, Centre National de la Recherche Scientifique UMR 8600, Université René Descartes, 4, Avenue de l'Observatoire, 75270 Paris Cedex 06, France. E-mail: [roques@pharmacie.univ-paris5.fr](mailto:roques@pharmacie.univ-paris5.fr)

1. CCK in panic attacks and anxiety .....	767
2. CCK and schizophrenia .....	769
3. CCK and depression .....	770
4. CCK and memory processes .....	770
5. Interactions between CCK and enkephalin systems .....	772
a. In the control of pain .....	772
b. In behavioral responses .....	772
VIII. Conclusion .....	774
IX. Acknowledgments .....	774
X. References .....	774

## I. Introduction

The peptide cholecystokinin (CCK)<sup>2</sup> was originally discovered in the gastrointestinal tract (Ivy and Oldberg, 1928) and has been shown to mediate pancreatic secretion and contraction of gallbladder. Then, CCK was described in the mammalian central nervous system (CNS) as a gastrin-like immunoreactive material (Vanderhaeghen et al., 1975), and it is now generally believed to be the most widespread and abundant neuropeptide in the CNS. This peptide, initially characterized as a 33-amino-acid sequence, is present in a variety of biologically active molecular forms derived from a 115-amino-acid precursor molecule (prepro-CCK; Deschenes et al., 1984), such as CCK-58, CCK-39, CCK-33, CCK-22, sulfated CCK-8 [Asp-Tyr(SO<sub>3</sub>H)-Met-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub>] and CCK-7, unsulfated CCK-8 and CCK-7, CCK-5, and CCK-4 (Trp-Met-Asp-Phe-NH<sub>2</sub>; Fig. 1; Rehfeld and Nielsen, 1995). The presence of CCK in both gut and brain raises the intriguing issue of the evolutionary significance of separate pools of a peptide in two systems originating from different embryonic zones (i.e., endoderm and ectoderm, respectively).

Receptors for CCK have been pharmacologically classified on the basis of their affinity for the endogenous peptide agonists CCK and gastrin, which share the same COOH-terminal pentapeptide amide sequence but differ in sulfation at the sixth (gastrin) or seventh (CCK) tyrosyl residue. Two types of CCK receptors (type A, "alimentary", and type B, "brain") have thus been distinguished. The CCK-A receptor was first characterized using pancreatic acinar cells (Sankaran et al., 1980), whereas the CCK-B receptor, with a different pharmacological profile, was discovered in the brain (CCK-B; Innis and Snyder, 1980b). The gastrin receptor mediating acid secretion in the stomach was initially thought to constitute a third type of high-affinity receptor on the basis of its location and small differences in affinity for

<sup>2</sup> Abbreviations: CCK, cholecystokinin; IUPHAR, International Union of Pharmacology; CNS, central nervous system; PKC, protein kinase C; Hpa, 4-hydroxyphenylacetyl; DRG, dorsal root ganglia; PLC, phospholipase C; IP<sub>3</sub>, inositol triphosphate; GPCR, G protein-coupled receptor; PLA<sub>2</sub>, phospholipase A<sub>2</sub>; MAPK, mitogen-activated protein kinase; BH, Bolton-Hunter; TM, transmembrane domain; ECL, extracellular loop; SOS, the product of son of sevenless.

## Preprocholecystokinin




FIG. 1. Predicted structure of human preprocholecystokinin. The signal peptide consists of residues -20 to -1. The amino terminal flanking peptide consists of residues 1 to 25. The largest characterized form from brain and intestine, CCK-58, consists of residues 26 to 83. Other active molecular forms are derived from this precursor, such as CCK-39, CCK-33, CCK-22, CCK-7, and CCK-5.

CCK and gastrin-like peptides (Song et al., 1993). However, subsequent cloning of gastrin and CCK-B receptors revealed their molecular identity (see later). CCK-A and CCK-B receptor types have been shown to differ by their relative affinity for the natural ligands, their differential distribution, and their molecular structure. The CCK-A receptor binds sulfated CCK with a 500- to 1000-fold higher affinity than sulfated gastrin or nonsulfated CCK

(Silvente-Poirot et al., 1993a). The CCK-B/gastrin receptor binds gastrin and CCK with almost the same affinity and discriminates poorly between the sulfated and non-sulfated CCK analogs (Saito et al., 1980). The distribution of CCK-A and CCK-B/gastrin receptors is tissue dependent (see below).

Based on pharmacological and biochemical studies, the existence of subtypes of CCK-A and CCK-B receptors has been postulated. Nevertheless, only two genes have been cloned. The initial nomenclature of the receptors as CCK-A and CCK-B receptors is generally accepted by pharmacologists and molecular biologists. Based on the guidelines defined by the International Union of Pharmacology (IUPHAR) Committee on Receptor Nomenclature and Drug Classification, receptors should be named after their endogenous ligands and identified by a numerical subscript corresponding to the chronological order of the formal demonstration of their existence by cloning and sequencing (Vanhoutte et al., 1996). Because the CCK-A receptor was the first to be cloned, it should be renamed CCK<sub>1</sub>, and the CCK-B receptor should become CCK<sub>2</sub>. According to these guidelines, new splice variants, if pharmacologically relevant, should be indicated by subscript lowercase letters, in parentheses, such as CCK<sub>1(a)</sub>, CCK<sub>1(b)</sub>, CCK<sub>2(a)</sub>, and CCK<sub>2(b)</sub> receptors. This new nomenclature would allow any newly discovered CCK receptor to be logically named according to the same informative guidelines (see Vanhoutte et al., 1996).

This rational nomenclature has been adopted in the present review, which is devoted to the two CCK receptors whose existence has been firmly established through cloning.

## II. Characterization of Cholecystokinin (CCK) Receptors

### A. CCK<sub>1</sub> (CCK-A) Receptors

1. *CCK<sub>1</sub> Receptor Clones.* The size of the CCK<sub>1</sub> receptor demonstrated by ligand affinity crosslinking studies varied depending on the ligand, the crosslinking reagent, the species, and the tissue expressing the CCK receptor (Svoboda et al., 1982; Rosenzweig et al., 1983; Miller, 1984; Fourmy et al., 1987; Pearson and Miller, 1987; Pearson et al., 1987a,b; Shaw et al., 1987; Schjoldager et al., 1988; Powers et al., 1991). In rat pancreatic acinar cells, the CCK<sub>1</sub> receptor was found to be an 85- to 95-kDa, *N*-linked glycoprotein with a 42- to 44-kDa protein core.

The CCK<sub>1</sub> receptor was purified to homogeneity from rat pancreas. The purified receptor had a molecular mass of 85 to 95 kDa consistent with previous crosslinking studies (Wank et al., 1992a). Microsequencing of five peptide products derived from either enzymatic digestion or chemical cleavage of the protein receptor allowed the design of degenerate oligonucleotide primers for cloning the cDNA of the CCK<sub>1</sub> receptor from a rat pancreatic cDNA library. The deduced sequence of the rat

CCK<sub>1</sub> receptor corresponds to a 429-amino-acid protein with a calculated molecular mass of 48 kDa. Hydrophathy analysis predicts seven transmembrane-spanning domains (TM) as expected for a member of the G protein-coupled receptor (GPCR) superfamily (Dohlman et al., 1991; Fig. 2). The sequence contains at least three consensus sites for *N*-linked glycosylation (Asn-X-Ser/Thr), consistent with the heavy and variable degree of glycosylation reported using ligand-affinity crosslinking techniques (de Weerth et al., 1993b). The CCK<sub>1</sub> receptor has three consensus sequence sites for protein kinase C (PKC) phosphorylation in the third intracellular loop (Graff et al., 1989), consistent with previous data showing that CCK-8- and 12-*O*-tetradecanoylphorbol-13-acetate-stimulated phosphorylation of serine and threonine residues involves predominantly the third intracellular loop and to a minor extent the cytoplasmic tail of the rat pancreatic CCK<sub>1</sub> receptor (Kawano et al., 1992; Ozcelebi and Miller, 1995). In addition, there are conserved cysteines in the first and second extracellular loops (ECLs) of both CCK<sub>1</sub> and CCK<sub>2</sub> receptors (Figs. 2 and 3), which may form a disulfide bridge required for stabilization of their tertiary structure (Silvente-Poirot et al., 1998), and another cysteine in the C terminus may serve as a membrane-anchoring palmitoylation site (O'Dowd et al., 1988; Ovchinnikov et al., 1988).

The CCK<sub>1</sub> receptor cDNA has subsequently been cloned from guinea pig gallbladder, pancreas, and gastric chief cell (de Weerth et al., 1993b), human gallbladder (de Weerth et al., 1993a; Ulrich et al., 1993), and rabbit gastric (Reuben et al., 1994) cDNA libraries using either low-stringency hybridization or polymerase chain reaction methods. The CCK<sub>1</sub> receptor is highly conserved among these species with an overall amino acid homology of 80% and a pairwise amino acid sequence identity of 87 to 92% in humans, guinea pig, rat, and rabbit (Table 1).

2. *Antagonists of CCK<sub>1</sub> Receptors.* Several structurally different CCK<sub>1</sub> receptor antagonists have been synthesized. They belong to various series of chemicals, including dipeptoid, benzodiazepine, pyrazolidinone, and amino acid derivatives, and have both excellent selectivity and high affinity for CCK<sub>1</sub> receptors.

The first CCK antagonists were derived from a naturally occurring benzodiazepine, asperlicin (Table 2), which has been isolated from the fungus *Aspergillus alliaceus* (Chang et al., 1985). The demonstrated high *in vitro* and *in vivo* potency of asperlicin at CCK<sub>1</sub> receptors conferred clear advantages over previously reported CCK antagonists as a tool for investigation of the physiological and pharmacological actions of CCK. The first analogs of asperlicin were designed to assess which structural features of asperlicin could be modified to further enhance its CCK inhibitory potency without compromising its CCK<sub>1</sub> selectivity. Unfortunately, this approach failed to overcome the key defects of asperlicin (Bock et al., 1986). Interestingly, asperlicin contains




FIG. 2. Schematic representation of the rat CCK<sub>1</sub> receptor showing the postulated transmembrane topology, sites for putative NH<sub>2</sub>-linked glycosylation (tridents), serine and threonine phosphorylation by PKC and protein kinase A (PO<sub>3</sub>), and conserved cysteines in the first and second ECLs, possibly forming a disulfide bridge, and a possible palmitoylated conserved cysteine in the cytoplasmic tail. NH<sub>2</sub>—, N terminus; COOH—, C terminus.

elements of the 1,4-benzodiazepine ring system found in antianxiety agents such as diazepam. On the other hand, several studies support the concept that the natural ligand for the antianxiety benzodiazepine receptor is a peptide (Guidotti et al., 1983; Alho et al., 1985), suggesting that the 5-phenyl-1,4-benzodiazepine ring is in fact a chemical structure that recognizes a peptide receptor. This explains why the 5-phenyl-1,4-benzodiazepine ring was proposed as the basis for the design of improved CCK receptor antagonists (Evans et al., 1986). Indeed, the 3-amino-5-phenyl-1,4-benzodiazepin-2-one derivatives, typified by L-364,718 (MK-329, devazepide; Tables 2 and 3), remained for several years the most potent CCK antagonists described with a good selectivity for CCK<sub>1</sub> receptors (IC<sub>50</sub> CCK<sub>2</sub>/CCK<sub>1</sub> = 3750).

Various tricyclic 1,4-benzodiazepine derivatives were also developed. On the basis of structure-activity relationship studies, as well as the stability and availability of the starting materials of those compounds, (*S*)-*N*-[1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxo-pyrrolo[3,2,1-*jk*][1,4]benzodiazepin-3-yl]-1*H*-indole-2-carboxamide (FK-480; Satoh et al., 1994; Tables 2 and 3) was selected as a candidate for further evaluation. The results obtained showed that FK-480 is a highly selective and potent CCK<sub>1</sub>

receptor antagonist (Akiyama and Otsuki, 1994; Ito et al., 1994a).

Several other potent and selective antagonists of the CCK<sub>1</sub> receptor have been described, including glutamic acid derivatives such as loxiglumide (CR-1505) or lorglumide (CR-1409; Makovec et al., 1985; Table 2), and partial sequences of the C-terminal region of CCK. The dipeptide, *N*-*tert*-butyloxycarbonyl-aspartyl-phenylalaninamide (Boc-Asp-Phe-NH<sub>2</sub>), representing the two-amino-acid C-terminal fragment common to both CCK and gastrin, is a low-affinity partial agonist at CCK<sub>2</sub> receptors but has no activity at CCK<sub>1</sub> receptors. This selectivity is abolished by removal of the C-terminal amide. Replacement of the *N*-*tert*-butyloxycarbonyl group in this dipeptide with an analog, the 2-naphthalene sulfonyl group, gave 2-naphthalenesulfonyl 1-aspartyl-(2-phenethyl)amide (2-NAP; Tables 2 and 3), which behaves as a competitive antagonist at CCK<sub>1</sub> receptors. Interestingly, this compound has a 300-fold greater affinity for CCK<sub>1</sub> than CCK<sub>2</sub> receptors (Hull et al., 1993).

On the other hand, further development of "dipeptides", initially characterized as CCK<sub>2</sub> receptor antagonists (see below), led to a molecule that has a 100-fold selectivity for the CCK<sub>1</sub> receptor, where it acts as a




FIG. 3. Schematic representation of the rat CCK<sub>2</sub> receptor showing the postulated transmembrane topology, sites for putative NH<sub>2</sub>-linked glycosylation (tridents), serine and threonine phosphorylation by PKC and protein kinase A (PO<sub>3</sub>), and conserved cysteines in the first and second ECLs, possibly forming a disulfide bridge, and a possible palmitoylated conserved cysteine in the cytoplasmic tail. NH<sub>2</sub>—, N terminus; COOH—, C terminus.

TABLE 1  
SwissProt accession numbers for the cloned receptors from various species

Receptor	Species	Accession No.
CCK <sub>1</sub>	Human	P32238
	Rat	P30551
CCK <sub>2</sub>	Guinea pig	Q63931
	Human	P32239
	Mouse	P56481
	Rat	P30553
	Bovine	P79266
	Dog	P30552
	Rabbit	P46627


potent competitive antagonist (PD-140,548; Boden et al., 1993).

Several years ago, synthetic peptides with CCK<sub>1</sub> receptor antagonist properties were described (Lignon et al., 1987). One of these compounds, designated JMV-179 [Tyr(SO<sub>3</sub>H)-Ahx-Gly-D-Trp-Ahx-Asp-phenylethylester], corresponds to the C-terminal heptapeptide of CCK in which the phenylalanine and the L-tryptophan residues were substituted by a phenylethyl ester and a D-tryptophan, respectively. In addition, to protect the peptide against oxidation, the two methionines were replaced by a 6-aminoheptanoic acid (Ahx) residue. The pharmacological

results obtained demonstrated that JMV-179 is a full CCK<sub>1</sub> receptor antagonist. In contrast, JMV-180 [Boc-Tyr(SO<sub>3</sub>H)-Nle-Gly-Trp-Nle-Asp-phenylethylester] appeared to be an agonist of the stimulatory phase of the amylase release by pancreatic acini (low concentration range) and an antagonist of the inhibitory phase (high concentrations; Galas et al., 1988).

A new serine derivative, (*R*)-1-[3-(3-carboxypyridine-2-yl)-thio-2-(indol-2-yl)carbonylamino]propionyl-4-diphenylmethylpiperazine (TP-680) has been recently developed (Akiyama et al., 1996; Tables 2 and 3). This compound showed approximately 2 and 22 times greater selectivity for CCK<sub>1</sub> receptors relative to CCK<sub>2</sub> receptors than L-364,718 and loxiglumide, respectively. Pharmacological data showed that TP-680 is a selective and irreversible antagonist of CCK<sub>1</sub> receptors (Akiyama et al., 1996).

Other CCK<sub>1</sub> receptor antagonists have been developed, such as T-0632 (Tables 2 and 3), which is a novel nonpeptide and water-soluble compound that inhibits the specific binding of <sup>125</sup>I-CCK-8 to rat CCK<sub>1</sub> receptor in a concentration-dependent and competitive manner. The *K*<sub>i</sub> value of T-0632 for the CCK<sub>1</sub> receptor, 0.24 nM, is 23,000-fold less than its *K*<sub>i</sub> value (5,600 nM) for the CCK<sub>2</sub> receptor (Taniguchi et al., 1996).

TABLE 2  
 CCK<sub>1</sub> receptor antagonists


Devazepide (L-364,718), (3*S*)-(-)-*N*-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1*H*-1,4-benzodiazepine-3-yl)-1*H*-indole-2-carboxamide; lorglumide, (±)-4-[(3,4-dichlorobenzoyl)amino]-5-(di-*n*-pentylamino)-5-oxopentanoic acid; loxiglumide, (±)-4-[(3,4-dichlorobenzoyl)amino]-5-(*N*-(3-methoxypropyl)-*N*-pentylamino)-5-oxopentanoic acid; SR 27897, 1-[[2-(4-chlorophenyl)thiazol-2-yl]aminocarbonyl]indolyl]acetic acid; IQM-95,333, (4*αS*,5*R*)-2-benzyl-5[[*N*-(*tert*-butoxycarbonyl)-*L*-tryptophyl]amino]-1,3-dioxoper-hydropyridin-2-yl]pyrimidine; FK-480, (*S*)-*N*-[1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxo-pyrrolo[3,2,1-*jk*][1,4]benzodiazepin-3-yl]-1*H*-indole-2-carboxamide; 2-NAP, 2-naphthalenesulfonyl-*L*-aspartyl-(2-phenethyl)amide; T-0632, sodium (*S*)-3-[1-(2-fluorophenyl)-2,3-dihydro-3-[[3-isoquinolyl-carbonyl]amino]-6-methoxy-2-oxo-1*H*-indole]propanoate; TP-680, (*R*)-1-[3-[(3-carboxypyridin-2-yl)thio]-2-[(indol-2-ylcarbonyl)amino]propionyl]-4-(diphenylmethyl)piperazine; PD-140,548, *N*-(*α*-methyl-*N*-[(tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-yl)oxy]carbonyl]-*L*-tryptophyl)-*D*-3-(phenylmethyl)-*β*-alanine.

Interest in nonpeptide CCK receptor-selective ligands has directed efforts toward the incorporation of conformationally restricted structures as spacers between Trp and Phe residues in the sequence of the CCK<sub>2</sub> receptor endogenous ligand CCK-4 (Trp-Met-Asp-Phe-NH<sub>2</sub>). Thus, recently, a new series of CCK-4 restricted analogs with a 3-oxoindolizidine ring were synthesized. The most remarkable results were obtained with IQM-95,333 (Tables 2 and 3), which displays a CCK<sub>1</sub>

receptor affinity ( $K_i = 0.62$  nM) similar to that of L-364,718, but with a much higher selectivity ( $K_i$  CCK<sub>2</sub>/ $K_i$  CCK<sub>1</sub> > 8000; Martin-Martinez et al., 1997).

Another CCK<sub>1</sub> receptor antagonist, SR-27,897 (Tables 2 and 3), which is chemically unrelated to peptoids, benzodiazepines, or glutamic acid derivatives, has been developed. This compound was obtained by optimization of a lead compound discovered through the random screening of a large chemical library. SR-27,897 is a

TABLE 3  
Affinities of CCK<sub>1</sub> receptor antagonists in brain and pancreas membranes

Antagonist	K <sub>i</sub>		Selectivity CCK <sub>2</sub> /CCK <sub>1</sub>	Reference
	CCK <sub>1</sub>	CCK <sub>2</sub>		
	nM			
L-364,718	0.1	375	3,750	Evans et al. (1986)
SR-27897	0.2	160	800	Gully et al. (1993)
IQM-93,333	0.6	>5,000	>8,000	Martin-Martinez et al. (1997)
PD-140,548	2.8 <sup>a</sup>	260 <sup>a</sup>	93	Boden et al. (1993)
FK-480	0.4 <sup>a</sup>	72 <sup>a</sup>	180	Ito et al. (1994a)
2-NAP	250	70,000	300	Hull et al. (1993)
T-0632	0.24	5,600	23,000	Taniguchi et al. (1996)
TP-680	1.2	1,812	1,510	Akiyama et al. (1996)

<sup>a</sup> IC<sub>50</sub> value.


highly potent (K<sub>i</sub> = 0.2 nM) and selective (CCK<sub>2</sub>/CCK<sub>1</sub> IC<sub>50</sub> = 800) antagonist of CCK<sub>1</sub> receptors (Gully et al., 1993).

3. *Agonists of CCK<sub>1</sub> Receptors.* Only a few compounds have been reported to be CCK<sub>1</sub>-selective agonists; most of them are tetrapeptides, hexapeptides, and benzodiazepine derivatives.


Two series of CCK analogs have been developed. One series, exemplified by A-71378 [des-NH<sub>2</sub>-Tyr(SO<sub>3</sub>H)-Nle-Gly-Trp-Nle-(NMe)Asp-Phe-NH<sub>2</sub>], contains an (NMe)Asp

TABLE 4  
CCK<sub>1</sub> receptor agonists

des-NH <sub>2</sub> -Tyr(SO <sub>3</sub> H)-Nle-Gly-Trp-Nle-(NMe)Asp-Phe-NH <sub>2</sub>	A-71378
Boc-Trp-Lys( <i>o</i> -tolylaminocarbonyl)-Asp-MePhe-NH <sub>2</sub>	A-71623
Boc-Trp-Lys( <i>p</i> -hydroxycinnamoyl)-Asp-(NMe)Phe-NH <sub>2</sub>	A-70874
4-hydroxyphenylacetyl(SO <sub>3</sub> H)-Nle-Gly-Trp-Nle-(Me)Asp-Phe-NH <sub>2</sub>	ARL-15849



GW-5823



GW-7854

GW-5823, 2-[3-(1*H*-indazol-3-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydrobenzo[*b*][1,4]diazepin-1-yl]-*N*-isopropyl-*N*-(4-methoxyphenyl) acetamide; GW-7854, 3-[3-[1-[(isopropylphenylcarbamoyl)methyl]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1*H*-benzo[*b*][1,4]diazepin-3-yl]ureido] benzoic acid.

residue that is critical for CCK<sub>1</sub> receptor selectivity (Holladay et al., 1992). The other series derived by replacement of the methionine residue of Boc-CCK-4 (Boc-Trp-Met-Asp-Phe-NH<sub>2</sub>) with side chain-substituted Lys derivatives: Boc-Trp-Lys(X)-Asp-(NMe)Phe-NH<sub>2</sub>, such as A-71623 (X = *o*-toluylaminocarbonyl [Tac]) and A-70874 (X = *p*-hydroxycinnamoyl [Hyc]; Lin et al., 1991; Tables 4 and 5). Exploration of this tetrapeptide series continued through the examination of the effects of *N*-methylation at the Asp residue. The results obtained showed that analogs containing either (NMe)Asp or (NMe)Asp-(NMe)Phe are highly potent (IC<sub>50</sub> values in the nanomolar range) and selective CCK<sub>1</sub> receptor agonists (Holladay et al., 1992).

The sulfate ester of CCK-8 borne by the tyrosine residue is a critical determinant of the biological activity of this peptide. To increase the stability of this molecule, the sulfated tyrosine has been replaced by a synthetic amino acid (LD)-Phe(*p*-CH<sub>2</sub>SO<sub>3</sub>Na) in which the OSO<sub>3</sub>H group was replaced by the nonhydrolyzable CH<sub>2</sub>SO<sub>3</sub>H group. The biological activity of the new derivative (LD)-Phe(*p*-CH<sub>2</sub>SO<sub>3</sub>Na)-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> displays high affinity for CCK<sub>1</sub> and CCK<sub>2</sub> receptors (nanomolar range; Marseigne et al., 1989).

In the hexapeptide series, it has also been reported that replacement of Asp-Tyr(SO<sub>3</sub>H) of CCK-8 with Hpa(SO<sub>3</sub>H) (Hpa is 4-hydroxyphenylacetyl) and *N*-methylation of Phe do not diminish the affinity for CCK<sub>1</sub> or CCK<sub>2</sub> receptors (Pierson et al., 1997). Inversion of the chirality of Asp7 in conjunction with *N*-methylation of Phe8 produces a compound [Hpa(SO<sub>3</sub>H)-Met-Gly-Trp-Met-D-Asp-MePhe-NH<sub>2</sub>] that exhibits high affinity and 2100-fold selectivity for CCK<sub>1</sub> receptors. Moreover, moving the *N*-methyl group from Phe to Asp decreased the affinity for CCK<sub>2</sub> receptors without affecting that for CCK<sub>1</sub> receptors, giving a compound Hpa(SO<sub>3</sub>H)-Nle-Gly-Trp-Nle-MeAsp-Phe-NH<sub>2</sub> (ARL-15849; Tables 4 and 5) with a 6600-fold higher selectivity for the latter receptors (Pierson et al., 1997).

Recently, a series of 1,5-benzodiazepines acting as CCK<sub>1</sub> receptor agonists in vitro and in vivo were discovered. Potency within this series was modulated by substituents on the *N*1-anilinoacetamide moiety (Aquino et al., 1996), with substitution and/or replacement of the C3-position phenylurea moiety (GW5823, GW7854; Hirst et al., 1996; Willson et al., 1996; Henke et al., 1997; Tables 4 and 5).

TABLE 5  
Affinities of CCK<sub>1</sub> receptor agonists in brain and pancreas membranes

Agonist	K <sub>i</sub>		Selectivity CCK <sub>2</sub> /CCK <sub>1</sub>	Reference
	CCK <sub>1</sub>	CCK <sub>2</sub>		
	nM			
A-71378	0.5 <sup>a</sup>	570 <sup>a</sup>	1140	Holladay et al. (1992)
A-71623	3.7 <sup>a</sup>	4500 <sup>a</sup>	1200	Lin et al. (1991)
A-70874	4.2 <sup>a</sup>	710 <sup>a</sup>	170	Lin et al. (1991)
ARL-15849	0.03	224	6590	Pierson et al. (1997)
GW-5823	22.9 <sup>a</sup>	1000 <sup>a</sup>	50	Henke et al. (1997)

<sup>a</sup> IC<sub>50</sub> value.

## B. CCK<sub>2</sub> (CCK-B) Receptors

1. *CCK<sub>2</sub> Receptor Clones.* Affinity crosslinking studies of the CCK<sub>2</sub> receptor using <sup>125</sup>I-[Leu or NLeu<sup>15</sup>]-gastrin-2-17, disuccinimidyl suberate and either a 60 to 70% pure canine gastric parietal cell preparation or a solubilized porcine gastric mucosal extract identified two glycoproteins of 78 and 74 kDa, respectively (Svoboda et al., 1982; Baldwin et al., 1986; Chiba et al., 1988; Baldwin, 1993).

Using low-stringency hybridization methods, the CCK<sub>2</sub> receptor cDNA was cloned from a rat pancreatic acinar carcinoma cell line (AR4-2J) cDNA library known to express CCK<sub>2</sub>/gastrin receptors. This cDNA was shown to be identical with the CCK<sub>2</sub> receptor cDNA cloned from a rat brain cDNA library (Wank et al., 1992b). At the same time, the gastrin receptor cDNA was also cloned from a canine parietal cell cDNA library using a COS cell plasmid expression approach (Kopin et al., 1992). The rat and canine CCK<sub>2</sub> receptors are 452 and 453 amino acids long, respectively, and share an 84% amino acid identity. This degree of homology is consistent with interspecies variations of the same receptor and has been considered as an early indication that the gastrin receptor is simply the CCK<sub>2</sub> expressed in the stomach (see below). Similar to the CCK<sub>1</sub> receptor, hydropathy analysis predicts seven TM domains as expected of a member of the GPCR superfamily (Dohman et al., 1991). The sequence contains at least three consensus sites for N-linked glycosylation (Asn-X-Ser/Thr), consistent with the heavy and variable degree of glycosylation reported using ligand affinity crosslinking techniques (Baldwin et al., 1986; Chiba et al., 1988; Baldwin, 1993). Similar to the CCK<sub>1</sub> receptor, there are conserved cysteines in the first and second ECLs that may form a disulfide bridge required for stabilization of the tertiary structure (Silvente-Poirot et al., 1998), and a cysteine in the C terminus of the receptor may serve as a membrane-anchoring palmitoylation site (O'Dowd et al., 1988; Ovchinnikov et al., 1988; Fig. 3).

To date, the CCK<sub>2</sub> receptor has been cloned through low-stringency hybridization of cDNA libraries from various sources: rat brain and stomach, the pancreatic tumoral cell line AR4-2J (Wank et al., 1992b), human brain (Pisegna et al., 1992; Ito et al., 1993; Lee et al., 1993; Denyer et al., 1994) and stomach (Pisegna et al., 1992), and guinea pig gallbladder and stomach (de Werth et al., 1993b). In addition, CCK<sub>2</sub> receptor cloning has been achieved from gastric enterochromaffin and parietal cells and brain of *Mastomys natalensis* (Nakata et al., 1992), calf pancreas (Dufresne et al., 1996), and a rabbit genomic library (Blandizzi et al., 1994; Table 1). The CCK<sub>2</sub> receptor is highly conserved in humans, canine, guinea pig, calf, rabbit, *M. natalensis*, and rat, with an overall amino acid identity of 72% and pairwise amino acid sequence identities of 84 to 93%.

2. *Gastrin Receptors Are CCK<sub>2</sub> Receptors.* Gastrin receptors in the stomach and CCK<sub>2</sub> receptors in the brain were historically viewed as distinct types of CCK receptors on the basis of their different relative affinities for CCK and gastrin-like peptides (Menozzi et al., 1989). However, the canine parietal cell gastrin receptor expressed in COS cells exhibits the same relative affinities for CCK-8 and gastrin as those of native human and guinea pig CCK<sub>2</sub> receptors. The canine parietal gastrin receptor was also considered to be a distinct receptor because of a reversal in affinity for L-364,718 versus L-365,260 in comparison with CCK<sub>2</sub> receptors in the brain of other species (Lotti and Chang, 1989). The basis for this reversal has subsequently been ascribed to a species-specific change of a single nucleotide resulting in a single amino acid substitution (Leu355 in canine receptor versus Val319 in the human receptor) in TMVI (Beinborn et al., 1993). Similar to the human, guinea pig, and rat CCK<sub>2</sub> receptors (Pisegna et al., 1992; Wank et al., 1992b), cloning of the CCK<sub>2</sub> receptor from canine brain (Wank, 1995) resulted in a single cDNA identical to that for the canine parietal cell gastrin receptor (Kopin et al., 1992). Clearly, the identification of a single CCK<sub>2</sub> receptor-encoding gene through low- and high-stringency hybridization of cDNA and genomic libraries and Northern and Southern blot analyses in numerous species indicates that gastrin receptors do correspond to CCK<sub>2</sub> receptors located in the gastrointestinal tract and do not constitute a third type of CCK receptor (Wank, 1995).

3. *Antagonists of CCK<sub>2</sub> Receptors.* Many attempts have been made to develop potent and specific nonpeptide antagonists of CCK<sub>2</sub>/gastrin receptor. As a result, several new chemical entities appeared, exhibiting high selectivity for specific populations of CCK<sub>2</sub>/gastrin receptors. The various compounds under development belong to the following main chemical classes: amino acid, benzodiazepine, dipeptoid, pyrazolidinone, and ureidoacetamides derivatives (for a review, see Makovec and D'Amato, 1997).

Efforts were notably devoted to the design of an optimized asperlicin structure. Because the asperlicin structure is composed of several heterocyclic domains, it was hypothesized that alternative substructures embedded within the molecular framework of this natural product may provide a rational starting point for the design of novel nonpeptide CCK receptor ligands. On this basis, scientists at Eli Lilly Corp. developed a series of quinoxaline derivatives by using a bond disconnection approach (Yu et al., 1991). A combination of the key fragments of the Lilly and Merck series led to the development of novel nonpeptide CCK<sub>2</sub> receptor antagonists with substitution on the quinoxalinone and phenyl rings. Binding data for this class of compounds suggest that the linker between these rings is a critical determinant for CCK<sub>2</sub> receptor-binding affinity. However, these new compounds have a low selectivity for




CCK<sub>2</sub> receptor (Padia et al., 1997). Indeed, the spatial arrangement of the two moieties appears to be critical for both potency and selectivity. The introduction of —NH— as a linker significantly enhanced CCK<sub>2</sub> receptor-binding affinity and selectivity, providing compounds with nanomolar binding affinity and good selectivity ( $K_i$  CCK<sub>1</sub>/ $K_i$  CCK<sub>2</sub> > 500). Moreover, these

compounds are active when administered per os (Padia et al., 1998).

On the other hand, the moderate affinity of L-364,718 for CCK<sub>2</sub> receptors suggested that the benzodiazepine nucleus might also hold a key to selective ligands for these receptors. The first compound of interest developed using this strategy was L-365,260 (Tables 6 and 7),

TABLE 6  
CCK<sub>2</sub> receptor antagonists



L-365,260, (3*R*)(+)-*N*-(2,3-dihydro-1-methyl-2-oxo-phenyl-1*H*-1,4-benzodiazepin-3-yl)-*N'*-(3-methylphenyl)urea; YM-022, (*R*)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea; LY-288,513, (4*S*,5*R*)-*N*-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidine carboxamide; RP-73870, ([[*N*-(methoxy-3-phenyl)-*N'*-(*N*-methyl-*N*-phenyl-carbamoylmethyl)-carbamoylmethyl]-3-ureido-3-phenyl]-2-ethyl-sulfonate-(*RS*); PD-134,308, 4-[[2-[[3-(1*H*-indol-3-yl)-2-methyl-1-oxo-2-[[tricyclo-[3.3.1.1<sup>3,7</sup>]-dec-2-yloxy]-carbonyl]amino]propyl]amino]-1-phenyl-ethyl]amino]-4-oxo-[*R*\*,*R*\*]butanoic acid; RB 210, *N*-[*N*-[(2-adamantyl)oxy]carbonyl]-DL- $\alpha$ -methyltryptophanyl]-*N'*-(2-phenylethyl)glycine; compound 19 (Augelli-Szafran et al., 1996), 3-[2-(adamantan-2-yloxy)carbonylamino]-3-(1*H*-indol-3-yl)-2-methylpropionyl-amino]-4-(4-fluorophenyl)butyric acid; CP-212,454, *N*-*tert*-butyl-2-[3-(3-(3-chlorophenyl)ureido)-2-oxo-5-phenyl-8-methyl-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl]ethanoic acid amide; L-740,093, *N*-[(3*R*)-5-(3-azabicyclo[3.2.2]nonan-3-yl)-2,3-dihydro-1-methyl-2-oxo-1*H*-1,4-benzodiazepin-3-yl]-*N'*-(3-methylphenyl)urea; YF-476, (3*R*)-*N*-(1-(*tert*-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1*H*-1,4-benzodiazepin-3-yl)-*N'*-(3-methylamino)phenyl)urea; CI-1015, tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-yl[1*S*-[1 $\alpha$ (*S*\*)2 $\beta$ ]-[2-(2-hydroxycyclohexyl)amino]-1-(1*H*-indol-3-yl)methyl]-1-methyl-2-oxoethyl]carbamate.

TABLE 7  
Affinities of CCK<sub>2</sub> receptor antagonists in brain and pancreas membranes

Antagonist	K <sub>i</sub>		Selectivity CCK <sub>1</sub> /CCK <sub>2</sub>	Reference
	CCK <sub>1</sub>	CCK <sub>2</sub>		
	nM			
L-365,260	800	7	115	Lotti and Chang (1989)
PD-134,308	1,440	0.9	1,600	Horwell et al. (1991)
LY-288,513	11,600	31	370	Howbert et al. (1992)
RP-73,870	1,634	0.5	3,300	Pendley et al. (1995)
YM-022	150	0.1	1,500	Nishida et al. (1994)
RB-210	1,518	14	110	Blommaert et al. (1993)
CP-212,454	180	0.5	360	Lowe et al. (1995)
L-740,093	1,600	0.1	16,000	Patel et al. (1994)
YF-476	113 <sup>a</sup>	0.2 <sup>a</sup>	565	Semple et al. (1997)
CI-1015	2,900	3	967	Trivedi et al. (1998)

<sup>a</sup> IC<sub>50</sub> value.

which revealed to be the first potent and selective non-peptide CCK<sub>2</sub> receptor antagonist (Bock et al., 1989). One factor that determined CCK receptor selectivity in this series was the C3-stereochemistry of the benzodiazepine ring system, with the (3*R*)-enantiomer generally providing CCK<sub>2</sub> receptor selectivity. Moreover, recent studies have shown that the C5-phenyl moiety of the core benzodiazepine structure could be replaced by C5-cycloalkyl groups, a modification that retained CCK<sub>2</sub> receptor affinity and selectivity. In particular, the C5-cyclohexyl analog displayed subnanomolar affinity for CCK<sub>2</sub> receptors (IC<sub>50</sub> = 0.28 nM), with improved selectivity ( $K_i$  CCK<sub>1</sub>/ $K_i$  CCK<sub>2</sub> = 6500) compared with L-365,260 (Chambers et al., 1993).

A major drawback associated with these early benzodiazepine-derived CCK<sub>2</sub> antagonists was their limited bioavailability and inactivity via the oral route of administration. The incorporation of a (*tert*-butylcarbonyl) methyl group at the 1-position (Semple et al., 1996a) or a 2-pyridyl group at the 5-position (Semple et al., 1996b) of the parent benzodiazepine structure provides a significant increase in absorption. Similar results have been achieved through the incorporation of an amine-based cationic solubilizing group within the benzodiazepine framework, with a cyclic amine to form an amidino functionality in the 5-position (L-740,093; Showell et al., 1994; Tables 6 and 7). Other attempts to improve aqueous solubility included the introduction of acidic groups (L-368,935 and L-369,466; Bock et al., 1994) or lipophilic surrogates (Chambers et al., 1995) into the 3-position of the aryl urea component of either the 1,4-benzodiazepin-2-one parent system or closely related structures (CP-212,454; Lowe et al., 1995; Tables 6 and 7). The opposite strategy has also been used with the introduction of basic amino substituents into the same region. YM022 is the optimal structure of this new series, with subnanomolar affinity for CCK<sub>2</sub> receptors (Nishida et al., 1994). Moreover, when these modifications are combined within the same molecule, the resulting improvements in the *in vivo* effects appear to be essentially additive, as shown by the compound YF476 (Tables 6 and 7), which

has a good oral bioavailability in dogs (Semple et al., 1997).

Other nonpeptide CCK<sub>2</sub> receptor antagonists have been developed, derived through rational design from the CCK tetrapeptide (Hughes et al., 1990). This led to tryptophan dipeptoid derivatives such as PD-134,308 (CI-988; Tables 6 and 7) with nanomolar affinity for CCK<sub>2</sub> receptors (Horwell, 1991; Horwell et al., 1991). PD-134,308 exhibits a 1600-fold selectivity for CCK<sub>2</sub> over CCK<sub>1</sub> receptors. C-terminal modifications of this compound led to molecules with subnanomolar affinity for CCK<sub>2</sub> receptors. For example, further attempts to optimize the substitution on the phenyl ring led to a compound 19, which has an extraordinarily high affinity for the CCK<sub>2</sub> receptor (IC<sub>50</sub> = 0.08 nM) and a high degree of selectivity ( $K_i$  CCK<sub>1</sub>/ $K_i$  CCK<sub>2</sub> = 940; Augelli-Szafran et al., 1996). A direct comparison of the structure of the dipeptoid derivatives showed that the size of these molecules could be reduced to increase their lipophilicity. Such compounds have been synthesized, and some of them have been found to be potent and selective CCK<sub>2</sub> receptor antagonists. Moreover, as expected, one of them (RB 211) was shown to be more efficient in crossing the blood-brain barrier than the parent compounds (Blommaert et al., 1993) and devoid of the weak CCK<sub>1</sub> receptor agonist properties of dipeptoids (Höcker et al., 1993; Ding et al., 1995). On the other hand, to improve the properties of PD-134,308, numerous conformational restrictions were introduced in its structure. Unfortunately, neither N-terminal cyclization (Fincham et al., 1992b), macrocyclization (Didier et al., 1992; Bolton et al., 1993), nor rigidification of the amide bond (Fincham et al., 1992a) led to any positive result. Only a C-terminal cyclization of PD-134,308 derivatives, by means of a tetrahydronaphthyl group, has been reported to increase the affinity for CCK<sub>2</sub> receptors (Higginbottom et al., 1993). This approach has also been used for compounds such as RB 210 (Tables 6 and 7), in which C-terminal constraints can be easily introduced. Thus, the  $\beta$ -carbon of the phenethyl side chain of RB 210 was linked to the  $\alpha$ -carbon bearing the carbonyl function, by means of a methylene bridge. This resulted in the formation of a proline ring (Bellier et al., 1997). The most potent compounds of this new series had similar affinities for CCK<sub>2</sub> receptors as RB 210. Structure-affinity relationships of this series indicated that lengthening of the distance between the amide nitrogen atom and the phenyl ring was of little importance, whereas the position of the carboxylate group could not be modified. Therefore, the pyrrolidine ring was replaced by piperidine to slightly modify the possible orientation of the aromatic moiety toward the carboxylate without violating any of the requirements previously established in both linear and constrained series for the recognition of CCK<sub>2</sub> receptors. However, the resulting compounds behave as moderately potent CCK<sub>2</sub> receptor antagonists (Bellier et al., 1998).

As previously mentioned, the clinical development of PD-134,308 (CI-988) was limited due to its poor bioavailability, which was attributed to poor absorption and efficient hepatic extraction. Scientists at Parke-Davis also envisaged that reducing the molecular weight of the parent compound would lead to better absorption. Thus, they synthesized a series of analogs in which the key  $\alpha$ -methyltryptophan and adamantyloxycarbonyl moieties, required for receptor binding, were kept intact and the C terminus was extensively modified. These modifications led to compounds such as CI-1015 (Tables 6 and 7) for which the oral bioavailability in rat was improved nearly 10-fold and the blood-brain barrier permeability was also enhanced relative to CI-988 (Trivedi et al., 1998).

Two other series have been described, leading to the synthesis of derivatives that have both excellent selectivity and high affinity for CCK<sub>2</sub> receptors: the ureidoacetamide class of CCK<sub>2</sub> receptor antagonists (RP-73,870; Pendley et al., 1995) and the pyrazolidinones (LY-288,513; Howbert et al., 1992; Tables 6 and 7). Development of the latter series has been discontinued because of adverse effects in preclinical toxicological studies. The nonpeptide ureidoacetamides are potent and selective ligands with nanomolar or subnanomolar affinities for CCK<sub>2</sub> receptors and a 100- to 1000-fold selectivity for these receptors over CCK<sub>1</sub> receptors. Despite its relatively poor oral bioavailability, RP-73,870 was as potent as other antiulcer compounds after oral administration in a duodenal ulceration model (Pendley et al., 1995).

**4. Agonists of CCK<sub>2</sub> Receptors.** Different strategies have been followed to design potent and selective agonists of CCK<sub>2</sub> receptors. One of these was to protect CCK-8 [Asp-Tyr(SO<sub>3</sub>H)-Met-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub>] from degrading enzymes such as aminopeptidase A (Migaud et al., 1996) and a thiol/serine protease cleaving this peptide at the Met-Gly bond (Camus et al., 1989; Rose et al., 1996). The biologically active Boc[Nle<sup>28,31</sup>]CCK27-33 (BDNL; Ruiz-Gayo et al., 1985) was used as the parent compound to design enzyme-resistant analogs. In this compound, the major sites of cleavage are at the Trp30/Nle31 and Nle28/Gly29 bonds. BDNL is potentially resistant to aminopeptidase cleavage due to its *tert*-butyloxycarbonyl N-terminal-protecting group (Ruiz-Gayo et al., 1985; Durieux et al., 1986a).

Thus, several enzyme-resistant BDNL analogs containing either a retro-inversion of the Nle28-Gly amide bond, an (NMe)Nle31 residue, or a combination of these two modifications have been synthesized (Charpentier et al., 1988a). This led to BC 264 (Tables 8 and 9), a highly potent CCK<sub>2</sub> receptor agonist that exhibits about the same affinity ( $K_i = 0.1$ – $0.5$  nM) in all species (guinea pig, rat, mouse, monkey, humans) and was at that time the only systemically active CCK<sub>2</sub> receptor agonist (Charpentier et al., 1988a; Durieux et al., 1991). The peptidase-resistant bioactive analog [<sup>3</sup>H]pBC264 was also developed (Durieux et al., 1989) by replacing the Boc group with a tritiated propionyl residue. The radioactivity present in the mouse brain 15 min after i.v. injection of the tritiated compound represented 1.6/10,000 of the total radioactivity injected. Moreover, as shown by HPLC, [<sup>3</sup>H]pBC264 was very resistant to metabolism, because more than 85% of the radioactivity present in the brain corresponded to the intact molecule (Ruiz-Gayo et al., 1990). On the other hand, despite its intrinsic flexibility, CCK-8 was found through NMR to exist preferentially under a folded form in aqueous solution (Fournié-Zaluski et al., 1986) with a proximity between Asp1 and Gly4. This property was used to synthesize cyclic peptides through amide bond formation between Asp1 or between  $\alpha$ - or  $\beta$ -carboxyl group of Glu1 and Lys4 side chains, such as BC 254 and BC 197 (Tables 8 and 9), which were found highly potent and selective CCK<sub>2</sub> receptor agonists (Charpentier et al., 1988b, 1989). Another nonsulfated CCK-8 analog, [N-methyl-Nle<sup>28,31</sup>]CCK26-33 (SNF-8702; Tables 8 and 9), has also been described, which has about 4000-fold greater affinity for CCK<sub>2</sub> than for CCK<sub>1</sub> receptors (Knapp et al., 1990).

The role of the amino acid in position 31 of CCK-8 in the recognition of CCK<sub>1</sub> and CCK<sub>2</sub> receptors was investigated through the replacement of Met31 by amino acids with side chains of varying chemical nature. Thus, the introduction of a Phe residue in position 31 in Boc[Nle<sup>28,31</sup>]CCK27-33 slightly modified the affinity for CCK<sub>2</sub> receptor ( $K_i = 3.7$  nM) but led to a larger decrease ( $K_i = 220$  nM) in the affinity for CCK<sub>1</sub> receptors. A similar discrimination was observed when the amino acid in position 31 is an alanine residue (Marseigne et al., 1988).

TABLE 8  
CCK<sub>2</sub> receptor agonists

Boc-D-Asp-Tyr(SO <sub>3</sub> H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH <sub>2</sub>	BC 197
Boc-Tyr(SO <sub>3</sub> H)-gNle-mGly-Trp-NMe(Nle)-Asp-Phe-NH <sub>2</sub>	BC 264
HOOC-CH <sub>2</sub> -CO-Trp-NMe(Nle)-Asp-Phe-NH <sub>2</sub>	RB 400
Asp-Tyr(SO <sub>3</sub> H)-(NMe)Nle-Gly-Trp-(NMe)Nle-Asp-Phe-NH <sub>2</sub>	SNF-8702
Boc- $\gamma$ D-Glu-Tyr(SO <sub>3</sub> H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH <sub>2</sub>	BC 254

TABLE 9  
Affinities of CCK<sub>2</sub> receptor agonists in brain and pancreas membranes

Agonist	K <sub>i</sub>		Selectivity CCK <sub>1</sub> /CCK <sub>2</sub>	Reference
	CCK <sub>1</sub>	CCK <sub>2</sub>		
	<i>nM</i>			
BC 197	2900	150	20	Charpentier et al. (1989)
BC 264	78	0.1	780	Charpentier et al. (1988b)
RB 400	>3000	0.42	>7000	Million et al. (1997)
SNF-8702	3800	0.9	4000	Knapp et al. (1990)
BC 254	2500	0.56	4500	Charpentier et al. (1989)

Because nonpeptide ligands have historically offered greater opportunity for manipulation of both pharmacodynamic (selectivity and efficacy) and pharmacokinetic (oral bioavailability, duration) parameters, the development of nonpeptidic CCK<sub>2</sub> receptor selective agonists endowed with good stability and bioavailability should provide useful pharmacological tools and possibly therapeutic agents. To design such derivatives, the C-terminal tetrapeptide CCK-4 appeared to be a good molecule to start with, because of its significant CCK<sub>2</sub> receptor affinity and selectivity, although it has been shown to trigger panic attacks in humans (de Montigny, 1989; Bradwejn et al., 1991b). Several modifications were made to CCK-4, such as the N-terminal protection of the tetrapeptide in Boc-CCK<sub>4</sub> (Harhammer et al., 1991) or modifications of the different amino acids such as the replacement of Met by Nle or (NMe)Nle (Corringer et al., 1993). Recent NMR and molecular dynamics studies indicated that the CCK<sub>2</sub> receptor-selective CCK-4 analogs adopt an S-shaped conformation with a relatively well-defined orientation of the side chains (Goudreau et al., 1994). The same type of folded structures has been reported for several potent agonists derived from CCK-4 and containing a [*trans*-3-propyl-L-proline] (Nadzan et al., 1991), a diketopiperazine skeleton (Shiosaki et al., 1990), or a [(alkylthio)proline] residue (Kolodziej et al., 1995). With this template, other cyclic CCK-4 analogs have been synthesized in which the Trp-Met dipeptide was changed to a diketopiperazine moiety resulting from a cyclization between Nle and *N*-substituted (D)Trp residues and coupled with a small linker to Asp-Phe-NH<sub>2</sub> (Weng et al., 1996a). Moreover, the side chain of Nle in the compound Boc-Trp-(NMe)Nle-Asp-Phe-NH<sub>2</sub> together with the N terminus of Trp appeared to be good candidates for another possible cyclization. Thus, cyclic compounds were designed through molecular modeling to mimic the proposed biologically active conformation of these CCK-4 analogs. The goal of this study was to stabilize the bioactive conformation of CCK<sub>2</sub> receptor agonists to aid in the design of nonpeptide ligands. This led to the development of macrocyclic constrained CCK-4 analogs that are endowed with agonist properties and able to cross the blood-brain barrier (Blommaert et al., 1997).

Selective and peptidase-resistant CCK<sub>2</sub> receptor ligands that derive from Boc-[Nle<sup>31</sup>]CCK30-33 through

the incorporation of non-natural hydrophobic amino acids have also been developed (Weng et al., 1996b). Among these compounds, Boc-[Phg<sup>31</sup>,Nal<sup>33</sup>]CCK30-33 proved to be a full agonist at rat hippocampal CCK<sub>2</sub> receptors. Moreover, it appeared that modifications of the hydrophobic and steric character of either the C- or N-terminal amino acid substituents of CCK-4 derivatives could affect the agonist or antagonist profile of these peptides. This was shown by the fact that the agonist Boc-[Phg<sup>31</sup>,Nal<sup>33</sup>]CCK30-33 could be chemically converted to an antagonist through the addition of two alkyl groups on the terminal CONH<sub>2</sub> (Weng et al., 1996b).

Very recently, a new series of highly potent and selective CCK<sub>2</sub> receptor agonists were developed (Million et al., 1997). Boc-Trp-(NMe)Nle-Asp-Phe-NH<sub>2</sub>, the C-terminal tetrapeptide of BC 264, was shown to have a high affinity and to behave as a specific agonist at CCK<sub>2</sub> receptors and to adopt the S-shaped preferential conformation. To determine the essential structural components of specific CCK<sub>2</sub> receptor agonists, a step-by-step lengthening of the C-terminal tetrapeptide of BC 264 was carried out. Various diacidic moieties, such as malonate or succinate residues, were coupled to the N-terminal portion of the tetrapeptide, leading to RB 400 [HOOC-CH<sub>2</sub>-CO-Trp-(NMe)Nle-Asp-Phe-NH<sub>2</sub>] and RB 403 (Tables 8 and 9). RB 400 was also derivatized under its benzylamide and methyl ester forms. Compounds that belong to the RB 400 series possess high affinities for the CCK<sub>2</sub> receptor, with a subnanomolar affinity (K<sub>i</sub> = 0.42 nM) being obtained in case of RB 400 itself (Million et al., 1997).

### III. Molecular Biology of CCK Receptors

#### A. CCK Receptor Gene Structure

The genes encoding the CCK<sub>1</sub> receptor (Miller et al., 1995; Wank, 1995; Inoue et al., 1997) and the CCK<sub>2</sub> receptor (Song et al., 1993) in humans are organized in a similar manner consisting of five exons and four introns. The receptor genes have homologous exon/intron splice sites with exon 1 coding for the extracellular N-terminal sequence, exon 2 coding for the sequence from the beginning of TMI to the first part of TMIII, exon 3 coding for the sequence from TMIII to the beginning of TMV, exon 4 coding for the sequence from TMV to the first fourth of the third intracellular loop, and exon 5 coding for the remainder of the receptor (Fig. 4). The genes for the rat (Takata et al., 1995) and mouse (Lacourse et al., 1997) CCK<sub>1</sub> receptors and rabbit (Blandizzi et al., 1994) and mouse (Nagata et al., 1996) CCK<sub>2</sub> receptors are organized similarly to those for humans. This high degree of conservation of the sequence and organization between CCK<sub>1</sub> and CCK<sub>2</sub> receptor genes and the fact that the brain and pancreas of the bullfrog *Rana catesbeiana* and *Xenopus laevis* express only one CCK receptor (Vigna et al., 1984, 1986) suggest that the




FIG. 4. Schematic representation of genes encoding human CCK<sub>1</sub> and CCK<sub>2</sub> receptors. Shown are position and size of the exons (shaded boxes) and introns (lines) comprising the genes for the CCK<sub>1</sub> and the CCK<sub>2</sub> receptors; smaller arabic numbers represent size of each exon and intron in base pairs. Roman numerals refer to putative transmembrane-spanning regions encoded within each exon. ATG and TGA, putative start and stop codons, respectively. CCK<sub>2</sub> receptor gene: the second splice variant (short form) differs only in the size of exon 4, in which a sequence is absent compared with long form, corresponding to a block of five amino acids within the third intracellular loop. The third splice variant encodes an N-terminally truncated receptor. The gene structure is similar, except that there is an alternative first exon (exon 1b) that makes up the 5' untranslated region of this truncated receptor.

CCK<sub>1</sub> and CCK<sub>2</sub> receptor genes evolved sometime after amphibia from duplication of a common ancestral gene (as for the gene encoding the receptor ligands, CCK and gastrin). This concept is further supported by the cloning of a gene encoding a CCK receptor from a *X. laevis* brain cDNA library. This receptor is expressed in brain and stomach but is undetectable in pancreas. The deduced amino acid sequence from this gene has 55 and 56% amino acid identity with the human CCK<sub>1</sub> and CCK<sub>2</sub> receptors, respectively. This receptor expressed in COS-7 cells has a CCK<sub>1</sub> receptor type pharmacological profile (sulfated CCK > gastrin-17 > nonsulfated CCK-8 > CCK-4) like that of the native receptor in *X. laevis* brain and pancreas (Vigna et al., 1986; Schmitz et al., 1996) but with a relatively high affinity for sulfated gastrin, as expected for a CCK<sub>2</sub> receptor. Nevertheless, like typical CCK<sub>1</sub> receptors, the CCK receptor obtained from the *X. laevis* brain cDNA library has a higher affinity for L-364,718 than for L-365,260, and it is not recognized by CAM 1714 or CAM 1028 (Schmitz et al., 1996).

Alternative splicing of exon 4 of the human CCK<sub>2</sub> receptor gene results in two CCK<sub>2</sub> receptor transcripts that differ by a block of five amino acids within the third intracellular loop (Song et al., 1993; Fig. 4). The shorter transcript is largely predominant in stomach, although its relative distribution in individual cell types has not been examined. To date, the physiological relevance of the two isoforms of the human CCK<sub>2</sub> receptor is not known. A comparison of the shorter and longer isoforms revealed no significant differences in agonist affinity and signal transduction (Ito et al., 1993, 1994b; Wank et al., 1994b).

Another splice variant of the human CCK<sub>2</sub> receptor transcript, designated  $\Delta$ CCK<sub>2</sub> receptor, which differs at the 5' end from the CCK<sub>2</sub> receptor transcript described earlier, was discovered using a polymerase chain reaction-based cloning strategy (Miyake, 1995).  $\Delta$ CCK<sub>2</sub> receptor encodes an N-terminally truncated receptor that starts with the methionine Met67 in TMI and is otherwise identical in the remaining sequence. The gene structure is similar to that previously reported for the human CCK<sub>2</sub> receptor (Song et al., 1993) except that the first intron was of ~10 kb (compared with 1.177 kb) and contained the sequence for the alternative first exon that makes up the 5' untranslated region of  $\Delta$ CCK<sub>2</sub> receptor (Fig. 4). The first methionine of exon 2, which is common to both CCK<sub>2</sub> and  $\Delta$ CCK<sub>2</sub> receptors, serves as the translational initiation site for the  $\Delta$ CCK<sub>2</sub> receptor.  $\Delta$ CCK<sub>2</sub> receptor transiently expressed in COS-7 cells has a ~3-fold lower affinity for CCK-8 and a ~30-fold lower affinity for gastrin compared with the CCK<sub>2</sub> receptor, but its affinity for the antagonists L-365,260 and L-364,718 is unchanged. Both CCK<sub>2</sub> and  $\Delta$ CCK<sub>2</sub> receptor transcripts have been detected in brain, stomach, and pancreas through the use of reverse transcription-polymerase chain reaction (Miyake, 1995). According to the guidelines defined by the IUPHAR committee, because these splice variants do not appear to be major variants, they are not indicated by subscript lowercase letters.

On the other hand, Jagerschmidt et al. (1994) isolated several CCK<sub>2</sub> receptor mRNA isoforms from rat brain tissue, including a truncated mRNA species. Unspliced precursor mRNA and the mature form were identified in the cerebral cortex, hypothalamus, and hippocampus in

apparently differing proportions according to the region examined, suggesting that the expression of the CCK<sub>2</sub> receptor could be modulated at a post-transcriptional level. Thus, although five precursor mRNAs were found in the cerebral cortex and the hypothalamus, only one fully processed messenger was detected in the hippocampus. In the case of the cerebellum, only a completely unspliced mRNA form was found, which is in agreement with previous studies showing that CCK<sub>2</sub> receptor-binding sites are not expressed in this structure in the rat (Pélaprat et al., 1987).

### B. Chromosomal Localization of CCK Receptor Genes

The human CCK<sub>1</sub> receptor gene has been localized to chromosome 4 using a panel of human/hamster hybrid DNAs (Huppi et al., 1995). The mouse CCK<sub>1</sub> receptor gene has been mapped to a syntenic region on chromosome 5 using a wild × inbred backcross panel of mice [(BALB/cAN × Mus spretus) F<sub>1</sub> × BALB/cAN] (Huppi et al., 1995). This region of mouse chromosome 5 is syntenic with human chromosome 4p16.2-p15.1 (Huppi et al., 1995). The human CCK<sub>1</sub> receptor was further mapped to 4p15.1-p15.2 using fluorescence in situ hybridization and physically mapped between the markers AFMb355ya5 and AFMa283yh5 (Inoue et al., 1997). The rat CCK<sub>1</sub> receptor gene has been localized to a syntenic region on chromosome 14 by fluorescence in situ hybridization (Takiguchi et al., 1997).

The human CCK<sub>2</sub> receptor has been localized to chromosome 11 in humans and a syntenic region on chromosome 7 in the mouse using a panel of human/hamster hybrid DNAs (Huppi et al., 1995). Fluorescence in situ hybridization of human metaphase chromosomal spreads has further localized the human CCK<sub>2</sub> receptor gene to the distal short arm of chromosome 11 (11p15.4; Song et al., 1993; Zimonjic et al., 1994). The colocalization of the CCK<sub>1</sub> receptor gene with the dopamine D<sub>5</sub> receptor gene at 4p15.1-p15.3 (Sherrington et al., 1993) and of the CCK<sub>2</sub> receptor gene with the gene encoding the dopamine D<sub>4</sub> receptor at 11p15.4-p15.5 (Gelernter et al., 1992; Pisegna et al., 1992) is especially interesting in view of the coexistence of CCK and dopamine in mid-brain neurons and the regulation of mesolimbic dopaminergic pathways by both CCK<sub>1</sub> and CCK<sub>2</sub> receptors (Crawley and Corwin, 1994).

### C. Animal Models without Detectable Levels of CCK Receptors

An inbred strain of Long Evans rats, the Otsuka Long-Evans Tokushima Fatty rats, that is considered to be a model for late-onset non-insulin-dependent diabetes mellitus, was discovered to have no detectable levels of CCK<sub>1</sub> receptor gene expression. Subsequent cloning of their CCK<sub>1</sub> receptor gene revealed a deletion of 6847 bp encompassing the promoter region and first and second exons (Takiguchi et al., 1997). Although these rats are known to have polygenic abnormalities, the presence of

several metabolic and behavioral abnormalities has been attributed to the loss of CCK<sub>1</sub> receptor expression.

Targeted disruption of the CCK<sub>2</sub> receptor gene has been achieved in mice (Nagata et al., 1996). Homozygous mutant mice were viable and fertile and appeared to be grossly normal into adulthood (Langhans et al., 1997). CCK<sub>2</sub><sup>-/-</sup> mutant mice have much fewer gastric parietal and ECL cells than so wild-type animals, which is in line with the growth-promoting effects of gastrin at the CCK<sub>2</sub> receptor previously seen in patients with hypergastrinemia due to the Zollinger-Ellison syndrome. Also, as expected, these mice were hypochlorhydric and hypergastrinemic (Nagata et al., 1996). Together, these results demonstrate the importance of the CCK<sub>2</sub> receptor in maintaining the normal cellular composition and function of the gastric mucosa.

Moreover, the physiological implication of CCK<sub>2</sub> receptor can now be further investigated in CCK<sub>2</sub> receptor-deficient mice obtained through gene targeting. The first experiments reported with this interesting model show a critical role of CCK<sub>2</sub> receptors in memory process. CCK<sub>2</sub> receptor-deficient mice have an impairment of performance in the memory task (Sebret et al., 1999; for more details, see *VIIB4. CCK and Memory Processes*).

## IV. Receptor Structure/Function Studies

### A. Signal Transduction

1. *CCK<sub>1</sub> Receptors.* The modulation of CCK<sub>1</sub> receptor affinity by guanine nucleotides in early studies suggested that they belong to the GPCR superfamily. This has been confirmed through the cloning of CCK<sub>1</sub> receptors (Wank et al., 1992a), which revealed their seven-transmembrane receptor structure.

In the pancreas, CCK is well known to be a major regulatory peptide that stimulates digestive enzyme secretion. The mode of action of CCK has been extensively explored. CCK-stimulated enzyme secretion is believed to be initiated by the binding of CCK to CCK<sub>1</sub> receptors localized on pancreatic acinar cells. Furthermore, it has been shown that the breakdown of phosphatidylinositol 4,5-bisphosphate, which thereby produces both diacylglycerol and inositol trisphosphate (IP<sub>3</sub>), is activated by CCK<sub>1</sub> receptor stimulation. Subsequent activation of Ca<sup>2+</sup> phospholipid-dependent protein kinase by diacylglycerol and intracellular Ca<sup>2+</sup> mobilization induced by IP<sub>3</sub> have been considered to act synergistically to cause digestive enzyme secretion (Pandol et al., 1985). The insensitivity of CCK<sub>1</sub> receptor inositol phosphate signaling to pertussis toxin suggests that it couples through the G<sub>q</sub> family of G proteins (Pang and Sternweiss, 1990). Recently, a study using both phospholipase C (PLC) and G protein α-subunit-specific antibodies indicated that both G<sub>q</sub> and G<sub>11α</sub> are present in pancreas and that the CCK<sub>1</sub> receptor couples to G<sub>q</sub> or G<sub>11</sub> to activate PLC-β1 in pancreatic cell membranes (Piiper et al., 1997).

On the other hand, it has been demonstrated in rat pancreatic acini that the CCK<sub>1</sub> receptors are coupled to the phospholipase A<sub>2</sub> (PLA<sub>2</sub>)/arachidonic acid pathways to mediate Ca<sup>2+</sup> oscillations and amylase secretion (Yule et al., 1993; Yoshida et al., 1997). Nevertheless, other studies have shown that there are at least two pathways responsible for the increased production of arachidonic acid in response to CCK<sub>1</sub> receptor stimulation. One is the sequential effects of phospholipase C (PLC) and diglyceride lipase on phosphatidylinositol, and the other involves the action of the PLA<sub>2</sub> effect on phosphatidylcholine. Both pathways cause stimulation of amylase release (Pandol et al., 1991). In addition to the activation of the PLC and PLA<sub>2</sub> signal-transduction pathways, CCK<sub>1</sub> receptor stimulation can lead to an increase in the adenylyl cyclase signal-transduction cascade (Marino et al., 1993).

Thus, CCK<sub>1</sub> receptor is capable of coupling to both PLC and adenylyl cyclase at physiological concentrations in native cells. It is not clear whether this is a result of the independent coupling of CCK<sub>1</sub> receptor to G<sub>s</sub> and G<sub>q</sub> or simply the result of G protein βγ-subunit activation of an isotope of adenylyl cyclase. A study using a chimeric CCK receptor in which the first intracellular loops between CCK<sub>1</sub> and CCK<sub>2</sub> receptors were exchanged showed that Arg68 and Asn69 belonging to the loop of CCK<sub>1</sub> receptor are important for the stimulatory coupling of this receptor with adenylyl cyclase but are not involved in its coupling with G<sub>q</sub>. These results support the idea that the CCK<sub>1</sub> receptor is directly coupled with both G<sub>s</sub> and G<sub>q</sub> (Wu et al., 1997).

Recent studies (for reviews, see Müller and Lohse, 1995; Daaka et al., 1997) have shown that some GPCRs use the same effectors as those of the tyrosine kinase receptor pathway [e.g., Shc (adapter protein)/growth factor receptor-bound protein 2/product of son of sevenless (SOS)], resulting in Ras and mitogen-activated protein kinase (MAPK) activation and leading to expression of transcriptional factors, such as *c-myc*, *c-jun*, and *c-fos*. It was recently shown that MAPKs and c-Jun NH<sub>2</sub>-terminal kinases (JNKs, which phosphorylate serine residues of c-Jun) are rapidly activated by CCK-8 in rat pancreas both in vitro and in vivo (Dabrowski et al., 1996a,b; Tateishi et al., 1998). These results suggest that CCK might stimulate cell proliferation via its action at CCK<sub>1</sub> receptors. Moreover, the activation of both MAPKs and JNKs may be of importance in the early pathogenesis of acute pancreatitis (Dabrowski et al., 1996a). The mechanism by which the G<sub>q</sub> protein-coupled CCK receptor activates Ras is not well understood. Results obtained by Dabrowski et al. (1996b) suggest that formation of Shc/growth factor receptor-bound protein 2/SOS complex via a PKC-dependent mechanism may provide the link between G<sub>q</sub> protein-coupled CCK receptor stimulation and Ras activation.

A case report of a woman with gallstones and obesity was ascribed to abnormal processing of transcripts from

a normal CCK<sub>1</sub> receptor gene that resulted in the predominance of mRNA with a 262-bp deletion corresponding to the third exon. Although this mutation could negatively affect expression or coupling to G proteins, neither in vivo nor in vitro data were obtained in support of such inferences. Unfortunately, other affected family members were not examined and expected splicing abnormalities in transcripts from other genes were not studied, so only an association could be established between the common phenotype of gallstones and obesity and the putative RNA processing abnormality in the affected patient (Miller et al., 1995).

**2. CCK<sub>2</sub> Receptors.** Molecular cloning of CCK<sub>2</sub> receptors has shown that this receptor is a member of the seven-transmembrane domain GPCR superfamily (Wank et al., 1992b). This confirmed previous results showing that nonhydrolyzable GTP analogs reduced the binding of selective CCK<sub>2</sub> receptor agonists, as expected of the coupling of these receptors with G proteins (Knapp et al., 1990; Durieux et al., 1992).

In contrast to CCK<sub>1</sub> receptors, the signal-transduction cascade for CCK<sub>2</sub> receptors has been rather poorly characterized, in large part because of the difficulty of working with isolated neurons or isolated gastric mucosal cells expressing CCK<sub>2</sub> receptors. Thus, for a long time, central CCK<sub>2</sub> receptors have not been proved to be linked to a well characterized second-messenger system in the brain, including the phosphoinositide system, although phosphoinositide metabolism was shown to be affected by CCK in neuroblastoma (Barrett et al., 1989) and in the embryonic pituitary cell line (Lo and Hughes, 1988). More recently, Zhang et al. (1992) showed that CCK-8 increased the turnover of phosphoinositides and IP<sub>3</sub> labeling in dissociated neonatal rat brain cells, in which both CCK<sub>1</sub> and CCK<sub>2</sub> receptors were expressed. One study of CCK<sub>2</sub> receptors, using synaptoneurosome from guinea pig cortex, failed to provide support to their possible coupling with adenylyl cyclase or PLC, although Ca<sup>2+</sup> release from intracellular stores, possibly via a G protein-independent mechanism, could be triggered by a CCK analog (Galas et al., 1992).

Expression of receptor cDNAs in a mammalian expression system allows for a readily available source of receptor for functional studies. In transfected cells (Cos, Chinese hamster ovary), it has been shown that like the CCK<sub>1</sub> receptor, the CCK<sub>2</sub> receptor couples to a pertussis toxin-insensitive G protein (Roche et al., 1990) that is probably related to the G<sub>q/11</sub> family, thereby causing activation of PLC (Tsunoda et al., 1988a,b, 1989; Delvalle et al., 1992). The region of the CCK<sub>2</sub> receptor interacting with G<sub>q</sub> was determined in CCK<sub>2</sub> receptor with Lys333 Met, Lys334 Thr, and Arg335 Leu mutations transiently expressed in COS-7 cells and *X. laevis* oocytes. Indeed, these mutations resulted in the loss of G<sub>q</sub> activation without affecting receptor affinity (Wang, 1997).

Site-directed mutagenic replacement of Asp100 in the rat CCK<sub>2</sub> receptor, a highly conserved residue in TMII of most GPCRs, results in a 50% reduction in CCK-8-stimulated phosphoinositide turnover with no change in CCK-8 affinity and only a small (<6-fold) decrease in antagonist affinity (Jagerschmidt et al., 1995). These data led to the hypothesis that Asp100 points in the direction of the cluster of basic amino acids (Lys333/Lys334/Arg335), located in the third intracellular loop of the receptor at the bottom of the TMVI, that plays a critical role in CCK<sub>2</sub> receptor activation of G<sub>q</sub> proteins (Wang, 1997).

Another residue, Phe347, which belongs to the TMVI domain, was identified as essential for the signal transduction process. Thus, the exchange of Phe347 for alanine disrupts the phosphatidylinositol-signaling pathway without affecting the binding of CCK receptor agonists (Jagerschmidt et al., 1998). This amino acid could be a residue implicated in transduction processes through its possible role in agonist-induced changes in receptor conformation and subsequent triggering of G protein activation. Indeed, the exchange of Phe347 for Ala could produce a conformational change in the sequence containing the basic triplet, located just beneath TMVI.

On the other hand, by analogy with CCK<sub>1</sub> receptors, it has been shown that CCK<sub>2</sub> receptors are coupled to a phospholipase pathway leading to the release of arachidonic acid via a PTX-sensitive G protein (Pommier et al., 1999) and to an MAPK pathway (Taniguchi et al., 1994).

## B. Ligand-Receptor Interaction

**1. Agonists.** The examination of a 42-amino-acid N-terminal truncation of the human CCK<sub>1</sub> receptor and site-directed mutants in the region near the top of TMI suggested the interaction of amino acid residues Trp39 and Gln40 with CCK. Further binding data for the interaction between wild-type and Trp39Phe and Gln40Asn mutant CCK<sub>1</sub> receptors and a series of N-terminally modified CCK analogs that were applied to a model of the CCK<sub>1</sub> receptor (based on data from bacteriorhodopsin, rhodopsin, and the  $\beta$ -adrenergic receptors) suggested that the N-terminal moiety of CCK-8 interacts via hydrogen bonding with Trp39 and Gln40 (Kennedy et al., 1997). However, photoaffinity labeling with <sup>125</sup>I-desaminotyrosyl-Gly-[Nle<sup>28,31</sup>,pNO<sub>2</sub>-Phe<sup>33</sup>]CCK-(26-33) of rat CCK<sub>1</sub> receptors overexpressed in Chinese hamster ovary cells demonstrated just the opposite result: the placement of Trp39 proximate to the C-terminal pNO<sub>2</sub>-Phe33 residue of the probe (Ji et al., 1997). The interaction of CCK with the CCK<sub>1</sub> receptor was further modeled using separate single amino acid mutations, Lys105Val and Arg337Val, that resulted in a loss in CCK-8-stimulated calcium release. These data suggest that Lys105 and Arg337 in the CCK<sub>1</sub> receptor interact with Tyr(SO<sub>3</sub>H) and Asp of CCK-8, respectively (Tsunoda et al., 1997).

A study of 58 chimeric receptors in which one to four divergent amino acids in the TM of the human CCK<sub>2</sub> receptor were replaced with the corresponding amino acids from the CCK<sub>1</sub> receptor identified only a single residue, Ser131, at the top of TMIII that confers a ~6-fold subtype selectivity for gastrin versus CCK-8 (Kopin et al., 1995). Chimeric and site-directed mutagenesis studies of the rat CCK<sub>2</sub> receptor containing CCK<sub>1</sub> receptor segmental substitutions suggested that a block of five amino acids (residues 204–208, including Cys205, which putatively forms a disulfide bridge with Cys127 at the top of TMIII) is important for gastrin selectivity (Silvente-Poirot and Wank, 1996) and that His207 is also important for CCK-8 affinity (Silvente-Poirot et al., 1998). Studies of human chimeric CCK<sub>1</sub>/CCK<sub>2</sub> receptors made through exon shuffling of the respective receptor genes also demonstrated the importance of this area near the top of TMIII for conferring high gastrin affinity (Wu et al., 1997). Chimeric studies replacing the *X. laevis* CCK receptor with variable-length N-terminal segments of the human CCK<sub>2</sub> receptor revealed the need for multiple contact points in the N-terminal two-thirds (through TMV) of the CCK<sub>2</sub> receptor for conferring gastrin selectivity (Schmitz et al., 1996). Studies of Ala scanning mutagenesis in the N terminus near the top of TMI and the first ECL (ECL1) of the rat CCK<sub>2</sub> receptor identified one nonconserved (Arg57Ala) and four conserved amino acids (Asn115Ala, Leu116Ala, Phe120Ala, and Phe122Ala) that adversely affected CCK-8 affinity when mutated to Ala. Reciprocal mutations of these amino acids at equivalent positions in the rat CCK<sub>1</sub> receptor revealed only two mutations, Leu103Ala and Phe107Ala, that decreased CCK-8 affinity (Silvente-Poirot et al., 1998). These studies suggest that CCK peptide agonists interact with multiple amino acids in the extracellular domain of CCK receptors and that CCK<sub>1</sub> and CCK<sub>2</sub> receptors have distinct binding sites despite their shared high affinity for CCK-8. With the use of site-directed mutagenesis, the roles of three aromatic residues located in TMV (Phe227) and TMVI (Phe347 and Trp351) of the rat CCK<sub>2</sub> receptor were also evaluated in binding experiments. The results demonstrated that the highly conserved residues in GPCRs, Phe227 and Phe347, do not play an important role in the recognition of the agonists. In contrast, Trp351 appeared to be in the agonist-binding site of the receptor, where it probably interacts with the C-terminal sequence of CCK-8, as illustrated by the similar reduction in affinity for both CCK-8 and CCK-4 (Jagerschmidt et al., 1998).

**2. Antagonists.** Data from CCK receptor chimeric and site-directed mutagenesis studies suggest that the outer third of TMVI and TMVIII interacts with the benzodiazepine-based antagonists, L-364,718 and L-365,260. A survey of all TM amino acids of the human CCK<sub>2</sub> receptor in which one to four amino acids were replaced with the corresponding CCK<sub>1</sub> receptor amino acids identified two single-point mutations, Thr111Asn and His376Leu, that



cause a 23-fold decrease in L-365,260 affinity and a 63-fold increase in L-364,718 affinity, respectively (Kopin et al., 1995). The importance of the TMVII domain for antagonist affinity was confirmed by a rat CCK<sub>2</sub> receptor TMVII chimera with a 13-fold decrease in L-364,718 affinity (Mantamadiotis and Baldwin, 1994) that could be explained by the single-point mutation His381Leu (Jagerschmidt et al., 1996). The reversal of the relative affinity for L-364,718 and L-365,260 between canine gastrin receptor and both the rat and human CCK<sub>2</sub> receptors noted earlier has been explained by an interspecies variation of a single amino acid in TMVI (Leu355 in dog versus the corresponding Val349 in humans; Marino et al., 1993). The lack of effect of these TMVI and TMVII mutations on agonist affinity suggests that agonist- and antagonist-binding sites are, at best, only partially overlapping.

**C. Receptor Regulation.** GPCR function is significantly regulated by the mechanisms that determine receptor trafficking within the cell. The molecular and cellular mechanisms involved in regulation of translocation, sequestration, recycling, and degradation of GPCRs are not well understood, and the available data are largely controversial. Fusion of the C terminus of GPCR to the N terminus of the green fluorescent protein is a valuable tool in the study of receptor localization and trafficking. CCK<sub>1</sub>-green fluorescent protein allowed for the direct observation of spontaneous and ligand-induced internalization of the receptor (Tarasova et al., 1997).

CCK<sub>1</sub> receptor internalization is independent of the state of phosphorylation and the presence of the C-terminal tail (Rao et al., 1997; Go et al., 1998). In contrast, internalization of the CCK<sub>2</sub> receptor is at least in part dependent on the phosphorylation of Ser/Thr residues in its C terminus (Pohl et al., 1997). In the phosphorylation-deficient CCK<sub>1</sub> receptor mutant with PKC consensus site mutations Ser260Ala and Ser264Ala, desensitization of the CCK-stimulated inositol 1,4,5-triphosphate response is delayed until the occurrence of receptor internalization (Rao et al., 1997). Desensitization of CCK<sub>2</sub> receptor stably expressed in Chinese hamster ovary cells does not require the C terminus and is independent of internalization, unlike the CCK<sub>1</sub> receptor (Choi et al., 1998).

## V. Radioligands and Binding Assays: Heterogeneity of CCK<sub>1</sub> and CCK<sub>2</sub> Receptors

Initial studies describing the distribution and the binding characteristics of CCK<sub>1</sub> and CCK<sub>2</sub> receptors have used nonselective CCK receptor radioligands. Because CCK-8 is the physiological ligand of CCK receptors, it was first considered to be the most suitable probe for the characterization of CCK receptors in radioligand-binding studies. Preparation of stable, high-specific-activity radioiodinated CCK through conjugation to <sup>125</sup>I-Bolton Hunter reagent (<sup>125</sup>I-BH) has been described

using several CCK fragments, such as CCK-8 or CCK-33 (Sankaran et al., 1979; Lin and Miller, 1985). Specific binding sites for CCK have also been characterized using a <sup>125</sup>I-CCK-8 probe made resistant to degradation through reaction with the iodinated form of the imidoester, methyl-*p*-hydroxybenzimidate (Praisman et al., 1983). Characterization of CCK<sub>1</sub> and CCK<sub>2</sub> receptors was performed in the presence of selective nonradiolabeled ligands to saturate only one of the CCK receptors (Hill and Woodruff, 1990). Now, selective radioligands are available for the specific labeling of CCK<sub>1</sub> or CCK<sub>2</sub> receptors.

### A. Radioligands at CCK<sub>1</sub> Receptors

[<sup>3</sup>H]-( $\pm$ )-L-364,718 is a potent and selective CCK<sub>1</sub> receptor antagonist that binds saturably and reversibly to rat pancreatic membranes. The radioligand recognizes a single class of binding sites with a high affinity ( $K_d = 0.23$  nM), and the potency of various CCK receptor agonists and antagonists to inhibit its binding correlates with both their ability to inhibit <sup>125</sup>I-CCK-8-specific binding and the known pharmacological properties of these compounds in peripheral tissues (Chang et al., 1986). Nevertheless, in a more recent study, Talkad et al. (1994) showed that <sup>125</sup>I-CCK-8 binds to two different states of the CCK<sub>1</sub> receptor in rat pancreatic acini (a high-affinity state and a low-affinity state), whereas [<sup>3</sup>H]L-374,718 binds to a low-affinity state and to a previously unrecognized very low-affinity state. Similar measurements using transfected COS cells also identified three different states of the CCK<sub>1</sub> receptor, suggesting that this feature is an intrinsic property of the CCK<sub>1</sub> receptor molecule itself (Huang et al., 1994).

The peptide antagonist of the CCK<sub>1</sub> receptor JMV-179 was modified at its N terminus through the incorporation of *p*-hydroxyphenylpropionate (BH reagent) and was subsequently radioiodinated (Silvente-Poirot et al., 1993b). The results obtained with this first antagonist radioligand, <sup>125</sup>I-BH-JMV-179, demonstrated that CCK<sub>1</sub> receptors exist under two interconvertible affinity states regulated by G proteins in rat pancreatic plasma membranes.

### B. Radioligands at CCK<sub>2</sub> Receptors

Several peptide ligands have been used to characterize CCK<sub>2</sub>-binding sites, such as [<sup>3</sup>H]pentagastrin, [<sup>3</sup>H]gastrin or <sup>125</sup>I-gastrin, and [<sup>3</sup>H]CCK-4 (Gaudreau et al., 1985; Clark et al., 1986; Durieux et al., 1988).

The highly potent agonist [<sup>3</sup>H]pBC264 (Durieux et al., 1989) has a subnanomolar affinity for CCK<sub>2</sub> receptors ( $K_d = 0.15$ – $0.20$  nM) in brain membranes from mouse, cat, rat, guinea pig, and humans (Durieux et al., 1992). [<sup>3</sup>H]pBC264 binds to membranes in a time-dependent, reversible, and saturable manner. Moreover, even in the rat brain, a tissue with high levels of nonspecific binding and low density of CCK receptors (Williams et al., 1986), the specific binding of [<sup>3</sup>H]pBC264 reached 80% of total

binding at a radioligand concentration close to the  $K_d$  value (Durieux et al., 1992). In guinea pig and mouse brain, specific [ $^3\text{H}$ ]pBC264 binding was almost not affected by NaCl and/or guanyl-5'-yl-imidodiphosphate. In contrast, in rat brain, the affinity of [ $^3\text{H}$ ]pBC264 was decreased and the maximal number of binding sites was increased by NaCl and the guanyl nucleotide, suggesting that a proportion of CCK<sub>2</sub> receptors are constitutively coupled to G proteins (Durieux et al., 1992).

The high selectivity of [ $^3\text{H}$ ]SNF8702 also permits the characterization of CCK<sub>2</sub> receptors in brain tissues without interference from the population of CCK<sub>1</sub> receptors present (Knapp et al., 1990). The results obtained in guinea pig brain cortex demonstrated that [ $^3\text{H}$ ]SNF8702 binds to a larger population of CCK<sub>2</sub> sites than [ $^3\text{H}$ ]pBC264, which is not the case in mouse brain. These results could reflect the presence of several CCK-binding states with different sensitivities to ions and nucleotides. Thus, a part of the receptors labeled by [ $^3\text{H}$ ]pBC264 in guinea pig brain may be insensitive to these reagents, unlike the additional sites bound by [ $^3\text{H}$ ]SNF8702 (Knapp et al., 1990; Durieux et al., 1992).

Selective nonpeptide antagonist radioligands have been developed. [ $^3\text{H}$ ]L-365,260 binds saturably and reversibly to brain membranes, and Scatchard analysis indicated a single class of high-affinity ( $K_d = 2$  nM) binding sites (Chang et al., 1989). Recently, a new series of nonpeptide CCK<sub>2</sub> receptor antagonists has been described by Horwell et al. (1991). Some of these compounds have been radioiodinated ( $^{125}\text{I}$ -PD-142,308; Horwell et al., 1995) or tritiated ( $^3\text{H}$ ]PD-140,376; Hill et al., 1993). The latter radioligand has advantages over the alternative radioligand [ $^3\text{H}$ ]L-365,260 because it has a greater selectivity and affinity for the CCK<sub>2</sub> receptors and yields a higher ratio of specific to nonspecific binding in both cerebral cortex and gastric mucosa (Hunter et al., 1993). Interestingly, in addition to the high-affinity population of CCK<sub>2</sub> receptors, [ $^3\text{H}$ ]PD-140,376 labeled a low-affinity state.

### C. Heterogeneity of CCK<sub>2</sub> Receptor-Binding Sites

Binding studies using linear or cyclic CCK-8 analogs allowed the discovery of a heterogeneity of CCK<sub>2</sub>-binding sites in guinea pig brain (Durieux et al., 1986b; Knapp et al., 1990; Rodriguez et al., 1990). Thus, CCK<sub>2</sub> receptors have been shown to exist in three different affinity states (Huang et al., 1994). This heterogeneity has been confirmed in saturation and competition binding studies. Thus, the Hill coefficient was in general significantly lower than unity in different tissues (Hunter et al., 1993; Huang et al., 1994; Harper et al., 1996).

The existence of CCK<sub>2</sub> receptor heterogeneity has also been proposed from experiments performed in the presence of guanosine-5'-( $\beta,\gamma$ -imido)diphosphate or guanosine-5'-O-(3-thio)triphosphate. The results obtained clearly showed that these nonhydrolyzable GTP analogs reduced the binding of selective CCK<sub>2</sub> receptor

ligands (Wennogle et al., 1988). However, different sensitivities to guanyl nucleotides were observed depending on the structures of the ligands used (Knapp et al., 1990; Durieux et al., 1992; Lallement et al., 1995; Suman-Chauhan et al., 1996).

Several authors have described CCK<sub>2</sub> receptor agonists apparently capable of discriminating two (Durieux et al., 1986b; Derrien et al., 1994b; Million et al., 1997) or even three (Huang et al., 1994) different affinity states. More recently, similar results have been obtained with antagonists (Hunter et al., 1993; Harper et al., 1996; Bellier et al., 1997).

Several hypotheses could be proposed to explain this apparent heterogeneity of CCK<sub>2</sub> receptor-binding sites. It is possible that the coupling of CCK<sub>2</sub> receptors to different G proteins (see *IVA2. CCK<sub>2</sub> Receptors*) induces different receptor conformation with different affinities for the ligands (for a review, see Kenakin, 1995). Another explanation would be that depending on the molecular interaction of a ligand with its binding site, preferential or differential coupling with a G protein can occur (Spengler et al., 1993).

## VI. Distribution of CCK Receptors

### A. Distribution in Central Nervous System

Specific CCK-binding sites were demonstrated in membranes from brain homogenates almost two decades ago (Hays et al., 1980; Innis and Snyder, 1980a,b; Saito et al., 1980; Praissman et al., 1983). Since then, numerous studies using autoradiography and, more recently, in situ hybridization and immunocytochemistry have investigated the regional distribution and specific cellular localization of CCK receptors throughout the neuraxis. Early studies used radioligands such as  $^{125}\text{I}$ -CCK-33,  $^{125}\text{I}$ -CCK-8, [ $^3\text{H}$ ]pentagastrin, [ $^3\text{H}$ ]CCK-8, [ $^3\text{H}$ ]CCK-4 or [ $^3\text{H}$ ]Boc[Nle<sup>28,31</sup>]CCK27-33 (Gaudreau et al., 1983, 1985; Zarbin et al., 1983; Van Dijk et al., 1984; Dietl et al., 1987; Pélaprat et al., 1987; Durieux et al., 1988; Niehoff, 1989) that do not distinguish between the two CCK receptors. In general, these studies performed in several species (e.g., rat, guinea pig, monkey, humans) showed high densities of CCK-binding sites in several areas, including the cerebral cortex, striatum, olfactory bulb and tubercle, and certain amygdaloid nuclei. Moderate levels were observed in the hippocampus, claustrum, substantia nigra, superior colliculus, periaqueductal gray matter, and pontine nuclei. Low densities were reported in several thalamic and hypothalamic nuclei and in the spinal cord (Fig. 5).

Initial evidence for species differences in the distribution of CCK receptors was also provided by these studies. For example, in the cerebellum, high densities of CCK-binding sites were present in guinea pig, whereas only low levels were detected in rat (Zarbin et al., 1983; Gaudreau et al., 1985; Mantyh and Mantyh, 1985). CCK-binding sites have now been identified and visual-




FIG. 5. Autoradiograms showing the distribution of [ $^3\text{H}$ ]BDNL binding to  $\text{CCK}_1$  and  $\text{CCK}_2$  receptors in the rat forebrain and midbrain. Moderate to high densities of receptors are observed in the olfactory bulbs (A), the anterior olfactory nucleus (B), the neocortex, and especially in layer III of the medial frontal (B–C) and cingulate (E–I) cortices, the layer IV of frontal (B and C) and frontoparietal (D–J) cortices, the layers II–IV of retrosplenial cortex (L), the olfactory tubercle (E–I), the endopiriform nucleus (E–K), the nucleus accumbens (D–F), the striatum (D–I), and the hippocampus, where  $\text{CCK}$  receptors are more concentrated in the dentate gyrus and subiculum (K). [ $^3\text{H}$ ]BDNL, Boc-Tyr( $\text{SO}_3\text{H}$ )-[ $^3\text{H}$ ]Nle-Gly-Trp-[ $^3\text{H}$ ]Nle-Asp-Phe- $\text{NH}_2$ .

ized in the nervous system of numerous species ranging from goldfish to humans (e.g., Dietl et al., 1987; Kritzer et al., 1988, 1990; Hyde and Peroutka, 1989; Miceli and Steiner, 1989; Hill et al., 1990; Ghilardi et al., 1992; Moons et al., 1992; Schiffmann et al., 1992; Kuehl-Kovarik et al., 1993; Madtes and King, 1994; Morency et al., 1994; Himick et al., 1996; Mercer et al., 1996; Oliver and Vigna, 1996). These studies showed both similarities and sometimes striking differences in the comparative distribution of  $\text{CCK}$  receptors from one species to another. More comprehensive analyses and discussion about  $\text{CCK}$  receptor distribution differences in several brain regions among multiple species can be found elsewhere (Gaudreau et al., 1985; Sekiguchi and Moroji, 1986; Williams et al., 1986; Dietl and Palacios, 1989).

With the advent of specific radioligands that could differentiate between the two types of  $\text{CCK}$  receptors, it has become apparent that  $\text{CCK}_1$  and  $\text{CCK}_2$  receptors exhibit a sometimes overlapping, yet distinct, distribu-

tion throughout the CNS. The vast majority of  $\text{CCK}$  receptors in the CNS are of the  $\text{CCK}_2$  type, with  $\text{CCK}_1$  receptors restricted to rather discrete regions. The precise anatomical localization of the two  $\text{CCK}$  receptor types, as detailed later, serves to provide morphological substrates for many of the diverse functions attributed to neural  $\text{CCK}$ , including involvement in feeding, satiety, cardiovascular regulation, anxiety, pain, analgesia, memory, neuroendocrine control, osmotic stress, dopamine-related behaviors, and neurodegenerative and neuropsychiatric disorders (see Crawley and Corwin, 1994).

**1.  $\text{CCK}_1$  Receptors.** Radioligand studies, initially conducted in the rat, showed  $\text{CCK}_1$  receptors to be mainly located in the interpeduncular nucleus, area postrema, and medial nucleus tractus solitarius, with additional areas of binding found in the habenular nuclei, dorso-medial nucleus of the hypothalamus, and central amygdala (Moran et al., 1986; Hill et al., 1987, 1988a; Moran and McHugh, 1988; Woodruff et al., 1991; Carlberg et

al., 1992; Zajac et al., 1996; Qian et al., 1997). Studies in primates have revealed dramatic species differences, demonstrating a much higher prevalence and broader distribution of CCK<sub>1</sub> receptors in the monkey and humans than that in rodents (Hill et al., 1988b, 1990; Graham et al., 1991). Thus, in the monkey, CCK<sub>1</sub> receptor-binding sites are located not only in the area postrema, nucleus, tractus solitarius, and hypothalamic dorsomedial nucleus, but also in the supraoptic nucleus, paraventricular nucleus, mammillary bodies, supramammillary region, infundibular region, dorsal motor nucleus of the vagus, and the neurohypophysis. In addition, the mesostriatal dopaminergic system exhibits CCK<sub>1</sub> receptor binding in both its origin (substantia nigra pars compacta and adjacent ventral tegmental area) and forebrain targets (caudate and putamen). CCK<sub>1</sub> receptors are also found in the dorsal horn of monkey and human spinal cord. Peripherally, the nodose ganglion and vagus nerve contain and transport CCK<sub>1</sub> receptors (Corp et al., 1993; Widdop et al., 1994).

As determined by *in situ* hybridization using a cRNA probe, CCK<sub>1</sub> receptor mRNA in the rat is distributed within most of the above areas exhibiting CCK<sub>1</sub> receptor-binding sites (Honda et al., 1993). Moreover, additional areas containing CCK<sub>1</sub> receptor mRNA were revealed. In the forebrain, moderate to light mRNA expression is localized in the olfactory bulb, anterior olfactory nuclei, olfactory tubercle, piriform cortex, neocortex, claustrum, taenia tecta, all principal cell layers of the hippocampal formation, medial nucleus of the amygdala, and nucleus of the lateral olfactory tract. Moderate expression is also present in the lateral septal nucleus, bed nucleus of the stria terminalis, preoptic nucleus, thalamic reticular nucleus, and several hypothalamic regions, including the arcuate nucleus and lateral and posterior hypothalamic areas. Limited labeling for CCK<sub>1</sub> mRNA has been observed in the brainstem, with expression found only in the dorsal motor nucleus of the vagus nerve and the interpeduncular, caudal linear raphe, and hypoglossal nuclei.

Finally, it should be noted that a recent report on the immunohistochemical distribution of the CCK<sub>1</sub> receptor in rat CNS, using a newly developed and partially characterized antiserum, described numerous brain regions displaying CCK<sub>1</sub> receptor-like immunoreactivity (Mercer and Beart, 1997). In addition to being present within most of the areas shown above to contain CCK<sub>1</sub> receptor-binding sites or mRNA, other regions with either perikaryal or axonal/dendritic immunolabeling included the nucleus accumbens, anteroventral thalamic nucleus, medial mammillary nucleus, superior colliculus, periaqueductal gray matter, nuclei raphe obscurus and dorsalis, and parabrachial, trigeminal, vestibular, and inferior olivary nuclei, as well as layers 2 to 6 of the spinal cord. Further studies are necessary to confirm these results.

**2. CCK<sub>2</sub> Receptors.** In the telencephalon, autoradiographic binding studies (Moran et al., 1986; Pélaprat et

al., 1987; Durieux et al., 1988; Woodruff et al., 1991; Carlberg et al., 1992; Qian et al., 1997) showed that high densities of CCK<sub>2</sub> receptors are localized in the external plexiform layer of the main olfactory bulb, middle layers of the neocortex (with particularly high levels in the retrosplenial and cingulate cortices), piriform cortex, nucleus accumbens, and parasubiculum (Table 10). Moderate levels are found in the olfactory bulb glomerular layer, deep layers of neocortex, olfactory tubercle, islands of Calleja, fundus striata, ventral pallidum, caudate-putamen, hippocampus, dentate gyrus, presubiculum, and some amygdaloid nuclei. Only low densities are present in other telencephalic areas such as the taenia tecta, septum, bed nucleus of the stria terminalis, diagonal band of Broca, globus pallidus, superficial layers of neocortex, and most amygdaloid nuclei. In the diencephalon, moderate levels of CCK<sub>2</sub> receptors are distributed within several hypothalamic nuclei, including the supra-chiasmatic, supraoptic and ventromedial nuclei, and within the thalamic reticular nucleus. Low binding densities are found in other diencephalic regions such as the medial preoptic, arcuate, and dorsomedial hypothalamic nuclei; paraventricular, mediodorsal and reuniens thalamic nuclei; and zona incerta and lateral habenular nucleus. In the mesencephalon, moderate densities of CCK<sub>2</sub> receptor binding are localized in the parabigeminal nucleus, substantia nigra, and superior colliculus, with low levels present in the inferior colliculus, parabrachial nucleus, dorsal raphe nucleus, and periaqueductal gray matter. Relatively few CCK<sub>2</sub> receptor-binding sites are found in the myelencephalon, with low to moderate levels distributed within the pontine and superior olivary nuclei, and nucleus tractus solitarius. As noted, CCK<sub>2</sub> receptor binding in the cerebellum is species dependent. Indeed, with autoradiographic studies, CCK<sub>2</sub> receptors have been detected in the guinea pig, human, and mouse cerebellum, but not in rat cerebellum (Sekiguchi and Moroji, 1986; Williams et al., 1986, Dietl et al., 1987; Jagerschmidt et al., 1994). Finally, low levels of binding are observed in the dorsal and ventral horns of the spinal cord. In the periphery, CCK<sub>2</sub> receptor-binding sites are located in the trigeminal and dorsal root ganglia (DRG; Ghilardi et al., 1992) and in the vagus nerve (Corp et al., 1993).

*In situ* hybridization studies using cRNA probes showed that the distribution of CCK<sub>2</sub> receptor mRNA (Honda et al., 1993) is in good agreement with that of CCK<sub>2</sub> receptor-binding sites (see also Shigeyoshi et al., 1994; Hansson et al., 1998). Although some discrepancies were observed, virtually all of the nuclei and regions described earlier were shown to exhibit hybridization for CCK<sub>2</sub> receptor mRNA, with particularly strong signals found in the neocortex, piriform cortex, anterior olfactory nuclei, and several amygdaloid nuclei. Some areas with moderate to weak expression included the olfactory bulb and tubercle, hippocampal formation, claustrum,

TABLE 10  
Distribution of [<sup>3</sup>H]CCK-4 binding to CCK receptors in the rat brain

Frontal cortex		Septal region	
Layers I–III	++	Septum	+
Layer III, medial part	++++	Bed nucleus of the stria terminalis	++
Layer IV	+++	Septohippocampal nucleus	++
Layer V	++	Hippocampus	
Layer VI	+++	Subiculum	+++
Frontoparietal motor cortex		CA1–CA3	+
Layers I–III	++	Dentate gyrus	+++
Layer IV	+++	Amygdala	
Layers V, VI	++	Lateral nucleus	++
Frontoparietal somatosensory cortex		Posteromedial nucleus	++
Layers I–III	++	Amygdalo-hippocampal area	++
Layer IV	+++	Hypothalamus	
Layers V, VI	++	Ventromedial nucleus	+++
Striate cortex		Paraventricular nucleus	+++
Layers I–V	+++	Supraoptic nucleus	+++
Temporal cortex (auditory area)		Thalamus	
Layers I–III	+++	Lateral habenula	+
Layer IV	++++	Paraventricular nucleus	++
Layers V, VI	+++	Reticular thalamic nucleus	+++
		Zona incerta	+
Cingulate cortex, layer III	++++	Midbrain	
Retrosplenial cortex	++++	Superior	++
Entorhinal cortex	+++	Substantia nigra	++
Endopyriform nucleus	++++	Periaqueductal gray matter	+
Olfactory-system			
Olfactory bulbs			
External plexiform layer	+++		
Glomerular layer	+++		
Anterior olfactory nucleus	++		
Olfactory tubercle	+++		
Primary olfactory cortex (superficial layer)	++++		
Basal ganglia			
Striatum			
Head	+++		
Body	+++		
Tail	+		
Nucleus accumbens			
Anterior part	++++		
Posterior part	+		
Globus pallidus	+		

++++, high level; +++, moderate level; ++, low level; +, very low level.

other amygdaloid nuclei, septum, nucleus accumbens, caudate-putamen, substantia nigra, thalamic reticular nucleus, paraventricular, supraoptic and ventromedial hypothalamic nuclei, interpeduncular nucleus, red nucleus, vestibular nuclei, dorsal column nuclei, reticular formation, and lateral cerebellar nucleus. Diffuse labeling was also reported throughout the spinal cord. In peripheral sensory ganglia, CCK<sub>2</sub> receptor mRNA has been localized to a small population of DRG neurons (Zhang et al., 1993).

**3. Regulation of CCK Receptors.** It has become apparent that expression of CCK receptor-binding sites and mRNAs in the nervous system is not static but rather is malleable on different kind of perturbations. This is particularly evident in the hypothalamus where the levels of binding sites and/or mRNA for CCK<sub>2</sub> and/or CCK<sub>1</sub> receptors have been shown to increase in response

to various physiological or pharmacological stimuli such as osmotic stress, hypophysectomy, food and water deprivation, and chronic morphine treatment (Day et al., 1989; Meister et al., 1994; Hinks et al., 1995; O'Shea and Gundlach, 1995; Munro et al., 1998). In primary sensory neurons, the expression of CCK<sub>2</sub> receptor mRNA is dramatically up-regulated after peripheral axotomy from the normal low percentage of in situ hybridization-labeled cells to encompass about two-thirds of all DRG neurons across all size categories on peripheral axotomy (Zhang et al., 1993). In contrast, mild cortical infarction results in decreased levels of CCK<sub>2</sub> receptor mRNA and binding sites in the entire ipsilateral cerebral hemisphere (Van Bree et al., 1995). These data on CCK receptor alterations are in line with previous demonstrations of changes in CCK mRNA and peptide levels after certain perturbations, thereby providing further evi-

dence that neural CCK ligand-receptor systems are capable of plastic responses to various stimuli.

### B. Distribution in Gastrointestinal and Other Systems

In the gastrointestinal tract and other peripheral systems, CCK<sub>1</sub> receptors are present in pancreatic acinar cells, chief cells and D cells of the gastric mucosa, smooth muscle cells of the gallbladder, pyloric sphincter, sphincter of Oddi, some gastrointestinal smooth muscle and enteric neuronal cells, and anterior pituitary corticotrophs (for reviews, see Jensen et al., 1994; Wank et al., 1994a; Wank, 1995). CCK<sub>1</sub> receptors can also be expressed in several tumors, including pancreatic adenocarcinomas, meningiomas, and some neuroblastomas (Reubi et al., 1997a; Weinberg et al., 1997), as well as in certain pancreatic carcinoma, neuroblastoma, and lung cancer cell lines (Logsdon, 1986; Klueppelberg et al., 1990; Sethi et al., 1993). Furthermore, CCK<sub>1</sub> receptor mRNA has been found in esophageal, gastric, and colon cancers (Clerc et al., 1997). On the other hand, peripheral CCK<sub>2</sub> receptors are located in smooth muscle cells throughout the gastrointestinal tract (including the gallbladder), parietal, enterochromaffin-like, D cells and chief cells of the gastric mucosa, myenteric plexus neurons, pancreatic acinar cells, monocytes, and T lymphocytes (Sacerdote et al., 1991; Jensen et al., 1994; Mantyh et al., 1994; Wank et al., 1994; Wank, 1995; Song et al., 1996; Tarasova et al., 1996; Helander et al., 1997; Reubi et al., 1997b). Tumors and tumor cell lines expressing CCK<sub>2</sub> receptors include medullary thyroid, gastric, colon, ovarian and small cell lung carcinomas, astrocytomas, and certain pancreatic and lung cancer cell lines (Sethi et al., 1993; Wank, 1995; Reubi and Waser, 1996; Clerc et al., 1997; Reubi et al., 1997a).

## VII. Physiological Implications of CCK Receptors

### A. Peripheral Functions

As described in detail in *VIB. Distribution in Gastrointestinal and Other Systems*, CCK<sub>1</sub> receptors in the periphery are primarily localized in the pancreas, gallbladder, pylorus, intestine, and vagus nerve (Sankaran et al., 1980; Smith et al., 1984; Moran et al., 1987, 1990; Szcwoka et al., 1989; Hill et al., 1990; Wank et al., 1992a). In the pancreas, CCK acts at CCK<sub>1</sub> receptors on acinar cells to stimulate the secretion of the digestive enzyme pancreatic amylase (Liddle et al., 1984; Friedinger, 1989; Jensen et al., 1989). In the gallbladder, CCK acts at CCK<sub>1</sub> receptors to stimulate gallbladder contraction (Chang and Lotti, 1986; Gully et al., 1993). Commercial preparations of CCK are used clinically to evaluate gallbladder contraction in human gallbladder disease (Ondetti et al., 1970).

The role of peripheral CCK<sub>1</sub> receptors in the regulation of feeding behavior is an area of intense investigations. CCK<sub>1</sub> receptors appear to mediate the transmission of sensory information from the gut to the brain.

Peripherally administered CCK inhibits food consumption, even after fasting, in many species, including humans (Gibbs et al., 1973; Pi-Sunyer et al., 1982; Stacher et al., 1982; for reviews, see Smith and Gibbs, 1992; Crawley and Corwin, 1994). Furthermore, CCK<sub>1</sub> receptor antagonists increase food consumption and postpone satiety in several species, supporting the idea that endogenous CCK participates in the physiological regulation of feeding behavior (Dourish et al., 1989; Wolkowitz et al., 1990; Corwin et al., 1991; Reidelberger et al., 1991; Moran et al., 1992, 1993; for a review, see Crawley and Corwin, 1994). The entry of food into the intestine triggers the release of endogenous CCK by the intestinal mucosa, thereby activating CCK<sub>1</sub> receptors in the periphery. In particular, CCK<sub>1</sub> receptors on the vagus nerve (Moran et al., 1987) appear to be critical for the satiety-inducing action of CCK. Thus, lesions of the vagus nerve completely block the CCK-induced satiety syndrome (Crawley et al., 1981; Smith et al., 1981; South and Ritter, 1988). These findings have led to the hypothesis that CCK released from the intestine after a meal activates CCK<sub>1</sub> receptors on the vagus nerve to transmit sensations of fullness to the brain, which subsequently terminates feeding behaviors and initiates the




FIG. 6. Schematic representation of the mechanism of action of CCK in the regulation of feeding behavior. It is proposed that CCK from the intestine is delivered, after a meal, in the circulation to the stomach, where it acts directly on vagal afferents to transmit sensations of fullness to the brain. NTS, nucleus tractus solitarius; PVN, paraventricular nucleus; PBN, parabrachial nucleus; VMH, ventromedial nucleus of the hypothalamus (reproduced from Dockray, 1988).

sequence of behaviors associated with satiety (Smith and Gibbs, 1992; Fig. 6). CCK<sub>1</sub> receptor agonists have been proposed as anorectics for the treatment of obesity (Simmons et al., 1994; Wettstein et al., 1994). Conversely, CCK<sub>1</sub> receptor antagonists have been proposed for the treatment of anorexia disorders (Wolkowitz et al., 1990).

CCK<sub>2</sub> receptors in the periphery are primarily localized in the stomach (Kopin et al., 1992) and on the vagus nerve in some species (Mercer and Lawrence, 1992). As previously demonstrated, gastrin acts at CCK<sub>2</sub> receptors to stimulate gastric acid secretion (Schubert and Sham-burek, 1990). Similarly, CCK stimulates gastric acid secretion (Sandvik and Waldum, 1991), and this effect can be blocked by CCK<sub>2</sub> receptor antagonists (Bado et al., 1991; Pendley et al., 1995). To further explore the peptidergic pharmacology of the pyloric sphincter, it is desirable to have a preparation that would allow the examination of contraction independent of basal motor activity and could exclude contribution from the enteric nervous system. Such a preparation of isolated antral cells has been obtained through enzymatic disaggregation of tissue strips from different species, as well as disaggregated isolated cell preparations from the pyloric sphincter. Results obtained from these assays show that pyloric smooth muscle contractions are stimulated by low doses of CCK and that gastric emptying induced by a lipid-enriched meal is inhibited by CCK<sub>2</sub> receptor antagonists (Debas et al., 1975; Lopez et al., 1991). The latter compounds have been proposed for the treatment of gastric ulcers (Pendley et al., 1995).

Another relatively simple functional assay for CCK receptors is the guinea pig ileum longitudinal muscle myenteric plexus, which contains both CCK<sub>1</sub> and CCK<sub>2</sub> receptors. It has been demonstrated that CCK-8 elicits contraction through both receptors. Moreover, it has been shown that activation of CCK<sub>2</sub> receptor released only acetylcholine, whereas activation of CCK<sub>1</sub> receptor is responsible for the release of both substance P and acetylcholine (Dal Forno et al., 1992; Corsi et al., 1994).

## B. Central Functions

In line with its wide distribution in brain, CCK is involved in the modulation/control of multiple central functions. In particular, numerous experimental and clinical studies have clearly shown that CCK, through its action at CCK<sub>1</sub> and CCK<sub>2</sub> receptors, participates in the neurobiology of anxiety, depression, psychosis, cognition, and nociception.

*1. CCK in Panic Attacks and Anxiety.* The initial suggestion that the CCK system might be involved in anxiety came from experiments of Bradwejn and de Montigny (1984, 1985a,b) that showed that benzodiazepine receptor agonists could attenuate CCK-induced excitation of rat hippocampal neurons. Subsequent clinical studies demonstrated that bolus injections of the CCK<sub>2</sub> receptor agonist CCK-4 or pentagastrin provoke

panic attacks in patients with panic disorders (Bradwejn et al., 1990, 1991b, 1992a,b). The induced symptoms are comparable to those produced by a standard panic-provoking agent (35% CO<sub>2</sub>; Bradwejn and Koszycki, 1991) and can be attenuated by antipanic pharmacological agents such as antidepressants (Bradwejn and Koszycki, 1994; Shlik et al., 1997a; van Megen et al., 1997). CCK-4 also provokes panic attacks in healthy human subjects (de Montigny, 1989; Bradwejn et al., 1991a; McCann et al., 1994); however, sensitivity to the peptide is enhanced in panic disorder patients relative to healthy volunteers (Bradwejn et al., 1991b; van Megen et al., 1994), suggesting that endogenous CCK system may be altered in panic disorder and contributes to pathological anxiety. Recent investigations have revealed that the panicogenic effects of CCK<sub>2</sub> receptor agonists are not limited to panic disorder, because individuals with social phobia, generalized anxiety disorder, obsessive compulsive disorder, and premenstrual dysphoric disorder also exhibit an augmented behavioral response to these ligands (Le Melleo et al., 1995; De Leeuw et al., 1996; van Vliet et al., 1997; Brawman-Mintzer et al., 1997; Katzman et al., 1997). Although these data suggest that CCK sensitivity is not peculiar to panic disorder, the threshold of vulnerability to CCK<sub>2</sub> receptor agonists appears to be lower in panic disorder relative to other psychopathologies in which anxiety is a significant component (Katzman et al., 1997). In parallel, a number of investigators have reported that CCK peptides (Boc-CCK-4, BC 197) administered systemically or intracerebrally produce anxiogenic-like effects in different animal species, including mouse, rat, guinea pig, cat, and monkey (Blommaert et al., 1993; Harro et al., 1993; for a review, see Dauge and Roques, 1995). However, the anxiogenic effects of CCK peptides in animals have not been observed by all investigators, and the relevant negative findings should not be ignored (Shlik et al., 1997b). The conflicting data reported in the animal literature are attributable in part to the failure to address the various factors that potentially influence susceptibility to the anxiogenic effects of CCK (Bradwejn and Vasar, 1995). For instance, rats with low exploratory behavior (i.e., "anxious" rats) have been reported to exhibit a higher density of CCK receptor-binding sites in the frontal cortex and hippocampus relative to that in rats with high exploratory behavior (i.e., "nonanxious" rats; Harro et al., 1990; Koks et al., 1997). Thus, the effects of CCK compounds could vary considerably because of existing differences in the distribution and binding characteristics of CCK receptor types and/or affinity states among species. Recently, the effects of the selective CCK<sub>2</sub> receptor agonists BC 264 and BC 197 and of the nonselective CCK receptor agonist BDNL were investigated in rats subjected to the elevated plus-maze. Surprisingly, BDNL and BC 197 did induce anxiogenic-like effects, but BC 264 was devoid of any effect (Fig. 7). The behavioral responses to




FIG. 7. Effects of i.p. injection of BDNL, BC 197, and BC 264 administered 30 min before the experiment in the elevated plus-maze. The behavioral responses of rats were measured in the elevated plus-maze for 5 min. They are expressed as the percentage  $\pm$  S.E.M. of time spent in open arms. \* $P < .05$  and \*\* $P < .01$  compared with control group.

BDNL and BC 197 could be suppressed by CI-988, as expected from the involvement of CCK<sub>2</sub> receptors (Derrien et al., 1994b). On the other hand, Palmour et al. (1993) studied the anxiogenic effects of CCK receptor

agonists in a nonhuman primate model. CCK-4 administered i.v. to African green monkeys has strong and dose-related effects on behaviors thought to reflect anxiety and panic. Interestingly, BC 264 also produces these behavioral responses, but the profile of behavior is somewhat different because at low doses, hypervigilance and stereotypy are prominent.

The behavioral effects of CCK<sub>2</sub> receptor agonists in humans are accompanied by marked biological alterations, including robust increases in heart rate, blood pressure, and minute ventilation (Bradwejn et al., 1992a, 1998), increased hypothalamic-pituitary-adrenal axis activity (de Montigny, 1989; Abelson et al., 1991; Kellner et al., 1997; Shlik et al., 1997a), and elevated blood levels of dopamine, epinephrine, norepinephrine, and neuropeptide Y (Boulenger et al., 1996). The extent to which the biological alterations due to CCK<sub>2</sub> receptor agonist administration are comparable to those underlying naturally occurring panic attacks remains to be determined. Functional imaging studies in healthy volunteers have shown that CCK-4-induced anxiety is associated with cerebral blood flow activation in the anterior cingulate gyrus, the claustrum-insular-amygdala region, and the cerebellar vermis (Benkelfat et al., 1995). Although these studies indicate that brain mechanisms are activated after CCK-4 administration, they do not elucidate the precise neuronal circuitry subserving CCK-4-induced panic. It has been proposed that brainstem nuclei, including nucleus tractus solitarius, medulla, and parabrachial nucleus, are important sites of action of exogenous CCK-4 (Shlik et al., 1997b). These structures contribute to the regulation of respiration and cardiopulmonary function and have close anatomical and functional links with the locus ceruleus, a brain region involved in the expression of fear and anxiety. Studies in animals have shown that CCK interacts with brainstem structures to modulate respiration, heart rate, and blood pressure (Denavit-Saubié et al., 1985), and it is likely that the prominent cardiorespiratory symptoms elicited by exogenous CCK-4 in humans result from direct or indirect stimulation of CCK receptors in brainstem nuclei. The emotional symptoms evoked by CCK-4 may rise from an action of this peptide on brainstem structures and a subsequent activation or inhibition of higher CNS regions mediated through neuronal projections.

The neurobiological mechanisms by which CCK<sub>2</sub> receptor agonists provoke panic and concomitant biological changes have been the subject of considerable research activity. Animal studies suggest that anxious behavior induced by various CCK fragments is associated with selective CCK<sub>2</sub> receptor stimulation (Harro et al., 1993). CCK<sub>2</sub> receptors also appear to participate in the expression of anxiety in humans after systemic administration of CCK-4 and pentagastrin. Thus, acute treatment with the selective CCK<sub>2</sub> receptor antagonist L-365,260 was reported to block CCK-4-induced panic



attacks in panic disorder patients (Bradwejn et al., 1994) and pentagastrin-induced panic symptoms in healthy volunteers (Lines et al., 1995). Although CCK<sub>2</sub> receptors appear to be the key component from which CCK-4 triggers panic symptoms, there is growing evidence that the peptide produces its effects through interactions with other neurotransmitter systems. Animal studies have demonstrated that serotonin, norepinephrine, dopamine, opioids, corticotropin-releasing factor, and the benzodiazepine/ $\gamma$ -aminobutyric acid complex play salient roles in the induction of anxiety with CCK (Crawley, 1995; Zacharko et al., 1995). Similarly, clinical studies have revealed important interactions between CCK and serotonin (Shlik et al., 1997a; van Megen et al., 1997), norepinephrine (Le Melleo et al., 1998), and the benzodiazepine/ $\gamma$ -aminobutyric acid complex (de Montigny, 1989) in the induction of panic-like behavioral and physiological symptoms.

Interestingly, single-strand conformational polymorphism analysis showed that a significant association exists between panic disorder and polymorphism of the CCK<sub>2</sub> receptor gene (Kennedy et al., 1999). The CA repeat polymorphism in the upstream promoter region appears to be different in patients versus control subjects, suggesting that CCK<sub>2</sub> receptor gene variations may be a relevant factor in the neurobiology of panic disorder. In addition, a polymorphism, also revealed by single-strand conformational polymorphism analysis, has been found in the promoter region of the gene encoding the CCK precursor (Wang et al., 1998).

Recent attempts to evaluate the therapeutic effects of CCK<sub>2</sub> receptor antagonists in panic disorder have produced disappointing results (Adams et al., 1995; Kramer et al., 1995), mainly because the two compounds available for human use, L-365,260 and CI-988, have unfavorable pharmacokinetic properties. Fortunately, several pharmaceutical companies have developed CCK<sub>2</sub> receptor antagonists with superior pharmacokinetic profiles. These compounds are currently under evaluation for their potential interest in the treatment of anxiety and other psychopathologies.

**2. CCK and Schizophrenia.** To date, modifications in functioning of the dopamine system are generally accepted as a key component in the hypothetical pathophysiological mechanisms of schizophrenia. The existence of interactions between dopaminergic and CCKergic systems has been demonstrated by a large body of electrophysiological, behavioral, and neurochemical data (for a review, see Crawley, 1991; Derrien et al., 1993a; Ladurelle et al., 1993). Moreover, dopamine has been shown to be colocalized with CCK in the posterior part of the nucleus accumbens (Hökfelt et al., 1980). This observation can have clinical relevance because the A-10 dopaminergic neurons that project to the nucleus accumbens, much more than the other dopaminergic systems, are probably concerned by the pathophysiological mechanisms of schizophrenia (Crawley and Corwin,

1994). Numerous experiments have shown that CCK modulates the release of dopamine and that dopaminergic agents modulate the release of CCK (Crawley and Corwin, 1994). The interactions between CCK and dopamine are complex and often bidirectional, with CCK potentiating or inhibiting the action of dopamine, depending on the brain region examined. Thus, local administration of the CCK<sub>2</sub> receptor agonists BC 264 or CCK-8 reduced dopamine release in the nucleus accumbens of microdialysed rats, whereas via the i.p. route, the former agonist produced a large increase in dopamine release in the same area (Ladurelle et al., 1993, 1997). One hypothesis to account for the i.p. effects of BC 264 could be that this agonist, acting on the CCK<sub>2</sub> receptors located in the dorsal subiculum/CA1 of the hippocampus, stimulates the glutamatergic projections to the anterior nucleus accumbens, resulting in dopamine release (Sebret et al., 1999).

The precise role of CCK in schizophrenia remains incompletely understood. The most prominent finding relevant to this disorder is a reduction in postmortem CCK mRNA levels in different brain areas (frontal, cerebral and entorhinal cortices, and subiculum) of schizophrenic patients (Virgo et al., 1995; Bachus et al., 1997). In addition, significant reductions in CCK-like immunoreactivity have been reported in several brain regions of schizophrenic patients (Ferrier et al., 1983, 1985; Caruthers et al., 1984), especially those with predominantly negative symptoms. On the other hand, a lower density of CCK receptor-binding sites has been found in the hippocampus and frontal cortex of schizophrenic patients compared with controls (Farmery et al., 1985). However, it should be noted that not all studies confirmed the decrease in CCK mRNA levels in schizophrenia. Indeed, in the postmortem study of Schalling et al. (1990), schizophrenic patients had even higher CCK mRNA levels in the ventral tegmental area and substantia nigra than control subjects. Such a finding should suggest that elevated CCK synthesis in regions rich in dopaminergic neurons may be associated with schizophrenia. Methodological problems, study groups of patients that were too small, and patient heterogeneity might have contributed to these inconsistent results. Nevertheless, on the whole, the available data suggest that schizophrenia may be associated with reduced CCK activity. This reduction may be attributed to either a decreased processing of preproCCK in neurons or a reduction in synaptic levels of CCK due to activations in catabolic or putative reuptake processes (Migaud et al., 1995) or some neurodegeneration of CCKergic neurons in schizophrenia.

The inference that schizophrenia may be associated with hypoactive CCKergic transmission along with reports that CCK analogs have neuroleptic-like activity in animal paradigms relevant to schizophrenia spurred a great deal of interest in the potential antipsychotic activity of CCK peptides. Several open studies reported

that administration of nonselective CCK receptor agonists (CCK-8; CCK-33, cerulein) improved psychotic symptoms in schizophrenic patients when added to ongoing neuroleptic treatment (for a review, see Montgomery and Green, 1988; Payeur et al., 1993). These findings were encouraging and suggested that CCK receptor agonists in combination with typical neuroleptics may be useful for the treatment of schizophrenia. However, subsequent placebo-controlled studies indicated that nonselective CCK receptor agonists or antagonists are ineffective in the treatment of schizophrenia (Innis et al., 1986; Whiteford et al., 1992). New generations of agonists and antagonists acting with selectivity at CCK<sub>1</sub> or CCK<sub>2</sub> receptors are available, and clinical trials with these new compounds, alone or in combination with dopaminergic agents, are eagerly expected.

**3. CCK and Depression.** One of the physiological actions of the neuropeptide CCK seems to involve modulation of the nigrostriatal and mesolimbic dopaminergic pathways. Taking into consideration that the mesolimbic dopaminergic pathways play a crucial role in motivation and rewarding processes, which are likely to be altered in depression (for a review, see Willner, 1990), a role of CCK in mood disorders cannot be excluded.

Several studies have shown that selective CCK<sub>2</sub> receptor agonists, such as BC 264 and BC 197, potentiate the decrease in motor activity in mice that have been subjected to electric footshocks the day before (conditioned motility suppression test used to study antidepressant drugs), whereas CCK<sub>2</sub> receptor antagonists, on their own, exert an opposite effect (Smadja et al., 1995). These results suggest that CCK<sub>2</sub> receptor antagonists have antidepressant-like properties in mice.

The involvement of CCK in behavioral responses associated with anticipatory stress has already been demonstrated, and the importance of external stimuli, such as a novel environment, in revealing the behavioral effects of CCK receptor agonists or antagonists has been emphasized in several studies (Crawley, 1984; Daugé et al., 1989; O'Neill et al., 1991; Lavigne et al., 1992). In the conditioned immobility test, anticipatory stress on the day of the test might increase the sensitivity of the CCK system, allowing the effects of CCK<sub>2</sub> receptor agonists and antagonists to be detected. The antidepressant-like effects observed with CCK<sub>2</sub> receptor antagonists could result from an increase in extracellular dopamine, because they were preventable by both D<sub>1</sub> and D<sub>2</sub> receptor antagonists in the forced-swim test (Hernando et al., 1994; Fig. 8). Taken together, these data suggest that depression is associated with a hyperactive CCK<sub>2</sub> receptor system and that CCK<sub>2</sub> receptor antagonists may be useful in the treatment of depressive syndromes (Daugé and Roques, 1995).

However, relatively little is known about the role of CCK in clinical depression. Several laboratories have demonstrated that patients with major depression display cerebrospinal fluid CCK concentrations comparable




FIG. 8. Prevention of the effects of L-365,260 (1 mg/kg i.p.) by the selective dopamine D<sub>1</sub> receptor antagonist SCH-23390 (0.07 mg/kg s.c.) or the dopamine D<sub>2</sub> receptor antagonist sulpiride (25 mg/kg s.c.) in the forced-swim test in mice. \**P* < .05 compared with the control group; \**P* < .05 compared with the same dose of L-365,260 without antagonists (Newmann-Keuls test).

to those of control subjects (Gerner and Yamada, 1982; Geraciotti et al., 1993). However, there is some evidence that an increase in cerebrospinal fluid CCK levels can occur in particularly severe depression (Löfberg et al., 1998). On the other hand, postmortem studies have revealed that compared with healthy controls and patients with schizophrenia, suicide victims have elevated prepro-CCK mRNA levels and an increased density of CCK-containing neurons in the dorsolateral prefrontal cortex and a higher density of CCK receptors in the frontal cortex (Ferrier et al., 1985).

**4. CCK and Memory Processes.** There is increasing preclinical evidence that the CCK system may play a role in memory processes. The presence of CCK is conspicuous in brain regions suspected to underlie memory functions, including the hippocampal formation, amygdaloid nuclei, and cerebral cortex. It has been suggested that CCK<sub>1</sub> and CCK<sub>2</sub> receptors have different roles in learning and memory functions (Harro and Oreland, 1993). In particular, a balance between CCK<sub>1</sub> receptor-mediated facilitatory effects and CCK<sub>2</sub> receptor-mediated inhibitory effects on memory retention has been postulated (Lemaire et al., 1992, 1994). However, there are conflicting reports on the effects of CCK<sub>2</sub> receptor agonists in animal models of memory. For instance, although some groups have reported that selective CCK<sub>2</sub> receptor agonists (e.g., CCK-4, BC 264) impair memory (Katsuura and Itoh, 1986; Daugé et al., 1992; Lemaire et al., 1992; Derrien et al., 1994a), others have found that these peptides enhance memory (Gerhardt et al., 1994). Treatment with BC 264 has also been described to elicit prominent hypervigilance in monkeys and to increase behavioral arousal in rats (Daugé and Roques, 1995). The latter findings suggest a possible role for CCK<sub>2</sub>

receptor in attentional activation that can facilitate learning.

To date, only a few studies have been devoted to the effects of CCK receptor agonists on human memory. In one study, the administration of the nonselective CCK receptor agonist ceruletide had no demonstrable effect on recent or remote memory, although at higher doses it produced mild sedation. On the other hand, electrophysiological investigations of event-related brain potentials showed that ceruletide improved selective attention in healthy volunteers (Schreiber et al., 1995). Ceruletide has also been reported to improve cognitive processing in young, but not in elderly, healthy subjects (Dodt et al., 1996). Recently, Shlik et al. (1998) found that the continuous administration of the selective CCK<sub>2</sub> receptor agonist, CCK-4, had no effect on psychomotor performance, although it produced impairments in cognitive tests of free recall and recognition. The results of this study suggest that CCK-4 may exert a negative influence on memory consolidation and retrieval.

Factors that potentially contribute to discrepant findings include differences in experimental paradigms, dosage, and mode of drug administration. Another possible explanation of the discrepant findings on the role of CCK receptors in memory function might be due to the heterogeneity of CCK receptors (discussed earlier). In the two-trial memory task based on exploration of novelty, it has been shown that BC 264 enhanced spatial working memory, supporting the cognitive-enhancing properties of this agonist, whereas BC 197 was found to induce an amnesic effect (Fig. 9), a result in good agreement with the memory deficit obtained with CCK-4 (for a review, see Daugé and Léna, 1998). Interestingly, similar observations were made with a propionyl analog of BC 264, pBC 264, in both young and aged rats (Taghzouti et al., 1999). Thus, the latter CCK<sub>2</sub> receptor agonist enhanced consolidation and retrieval processes in young and aged rats but did not affect acquisition. Moreover, it has been shown through microdialysis that BC 264, injected i.p. at pharmacologically active doses, increased the extracellular levels of dopamine and its metabolites (dihydroxyphenyl acetic acid and homovanillic acid) in the anterior part of the nucleus accumbens (Ladurelle et al., 1997). Thus, it could be hypothesized that activation of dopaminergic transmission in the nucleus accumbens, which has been involved in some components of memory processes (Taghzouti et al., 1985; Ploeger et al., 1994; Floresco et al., 1996), could be the mechanism by which BC 264 produces its effect on attention and/or memory. On the other hand, the effects due to BC 197 might be non-specific. Indeed, BC 197 can exert anxiogenic-like effects (Derrien et al., 1994b), and the response observed after peripheral administration of this CCK<sub>2</sub> receptor agonist in the two-trial memory task could




FIG. 9. Effects of the selective CCK<sub>2</sub> receptor agonists BC 264 and BC 197 on working memory in a two-trial task in the Y maze. In the first trial (acquisition phase), one arm of the maze was closed and the rats were allowed to visit the other two arms for 3 min. During the second trial (retrieval phase), rats had free access to the three arms for 3 min. When the two trials were separated by a 2-h time interval, recognition memory allowed the control rats to spend more time in the novel arm. When the two trials were separated by a 6-h time interval, recognition memory was lost, and the control rats spent approximately the same time in the three arms of the maze. BC 264 or BC 197 was injected i.p. 30 min before the second trial (restitution phase). The CCK<sub>2</sub> receptor antagonist L365,260 was injected i.p. 60 min before the experiment. The results are expressed as mean  $\pm$  S.E. of the percentage of time spent in the novel arm. \* $P$  < .05 compared with control; \*\* $P$  < .05 and \*\*\* $P$  < .01 compared with CCK<sub>2</sub> receptor agonist alone (Duncan test).

reflect more such effects than a true disruption of memory processes (review in Daugé and Léna, 1998).

These results provide further evidence of the heterogeneity of CCK<sub>2</sub> receptors and show that their stimulation in rats, depending on the agonists used, can mediate

distinct behavioral responses. On the other hand, the modulation of memory processes by BC 264 or analogs could offer a new perspective in the treatment of attention/memory disorders associated with ageing or neurodegenerative diseases.

### 5. Interactions between CCK and Enkephalin Systems.

*a. In the Control of Pain.* Anatomical studies have shown that the distribution of CCK-8 and CCK receptors parallels that of endogenous opioids and opioid receptors in the pain-processing regions in both the brain and the spinal cord (Gall et al., 1987; Pohl et al., 1990). This overlapping distribution triggered numerous investigations on the role of CCK in nociception. Thus, several groups described a naloxone-reversible antinociceptive effect of CCK-8 or its analogs in relevant antinociceptive tests, such as the hot-plate, writhing, and tail-flick tests (for a review, see Baber et al., 1989). However, it has also been reported that CCK-8 has antiopioid properties. Thus, Faris et al. (1983) found that CCK reduced the antinociceptive effects produced by the release of endogenous opioids but did not modify opioid-independent analgesia induced by hind paw foot shock. In addition, numerous studies have shown that peripherally administered CCK receptor antagonists potentiate opioid antinociceptive responses, confirming the existence of a functional antagonism by endogenous CCK and opioid systems (for a review, see Roques and Noble, 1996). It has been hypothesized that CCK down-regulates opioid effects through activation of CCK<sub>2</sub> receptors. This hypothesis is supported by the data obtained with selective CCK<sub>2</sub> receptor antagonists. Indeed, these ligands strongly potentiate (+200–800%) the antinociceptive effects of endogenous enkephalins in rodents treated with RB 101, a mixed inhibitor of enkephalin-metabolizing enzymes (Fournié-Zaluski et al., 1992; Valverde et al., 1994). Interestingly, the combination of opioids with selective CCK<sub>2</sub> receptor antagonists enhanced the anti-allodynic effects of morphine, suppressed the development of autotomy behavior in a model of neuropathic pain in rat, and efficiently relieved the allodynia-like symptoms in spinally injured rats (review in Roques and Noble, 1996).

The occurrence of functional interactions between the CCK and enkephalin systems in the control of pain has been suggested (Noble et al., 1993; Fig. 10). Schematically, the potentiation of the effects of exogenous or endogenous opioids by BDNL, a nonselective CCK<sub>1</sub>/CCK<sub>2</sub> receptor agonist (Ruiz-Gayo et al., 1985), could be related to an increase in the release of enkephalins due to CCK<sub>1</sub> receptor activation (like that occurring by combined treatment with CCK-8 and a cocktail of peptidase inhibitors, Hendrie et al., 1989) and/or a direct improvement in the efficacy of transduction processes of the OP<sub>3</sub> ( $\mu$ ) opioid receptors, which might be allosterically evoked by CCK<sub>1</sub> receptor occupation (Magnuson et al., 1990). On the other hand, CCK<sub>2</sub> receptor activation




FIG. 10. Hypothetical model of the supraspinal interactions between CCK, via CCK<sub>1</sub> and CCK<sub>2</sub> receptors, and the opioid system via  $\delta$  (OP<sub>1</sub>)-opioid and  $\mu$  (OP<sub>3</sub>)-opioid receptors. CCK receptor agonists, endogenous or exogenous, stimulate CCK<sub>2</sub> and/or CCK<sub>1</sub> receptors, which can modulate the opioidergic (enkephalinergic) systems either directly (via the binding of opioid agonists or via C-fiber evoked activity) or indirectly (via the release of endogenous enkephalins). In addition, activation of  $\mu$  (OP<sub>3</sub>)-opioid receptors, which leads to antinociceptive responses, can negatively modulate the release of endogenous CCK, whereas  $\delta$  (OP<sub>1</sub>)-opioid receptor activation may enhance it.

could in turn negatively modulate the opioidergic system; this explains why the selective CCK<sub>2</sub> receptor agonist BC 264 produced a decrease in the lick latency in the hot-plate test in mice (Derrien et al., 1993b). If stimulation of CCK receptors is capable of modulating the opioid system, this system can in turn regulate the release of CCK peptides. Thus, the stimulation of OP<sub>3</sub> ( $\mu$ ) opioid receptors has an inhibitory influence on the K<sup>+</sup>-evoked release of CCK-like material at spinal and supraspinal levels (Ratray and De Belleruche, 1987; Rodriguez and Sacristan, 1989; Benoliel et al., 1991, 1992). On the other hand, in vitro studies have shown that OP<sub>1</sub> ( $\delta$ ) opioid receptor agonists enhance the K<sup>+</sup>-evoked release of CCK-like material from slices of rat substantia nigra and spinal cord (Benoliel et al., 1991, 1992). Also, the in vivo binding of the CCK<sub>2</sub> receptor selective agonist [<sup>3</sup>H]pBC 264 in the mouse brain was found to be reduced by the administration of RB 101, a mixed inhibitor of enkephalin-degrading peptidases or BUBU [Tyr-D-Ser(*O*-*tert*-butyl)-Gly-Phe-Leu-Thr(*O*-*tert*-butyl)], an OP<sub>1</sub> ( $\delta$ ) receptor-selective agonist, supporting the idea that endogenous enkephalins increase the extracellular levels of CCK (competing with [<sup>3</sup>H]pBC 264 at CCK<sub>2</sub> receptors) through the activation of OP<sub>1</sub> ( $\delta$ ) opioid receptors (Ruiz-Gayo et al., 1992).

*b. In Behavioral Responses.* In most behavioral studies, CCK has been found to behave as an antiopioid peptide (Noble et al., 1993; for a review, see Roques and Noble, 1996). A dysfunction in the balance between the two peptidergic systems involved in reward in the case of opioids and in attention and anxiety in the case of CCK could participate in the neurobiological mechanisms underlying vulnerability in drug addiction. Furthermore, it has been suggested that endogenous opioid peptides, especially enkephalins, might be involved in the cause of depression (for a review, see Roques et al., 1993) and that CCK-mediated processes might possibly counteract the antidepressant-like effects of opioids. In line with

these hypotheses, increasing the levels of endogenous enkephalins by RB 101 was shown to induce antidepressant-like effects in relevant paradigms, such as the forced swimming, conditioned suppression of motility, and learned helplessness tests (for a review, see Roques and Noble, 1996). In all these models of depression, rodents treated with RB 101 react to an adverse situation in the same way as after the administration of "classic" antidepressants, such as imipramine, desipramine, and amitriptyline.

Behavioral studies showed that blockade of CCK<sub>1</sub> and CCK<sub>2</sub> receptors produces opposite effects on the opioid-

induced reduction of conditioned suppression motility due to endogenous enkephalins protected from peptidase inactivation by RB 101. Thus, the antidepressant-like effects of RB 101 were suppressed by the CCK<sub>1</sub> receptor antagonist L-364,718 and enhanced by the CCK<sub>2</sub> receptor antagonist L-365,260 (Smadja et al., 1995; Fig. 11). Given the reliable and strong facilitatory effects of CCK<sub>2</sub> receptor antagonists on the behavioral responses to RB 101, it was of interest to investigate the regions involved in the endogenous interactions between CCK and opioid systems. Because the mesolimbic system is known to be widely involved in the control of motivational and affective responses, two me-




FIG. 11. Conditioned suppression of motility test in mice. Effects of the CCK<sub>1</sub> and CCK<sub>2</sub> receptor antagonists L-364,718 and L-365,260, respectively, on the antidepressant-like effects induced by i.v. injected RB 101. Mice were placed in a transparent rectangular cage with a metallic grid floor. Animal displacements were measured by drawing squares on the floor for counting. On the first day, the mouse was left in the test cage for 6 min and received electric footshocks. On the second day, the mouse was placed in the same cage without receiving electric footshocks, and motility changes were tested by counting the number of squares crossed, plus the number of rearings in 6 min. The mice belonging to the control group were handled in the same way as those in the conditioned suppression group except that they did not receive electric footshocks on the first day. \*\* $P < .01$  compared with control group; \* $P < .05$  and \*\*\* $P < .01$  compared with the same dose of RB 101 without antagonist.

solimbic structures were studied: the anterior nucleus accumbens and the central amygdala. Moreover, the nucleus accumbens has been implicated in the interaction between CCK and opioid systems in the control of other pharmacological responses (Kiraly and Van Ree, 1987; Mueller and Whiteside, 1990). The results obtained showed that the antidepressant-like effects of RB 101 were potentiated by microinjection of the CCK<sub>2</sub> receptor antagonist PD-134,308 in the anterior nucleus accumbens and the central amygdala, but not in the caudate nucleus, suggesting that the mesolimbic system plays an important role in the interaction between CCK and opioid systems in the control of these behavioral responses (Smadja et al., 1997).

On the other hand, the main challenge in the management of opioid addiction is to develop pharmacotherapy to minimize the short-term withdrawal syndrome and protracted opioid abstinence syndrome. Indeed, in the first days after the cessation of prolonged drug use, addicted subjects present an acute withdrawal syndrome, which consists of agitation, hyperalgesia, tachycardia, hypertension, diarrhea, vomiting, and subjective changes. Furthermore, a depression-like syndrome may persist for months or longer after the last dose of opiate. Relevant investigations have shown that during the acute morphine-withdrawal syndrome, there is an increased release of opioid peptides and that protection of these peptides by mixed enkephalin-degrading enzyme inhibitors reduces the opioid withdrawal syndrome (review in Roques et al., 1993). The recent demonstration that activation of CCK<sub>2</sub> receptors could negatively modulate the opioid system (see earlier) suggests that in contrast, the selective blockade of these receptors should increase the ability of mixed inhibitors to decrease the withdrawal signs. Indeed, this has recently been confirmed using RB 101 in association with the CCK<sub>2</sub> receptor antagonist PD-134,308 (Maldonado et al., 1995). Moreover, the protracted abstinence syndrome could be improved due to the antidepressant-like properties of mixed inhibitors administered alone or in combination with the selective CCK<sub>2</sub> receptor antagonists. Thus, the possibility of relapse, the most important problem in the management of opioid addiction, should be minimized.

Interestingly, all of these behavioral studies showed that CCK<sub>2</sub> receptor antagonists do not apparently potentiate the subjective effects of opioids (for a review, see Roques and Noble, 1996). This finding should have important clinical implications in the management of pain, taking into account the strong antinociceptive responses to opioids in association with the CCK<sub>2</sub> receptor antagonists.

### VIII. Conclusion

Since the original characterization of CCK by Ivy and Oldberg in 1928, followed by the isolation and sequencing of this hormone (Jorpes and Mutt, 1966), and its detection in the CNS (Vanderhaeghen et al., 1975), con-

siderable advances have been made in the knowledge of the roles of this neuropeptide. The actions of CCK and related peptides have been extended to include endocrine secretion; motility and growth in the gastrointestinal system; and regulation of satiety, anxiety, pain, and dopamine-mediated behavior in the central and peripheral nervous systems. These actions are mediated by at least two distinct receptors, which have been pharmacologically characterized. The existence of these CCK receptors (CCK<sub>1</sub> and CCK<sub>2</sub>) has subsequently been confirmed by their molecular cloning. Nevertheless, the large variety of functions mediated by CCK receptors, as well as pharmacological studies, suggests that some heterogeneity exists in CCK<sub>1</sub> and CCK<sub>2</sub> receptors. However, such a heterogeneity has not been confirmed in molecular biology studies, which have so far identified only two members of the CCK receptor family. The physiological and pathophysiological implications of these receptors can now be further investigated in CCK<sub>2</sub> receptor-deficient mice obtained through gene targeting (Nagata et al., 1996) and in Otsuka Long-Evans Tokushima Fatty rats, which have no functional CCK<sub>1</sub> receptors (Kobayashi et al., 1996). Several potential clinical applications concern the treatment of brain disorders and/or pain with CCK<sub>2</sub> receptor agonists or antagonists and of diseases involving food consumption with CCK<sub>1</sub> receptor ligands.

*Acknowledgments.* We thank C. Dupuis for typing the tables. All members of the laboratory and colleagues whose names appear in the references cited in this review are gratefully acknowledged.

### REFERENCES

- Abelson JL, Nesse RM and Vinik A (1991) Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder. *Biol Psychiatry* **29**:1220–1223.
- Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, Wisselink PG, Greiner M, Pierce MW and Pande AC (1995) A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. *J Clin Psychopharmacol* **15**:428–434.
- Akiyama T and Otsuki M (1994) Characterization of a new cholecystokinin receptor antagonist FK480 in vitro isolated rat pancreatic acini. *Pancreas* **9**:324–331.
- Akiyama T, Tachibana I, Hirohata Y, Shirohara H, Yamamoto M and Otsuki M (1996) Pharmacological profile of TP-680, a new cholecystokinin-A receptor antagonist. *Br J Pharmacol* **117**:1558–1564.
- Alho H, Costa E, Ferrero P, Fujimoto M, Cosenza-Murphy D and Guidotti A (1985) Diazepam-binding inhibitor: A neuropeptide located in selected neuronal populations of rat brain. *Science (Wash DC)* **229**:179–182.
- Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RAE, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen JE, Rimele TJ, Smith DN and Sugg EE (1996) Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger." *J Med Chem* **39**:562–569.
- Augelli-Szafran CE, Horwell DC, Kneen C, Ortwine DF, Pritchard MC, Purchase TS, Roth BD, Trivedi BK, Hill D, Suman-Chauhan N and Webdale L (1996) Cholecystokinin B antagonists: Synthesis and quantitative structure-activity relationships of a series of C-terminal analogs of CI-988. *Bioorg Med Chem* **4**:1733–1745.
- Baber NS, Dourish CT and Hill DR (1989) The role of CCK, caerulein, and CCK antagonists in nociception. *Pain* **39**:307–328.
- Bachus SE, Hyde TM, Herman MM, Egan MF and Kleinman JE (1997) Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. *J Psychiatr Res* **31**:233–256.
- Bado A, Durieux C, Moizo L, Roques BP and Lewin MJ (1991) Cholecystokinin-A receptor mediation of food intake in cats. *Am J Physiol* **260**:R693–R697.
- Baldwin GS (1993) Gastrin receptor structure, in *Gastrin* (Walsh JH ed) pp 195–207, Raven Press, New York.
- Baldwin GS, Chandler R, Scanlon DB and Weinstock J (1986) Identification of a gastrin binding protein in porcine gastric mucosal membranes by covalent cross-linking with iodinated gastrin-2-17. *J Biol Chem* **261**:12252–12257.
- Barrett RW, Steffy ME and Wolfram CAW (1989) Type-A CCK receptors in CHP 212 neuroblastoma cells: Evidence for association with G protein and activation of phosphoinositide hydrolysis. *Mol Pharmacol* **35**:394–400.

- Beinborn M, Lee YM, McBride EW, Quinn SM and Kopin AS (1993) A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non peptide antagonists. *Nature (Lond)* **362**:348–350.
- Bellier B, Da Nascimento S, Meudal H, Gincel E, Roques BP and Garbay C (1998) Novel constrained CCK-B dipeptid antagonists derived from pipercolic acid. *Bioorg Med Chem Lett* **8**:1419–1424.
- Bellier B, McCort-Tranchepain I, Ducos B, DaNascimento S, Meudal H, Noble F, Garbay C and Roques BP (1997) Synthesis and biological properties of new constrained CCK-B antagonists: Discrimination of two affinity states of the CCK-B receptor on transfected CHO cells. *J Med Chem* **40**:3947–3956.
- Benkelfat C, Bradwejn J, Meyer E, Ellenbogen M, Milot S, Gjedde A and Evans A (1995) Functional neuroanatomy of CCK-4-induced anxiety in normal healthy volunteers. *Am J Psychiatry* **152**:1180–1184.
- Benoliel JJ, Bourgoin S, Mauborgne A, Legrand JC, Hamon M and Cesselin F (1991) Differential inhibitory/stimulatory modulation of spinal CCK release by  $\mu$  and  $\delta$  opioid agonists, and selective blockade of  $\mu$ -dependent inhibition by  $\kappa$  receptor stimulation. *Neurosci Lett* **124**:204–207.
- Benoliel JJ, Mauborgne A, Bourgoin S, Legrand JC, Hamon M and Cesselin F (1992) Opioid control of the in vitro release of CCK-like material from the rat substantia nigra. *J Neurochem* **58**:916–922.
- Blandizzi C, Song I and Yamada T (1994) Molecular cloning and structural analysis of the rabbit gastrin/CCKB receptor gene. *Biochem Biophys Res Commun* **202**:947–953.
- Blommaert AG, Weng JH, Dorville A, McCort I, Ducos B, Durieux C and Roques BP (1993) Cholecystokinin peptidomimetics as selective CCK-B antagonists: Design, synthesis, and in vitro and in vivo biochemical properties. *J Med Chem* **36**:2868–2877.
- Blommaert AGS, Dhôtel H, Ducos B, Durieux C, Goudreau N, Bado A, Garbay C and Roques BP (1997) Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. *J Med Chem* **40**:647–658.
- Bock MG, DiPardo RM, Evans BE, Rittle KE, Whitter WL, Veber DF, Anderson PS and Freidinger RM (1989) Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. *J Med Chem* **32**:13–16.
- Bock MG, DiPardo RM, Mellin EC, Newton RC, Veber DF, Freedman SB, Smith AJ, Patel S, Kemp JA, Marshall GR, Fletcher AE, Chapman KL, Anderson PS and Freidinger RM (1994) Second-generation benzodiazepine CCK-B antagonists. Development of sub-nanomolar analogs with selectivity and water solubility. *J Med Chem* **37**:722–724.
- Bock MG, DiPardo RM, Rittle KE, Evans BE, Freidinger RM, Veber DF, Chang RSL, Chen TB, Keegan ME and Lotti VJ (1986) Cholecystokinin antagonists: Synthesis of asperlicin analogs with improved potency and water solubility. *J Med Chem* **29**:1941–1945.
- Boden PR, Higginbottom M, Hill DR, Horwell DC, Hughes J, Rees DC, Roberts E, Singh L, Suman-Chauhan N and Woodruff GN (1993) Cholecystokinin dipeptid antagonists: Design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and “mixed” CCK-A/CCK-B antagonists. *J Med Chem* **36**:552–565.
- Bolton GL, Roth BD and Trivedi BK (1993) Synthesis of conformationally constrained macrocyclic analogs of the potent and selective CCK-B antagonist CI-988. *Tetrahedron* **49**:525–536.
- Boulenger JP, Jerabek I, Jolicœur FB, Lavallee YJ, Leduc R and Cadieux A (1996) Elevated plasma levels of neuropeptide Y in patients with panic disorder. *Am J Psychiatry* **153**:114–116.
- Bradwejn J and de Montigny C (1984) Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. *Nature (Lond)* **312**:363–364.
- Bradwejn J and de Montigny C (1985a) Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: A microiontophoretic study in the rat. *Eur J Pharmacol* **112**:415–418.
- Bradwejn J and de Montigny C (1985b) Antagonism of cholecystokinin-induced activation of benzodiazepine receptor agonists. *Ann NY Acad Sci* **448**:83–85.
- Bradwejn J and Koszycki D (1991) Comparison of the panicogenic effect of cholecystokinin 30-33 and carbon dioxide in panic disorder. *Prog Neuropsychopharmacol Biol Psychiatry* **15**:237–239.
- Bradwejn J and Koszycki D (1994) Imipramine antagonism of the panicogenic effects of cholecystokinin-tetrapeptide in panic disorder patients. *Am J Psychiatry* **151**:261–263.
- Bradwejn J, Koszycki D, Annable L, Couetoux du Tertre A, Reines S and Karkanias C (1992a) A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. *Biol Psychiatry* **32**:903–912.
- Bradwejn J, Koszycki D and Bourin M (1991a) Dose ranging study of the effects of cholecystokinin in healthy volunteers. *J Psychiatry Neurosci* **16**:91–95.
- Bradwejn J, Koszycki D, Couetoux du Tertre A, van Megen H, den Boer J and Westenberg H (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. *Arch Gen Psychiatry* **51**:486–493.
- Bradwejn J, Koszycki D and Meterissian G (1990) Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. *Can J Psychiatry* **35**:83–85.
- Bradwejn J, Koszycki D, Payeur R, Bourin M and Borthwick (1992b) Replication of action of cholecystokinin tetrapeptide in panic disorder: Clinical and behavioral findings. *Am J Psychiatry* **149**:962–964.
- Bradwejn J, Koszycki D and Shriqui C (1991b) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. *Arch Gen Psychiatry* **48**:603–610.
- Bradwejn J, LeGrand JM, Koszycki D, Bates JH and Bourin M (1998) Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. *Am J Psychiatry* **155**:280–282.
- Bradwejn J and Vasar E (1995) Cholecystokinin and panic disorder, in *Cholecystokinin and Anxiety: From Neuron to Behavior* (Bradwejn J and Vasar E eds) pp 73–86, RB Landes Company, Austin.
- Brawman-Mintzer O, Lydiard RB, Bradwejn J, Villarreal G, Knapp R, Emmanuel N, Ware MR, He Q and Ballenger JC (1997) Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. *Am J Psychiatry* **154**:700–702.
- Camus A, Rose C and Schwartz JC (1989) Role of a serine endopeptidase in the hydrolysis of exogenous cholecystokinin by brain slices. *Neuroscience* **29**:595–602.
- Carlberg M, Gundlach AL, Mercer LD and Beart PM (1992) Autoradiographic localization of cholecystokinin A and B receptors in rat brain using [<sup>125</sup>I]D-Tyr<sup>25</sup>(Nle<sup>28,31</sup>)-CCK 25-33S. *Eur J Neurosci* **4**:563–573.
- Carruthers B, Dawbarn D, De Quidt M, Emson PC, Hunter J and Reynolds GP (1984) Changes in neuropeptide content of amygdala in schizophrenia (Abstract). *Br J Pharmacol* **81** (Suppl):190P.
- Chambers MS, Hobbs SC, Fletcher SR, Matassa VG, Mitchell PJ, Watt AP, Baker R, Freedman SB, Patel S and Smith AJ (1993) L-708,474: The C5-cyclohexyl analog of L-365,260, a selective, high affinity ligand for the CCK-B/gastrin receptor. *Bioorg Med Chem Lett* **3**:1919–1924.
- Chambers MS, Hobbs SC, Graham MI, Watt AP, Fletcher SR, Baker R, Freedman SB, Patel S, Smith AJ and Matassa VG (1995) Potent, selective, water-soluble benzodiazepine-based CCK-B receptor antagonists that contain lipophilic carboxylate surrogates. *Bioorg Med Chem Lett* **5**:2303–2308.
- Chang RSL, Chen TB, Bock MG, Freidinger RG, Chen R, Rosegay A and Lotti VJ (1989) Characterization of the binding of [<sup>3</sup>H]L-365,260: A new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. *Mol Pharmacol* **35**:803–808.
- Chang RSL and Lotti VJ (1986) Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. *Proc Natl Acad Sci USA* **83**:4923–4926.
- Chang RSL, Lotti VJ, Chen TB and Kunkel KA (1986) Characterization of the binding of [<sup>3</sup>H](±)-L-364,718: A new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. *Mol Pharmacol* **30**:212–217.
- Chang RSL, Lotti VJ, Monaghan RL, Birnbaum J, Stapley EO, Goetz MA, Albers-Schonberg G, Patchett AA, Liesch JM, Hensens OD and Springer JP (1985) A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from *Aspergillus alliaceus*. *Science (Wash DC)* **230**:177–179.
- Charpentier B, Dor A, Roy P, England P, Pham H, Durieux C and Roques BP (1989) Synthesis and binding affinities of cyclic and related linear analogs of CCK<sub>8</sub> selective for central receptors. *J Med Chem* **31**:1184–1190.
- Charpentier B, Durieux C, Pélaprat D, Dor A, Reibaud M, Blanchard JC and Roques BP (1988a) Enzyme-resistant CCK analogs with high affinities for central receptors. *Peptides* **9**:835–841.
- Charpentier B, Pélaprat D, Durieux C, Dor A, Reibaud M, Blanchard JC and Roques BP (1988b) Cyclic cholecystokinin analogs with high selectivity for central receptors. *Proc Natl Acad Sci USA* **85**:1968–1972.
- Chiba T, Fisher SK, Park J, Seguin EB, Agranoff BW and Yamada T (1988) Carbamylcholine and gastrin induce inositol lipid turnover in canine gastric parietal cells. *Am J Physiol* **255**:G99–G105.
- Choi J-K, Linehan C, Périn N, Pohl M and Wank SA (1998) Internalization is not important for desensitization or resensitization of the cholecystokinin type B receptor (CCKBR) (Abstract). *Gastroenterology* **114**:A1136.
- Clark CR, Daum P and Hughes J (1986) A study of the cerebral cortex cholecystokinin receptor using two radiolabelled probes: Evidence for a common CCK-8 and CCK-4 cholecystokinin receptor binding site. *J Neurochem* **46**:1094–1101.
- Clerc P, Dufresne M, Saillan C, Chastre E, André T, Escriveau C, Kennedy K, Vaysse N, Gespach C and Fourny D (1997) Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon. *Int J Cancer* **72**:931–936.
- Corp ES, McQuade J, Moran TH and Smith GP (1993) Characterization of type A and type B CCK receptor binding sites in rat vagus nerve. *Brain Res* **623**:161–166.
- Corringer PJ, Weng JH, Ducos B, Durieux C, Boudeau P, Böhme A and Roques BP (1993) CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK<sub>4</sub> derivatives. *J Med Chem* **36**:166–172.
- Corsi M, Palea S, Pietra C, Oliosi B, Gaviraghi G, Sugg E, Van Amsterdam FTM and Trist DG (1994) A further analysis of the contraction induced by activation of cholecystokinin A receptors in guinea pig isolated ileum longitudinal muscle-myenteric plexus. *J Pharmacol Exp Ther* **270**:734–740.
- Corwin RL, Gibbs J and Smith GP (1991) Increased food intake after type A but not type B cholecystokinin receptor blockade. *Physiol Behav* **50**:255–258.
- Crawley JN (1984) Cholecystokinin accelerates the rate of habituation to a novel environment. *Pharmacol Biochem Behav* **20**:23–27.
- Crawley JN (1991) Cholecystokinin-dopamine interactions. *Trends Pharmacol Sci* **12**:232–236.
- Crawley JN (1995) Interactions between cholecystokinin and other neurotransmitter systems, in *Cholecystokinin and Anxiety: From Neuron to Behavior* (Bradwejn J and Vasar E eds) pp 35–56, RG Landes Company, Austin.
- Crawley JN and Corwin RL (1994) Biological actions of cholecystokinin. *Peptides* **15**:731–755.
- Crawley JN, Hays SE and Paul SM (1981) Vagotomy abolishes the inhibitory effects of cholecystokinin on rat exploratory behaviors. *Eur J Pharmacol* **73**:379–380.
- Daaka Y, Luttrell LM and Lefkowitz RJ (1997) Switching of the coupling of the  $\beta$ 2-adrenergic receptor to different G proteins by protein kinase A. *Nature (Lond)* **390**:88–91.
- Dabrowski A, Grady T, Logsdon CD and Williams JA (1996a) Jun kinases are rapidly activated by cholecystokinin in rat pancreas both in vitro and in vivo. *J Biol Chem* **271**:5686–5690.
- Dabrowski A, VanderKuur JA, Carter-Su C and Williams JA (1996b) Cholecystokinin stimulates formation of Shc-Grb2 complex in rat pancreatic acinar cells through a protein kinase C-dependent mechanism. *J Biol Chem* **271**:27125–27129.
- Dal Forno G, Pietra C, Urciuoli M, Van Amsterdam FTM, Toson G, Gaviraghi G and Trist D (1992) Evidence for two cholecystokinin receptors mediating the contraction of the guinea pig isolated longitudinal muscle myenteric plexus. *J Pharmacol Exp Ther* **261**:1056–1063.
- Daugé V, Derrien M, Blanchard JC and Roques BP (1992) The selective CCK-B agonist, BC 264 injected in the antero-lateral part of the nucleus accumbens,

- reduces the spontaneous alternation behaviour of rats. *Neuropharmacology* **31**: 67–75.
- Daugé V, Dor A, Féger J and Roques BP (1989) The behavioral effects of CCK-8 injected into the medial nucleus accumbens are dependent on the motivational state of the rat. *Eur J Pharmacol* **163**:25–32.
- Daugé V and Léna I (1998) CCK in anxiety and cognitive processes. *Neurosci Biobehav Rev* **22**:815–825.
- Daugé V and Roques BP (1995) Opioid and CCK systems in anxiety and reward, in *Cholecystokinin and Anxiety: From Neuron to Behavior* (Bradwejn J and Vasar E eds) pp 151–171, RG Landes Company, Austin.
- Day NC, Hall MD and Hughes J (1989) Modulation of hypothalamic cholecystokinin receptor density with changes in magnocellular activity: A quantitative autoradiographic study. *Neuroscience* **29**:371–383.
- Debas HT, Farooq O and Grossman MI (1975) Inhibition of gastric emptying is a physiological action of cholecystokinin. *Gastroenterology* **68**:1211–1217.
- De Leeuw AS, den Boer JA, Slaap BR and Westenberg HG (1996) Pentagastrin has panic-inducing properties in obsessive compulsive disorder. *Psychopharmacology* **126**:339–344.
- Delvalle JY, Tsunoda Y, Williams JA and Yamada T (1992) Regulation of  $[Ca^{2+}]_i$  by secretagogue stimulation of canine gastric parietal cells. *Am J Physiol* **262**:G420–G426.
- de Montigny C (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. *Arch Gen Psychiatry* **46**:511–517.
- Denavit-Saubié M, Hurlé MA, Morin-Surun MP, Foutz AS and Champagnat J (1985) The effects of cholecystokinin-8 in the nucleus tractus solitarius. *Ann NY Acad Sci* **448**:375–384.
- Denyer J, Gray J, Wong M, Stolz M and Tate S (1994) Molecular and pharmacological characterization of the human CCKB receptor. *Eur J Pharmacol* **268**:29–41.
- Derrien M, Daugé V, Blommaert A and Roques BP (1994a) The selective CCK-B agonist, BC 264, impairs socially reinforced memory in the three-panel runway test in rats. *Behav Brain Res* **65**:139–146.
- Derrien M, Durieux C, Daugé V and Roques BP (1993a) Involvement of  $D_2$  dopaminergic receptors in the emotional and motivational responses induced by injection of CCK<sub>8</sub> in the posterior part of the nucleus accumbens. *Brain Res* **617**:181–188.
- Derrien M, McCort-Tranchepain I, Ducos B, Roques BP and Durieux C (1994b) Heterogeneity of CCK-B receptors involved in animal models of anxiety. *Pharmacol Biochem Behav* **49**:133–141.
- Derrien M, Noble F, Maldonado R and Roques BP (1993b) Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. *Neurosci Lett* **160**:193–196.
- Deschenes RJ, Lorenz LJ, Haun RS, Roos BA, Collier KJ and Dixon JE (1984) Cloning and sequence analysis of cDNA encoding rat preprocholecystokinin. *Proc Natl Acad Sci USA* **81**:726–730.
- de Weerth A, Pisegna JR, Huppi K and Wank SA (1993a) Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. *Biochem Biophys Res Commun* **194**:811–818.
- de Weerth A, Pisegna JR and Wank S (1993b) Guinea pig gallbladder and pancreas possess identical CCK-A receptor subtypes: Receptor cloning and expression. *Am J Physiol* **265**:G1116–G1121.
- Didier E, Horwell DC and Pritchard MC (1992) Synthesis and CCK-B binding affinities of cyclic analogs of the potent and selective CCK-B antagonist CI-988. *Tetrahedron* **48**:8471–8490.
- Dietl MM and Palacios JM (1989) The distribution of cholecystokinin receptors in the vertebrate brain: Species differences studied by receptor autoradiography. *J Chem Neuroanat* **2**:149–161.
- Dietl MM, Probst A and Palacios JM (1987) On the distribution of cholecystokinin receptor binding sites in the human brain: An autoradiographic study. *Synapse* **1**:169–183.
- Ding XQ, Chen D and Hakanson R (1995) Cholecystokinin-B/gastrin receptor ligands of the dipeptidyl series act as agonists on histidine decarboxylase in rat stomach anterochromaffin-like cells. *Pharmacol Toxicol* **76** (Suppl IV):81.
- Dockray GJ (1988) Regulatory peptides and the neuroendocrinology of brain-gut relations. *Q J Exp Physiol* **73**:703–727.
- Dotz C, Sarnighausen HE, Pietrowsky R, Fehm HL and Born J (1996) Ceruletide improves event-related potential indicators of cognitive processing in young but not in elderly humans. *J Clin Psychopharmacol* **16**:440–445.
- Dohlman HG, Thorner J, Caron MG and Lefkowitz RJ (1991) Model systems for the study of seven-transmembrane-segment receptors. *Annu Rev Biochem* **60**:653–680.
- Dourish CT, Ruckert AC, Tattersall FD and Iversen SD (1989) Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors. *Eur J Pharmacol* **173**:233–234.
- Dufresne M, Escriveau C, Clerc P, Le Huerou-Luron I, Prats H, Bertrand V, Le Meuth V, Guilloleau P, Vaysses N and Fourmy D (1996) Molecular cloning, ontogeny and characterization of a predominant pancreatic CCKB/gastrin receptor in the calf pancreas. *Eur J Pharmacol* **297**:165–179.
- Durieux C, Charpentier B, Pélaprat D and Roques BP (1986a) Investigation on the metabolism of CCK<sub>8</sub> analogs by rat brain slices. *Neuropeptides* **7**:1–9.
- Durieux C, Coppey M, Zajac JM and Roques BP (1986b) Occurrence of two cholecystokinin binding sites in guinea pig brain cortex. *Biochem Biophys Res Commun* **137**:1167–1173.
- Durieux C, Corringier PJ, Bergeron F and Roques BP (1989) [<sup>3</sup>H]pBC 264, first highly potent and very selective radioligand for CCK-B receptors. *Eur J Pharmacol* **168**:269–270.
- Durieux C, Pélaprat D, Charpentier B, Morgat JL and Roques BP (1988) Characterization of [<sup>3</sup>H]CCK-4 binding sites in mouse and rat brain. *Neuropeptides* **12**:141–148.
- Durieux C, Ruiz-Gayo M, Corringier PJ, Bergeron F, Ducos B and Roques BP (1992) [<sup>3</sup>H]pBC264, a suitable probe for studying cholecystokinin-B receptors: Binding characteristics in rodent brains and comparison with [<sup>3</sup>H]SNF 8702. *Mol Pharmacol* **41**:1089–1095.
- Durieux C, Ruiz-Gayo M and Roques BP (1991) In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCK-B agonist [<sup>3</sup>H]pBC 264. *Eur J Pharmacol* **209**:185–193.
- Evans BE, Bock MG, Rittle KE, DiPardo RM, Whitter WL, Veber DF, Anderson PS and Freidinger RM (1986) Design of potent, orally effective, nonpeptidyl antagonists of the peptide hormone cholecystokinin. *Proc Natl Acad Sci USA* **83**:4918–4922.
- Faris PL, Komisaruk BR, Watkins LR and Mayer DJ (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. *Science (Wash DC)* **219**:310–312.
- Farmery SM, Owen F, Poulter M and Crow TJ (1985) Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. *Life Sci* **36**:473–477.
- Ferrier IN, Crow TJ, Farmery SM, Roberts GW, Owen F, Adrian TE and Bloom SR (1985) Reduced cholecystokinin levels in the limbic lobe in schizophrenia: A marker for pathology underlying the defect state? *Ann NY Acad Sci* **448**:495–506.
- Ferrier IN, Roberts GW, Crow TJ, Johnstone EC, Owens DG, Lee YC, O'Shaughnessy D, Adrian TE, Polak JM and Bloom SR (1983) Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. *Life Sci* **33**:475–482.
- Fincham CI, Higginbottom M, Hill DR, Horwell DC, O'Toole JC, Ratcliffe GS, Rees DC and Roberts E (1992a) Amide bond replacements incorporated into CCK-B selective "dipeptidols." *J Med Chem* **35**:1472–1484.
- Fincham CI, Horwell DC, Ratcliffe GS and Rees DC (1992b) The use of a proline ring as a conformational restraint in CCK-B receptor "dipeptidols." *Biomed Chem Lett* **2**:403–406.
- Floresco SB, Seamans JK and Philipps AG (1996) A selective role for dopamine in the nucleus accumbens of the rat in random foraging but not delayed spatial win-shift-based foraging. *Behav Brain Res* **80**:161–168.
- Fourmy D, Zahidi A, Gabre R, Guidet M, Praydayrol L and Ribet A (1987) Receptors for cholecystokinin and gastrin peptides display specific binding properties and are structurally different in guinea pig and dog pancreas. *Eur J Biochem* **165**:683–692.
- Fournié-Zaluski MC, Belleney J, Lux B, Durieux C, Gérard G, Gacel G, Maigret B and Roques BP (1986) Conformational analysis of neuronal cholecystokinin CCK<sub>26-33</sub> and related fragments by <sup>1</sup>H NMR spectroscopy, fluorescence transfer measurements and calculations. *Biochemistry* **25**:3778–3787.
- Fournié-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R and Roques BP (1992) Mixed-inhibitor-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. *J Med Chem* **35**:2474–2481.
- Freidinger RM (1989) Non-peptide ligands for peptide receptors. *Trends Pharmacol Sci* **10**:270–275.
- Galas MC, Bernard N and Martinez J (1992) Pharmacological studies on CCK-B receptors in guinea pig synaptoneurosomes. *Eur J Pharmacol* **226**:35–41.
- Galas MC, Lignon MF, Rodriguez M, Mendre C, Fulcrand P, Laur J and Martinez J (1988) Structure-activity relationship studies on cholecystokinin: Analogues with partial agonist activity. *Am J Physiol* **255**:G176–G182.
- Gall C, Lauterborn J, Burks D and Serogy K (1987) Co-localization of enkephalins and cholecystokinin in discrete areas of rat brain. *Brain Res* **403**:403–408.
- Gaudreau P, Quirion R, St-Pierre S and Pert C (1983) Characterization and visualization of cholecystokinin receptors in rat brain using [<sup>3</sup>H]pentagastrin. *Peptides* **4**:755–762.
- Gaudreau P, St. Pierre S, Pert CB and Quirion R (1985) Cholecystokinin receptors in mammalian brain: A comparative characterization and visualization. *Ann NY Acad Sci* **448**:198–219.
- Gelernter J, Kennedy JL, Van Tol HHM, Civelli O and Kidd KK (1992) The D4 dopamine receptor (DRD4) maps to distal 11p close to HRAS. *Genomics* **13**:208–210.
- Geraciotti TD, Nicholson WE, Orth DN, Ekhaton NN and Loosen PT (1993) Cholecystokinin in human cerebrospinal fluid: Concentrations, dynamics, molecular forms and relationship to fasting and feeding in health, depression and alcoholism. *Brain Res* **629**:260–268.
- Gerhardt P, Voits M, Fink H and Huston JP (1994) Evidence for mnemotropic action of cholecystokinin fragments Boc-CCK-4 and CCK-8S. *Peptides* **15**:689–697.
- Gerner RH and Yamada T (1982) Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. *Brain Res* **238**:298–302.
- Ghilardi JR, Allen CJ, Vigna SR, McVey DC and Mantyh PW (1992) Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit and monkey: Possible site of opiate-CCK analgesic interactions. *J Neurosci* **12**:4854–4866.
- Gibbs J, Young RC and Smith GP (1973) Cholecystokinin decreases food intake in rats. *J Comp Physiol Psychol* **84**:488–495.
- Go WY, Holicky EL, Hadac EM, Rao RV and Miller LJ (1998) Identification of a domain in the carboxy terminus of CCK receptor that affects its intracellular trafficking. *Am J Physiol* **275**:G56–G62.
- Goudreau N, Weng JH and Roques BP (1994) Conformational analysis of CCK-B agonists using <sup>1</sup>H-NMR and restrained molecular dynamics: Comparison of biologically active Boc-Trp-(NMe)Nle-Asp-Phe-NH<sub>2</sub> and inactive Boc-Trp-(NMe)Phe-Asp-Phe-NH<sub>2</sub>. *Biopolymers* **34**:155–159.
- Graff JM, Stumpo DJ and Blackshear PJ (1989) Characterization of the phosphorylation sites in the chicken and bovine myristoylated alanine-rich C kinase substrate protein, a prominent cellular substrate for protein kinase C. *J Biol Chem* **264**:11912–11919.
- Graham WC, Hill DR, Woodruff GN, Sambrook MA and Crossman AR (1991) Reduction of [<sup>125</sup>I]Bolton Hunter CCK8 and [<sup>3</sup>H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey. *Neurosci Lett* **131**:129–134.
- Guidotti A, Forchetti CM, Corda MG, Konkel D, Bennett CD and Costa E (1983) Isolation, characterization, and purification to homogeneity of an endogenous



- polypeptide with agonistic action on benzodiazepine receptors. *Proc Natl Acad Sci USA* **80**:3531–3535.
- Gully D, Fréhel D, Marcy C, Spinazze A, Lespy L, Neliat G, Maffrand JP and Le Fur G (1993) Peripheral biological activity of SR 27897: A new potent non-peptide antagonist of CCK-A receptors. *Eur J Pharmacol* **232**:13–19.
- Hansson AC, Andersson A, Tinner B, Cui X, Sommer W and Fuxe K (1998) Existence of striatal nerve cells coexpressing CCK<sub>B</sub> and D<sub>2</sub> receptor mRNAs. *Neuroreport* **9**:2035–2038.
- Harhammer R, Schafer U, Henklein P, Ott T and Repke H (1991) CCK-8-related C-terminal tetrapeptides: Affinities for central CCKB and peripheral CCKA receptors. *Eur J Pharmacol* **209**:263–266.
- Harper EA, Roberts SP, Shankley NP and Black JW (1996) Analysis of variation in L-365,260 competition curves in radioligand binding assays. *Br J Pharmacol* **118**:1717–1726.
- Harro J, Kivert RA, Lang A and Vasar E (1990) Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. *Behav Brain Res* **39**:63–71.
- Harro J and Orelund L (1993) Cholecystokinin receptors and memory: A radial maze study. *Pharmacol Biochem Behav* **44**:509–517.
- Harro J, Vasar E and Bradwejn J (1993) Cholecystokinin in animal and human research on anxiety. *Trends Pharmacol Sci* **14**:244–249.
- Hays SE, Beinfeld MC, Jensen RT, Goodwin FK and Paul SM (1980) Demonstration of a putative receptor site for cholecystokinin in the rat brain. *Neuropeptides* **1**:53–62.
- Helander HF, Wong H, Poorkhalkali N and Walsh JH (1997) Immunohistochemical localization of gastrin/CCK-B receptors in the dog and guinea pig stomach. *Acta Physiol Scand* **159**:313–320.
- Hendrie CA, Shepherd JK and Rodgers RJ (1989) Differential effects of the CCK antagonist, MK-329, on analgesia induced by morphine, social conflict (opioid) and defeat experience (non-opioid) in male mice. *Neuropharmacology* **28**:1025–1032.
- Henke BR, Aquino CJ, Birkemo LS, Croom DK, Dougherty RW, Ervin GN, Grizzle MK, Hirst GC, James MK, Johnson MF, Queen KL, Sherrill RG, Sugg EE, Suh EM, Szcwyzk JW, Unwalla RJ, Yingling J and Willson TM (1997) Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. *J Med Chem* **40**:2706–2725.
- Hernando F, Fuentes JA, Roques BP and Ruiz-Gayo M (1994) The CCK-B receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. *Eur J Pharmacol* **261**:257–263.
- Higginbottom M, Hill DR, Horwell DC, Mostafai E, Suman-Chauhan N and Roberts E (1993) Conformationally restricted analogs of the potent CCK-B antagonist CI-988. *Bioorg Med Chem* **1**:209–217.
- Hill DR, Campbell NJ, Shaw TM and Woodruff GN (1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide antagonists. *J Neurosci* **7**:2967–2976.
- Hill DR, Horwell DC, Hunter JC, Kneen CO, Pritchard MC and Suman-Chauhan N (1993) Synthesis of a potent and selective non-peptide CCK-B/gastrin receptor antagonist tritiated ligand. *Biomed Chem Lett* **3**:885–888.
- Hill DR, Shaw TM, Dourish CT and Woodruff GN (1988a) CCK-A receptors in the rat interpeduncular nucleus: Evidence for a presynaptic location. *Brain Res* **454**:101–105.
- Hill DR, Shaw TM, Graham W and Woodruff GN (1990) Autoradiographical detection of cholecystokinin-A receptors in primate brain using <sup>125</sup>I-Bolton Hunter CCK-8 and <sup>3</sup>H-MK-329. *J Neurosci* **10**:1070–1081.
- Hill DR, Shaw TM and Woodruff GN (1988b) Binding sites for <sup>125</sup>I-cholecystokinin in primate spinal cord are of the CCK-A subclass. *Neurosci Lett* **89**:133–139.
- Hill DR and Woodruff GN (1990) Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. *Brain Res* **526**:276–283.
- Himick BA, Vigna SR and Peter RE (1996) Characterization of cholecystokinin binding sites in goldfish brain and pituitary. *Am J Physiol* **271**:R137–R143.
- Hinks GL, Poat JA and Hughes J (1995) Changes in hypothalamic cholecystokininA and cholecystokininB receptor subtypes and associated neuropeptide expression in response to salt-stress in the rat and mouse. *Neuroscience* **68**:765–781.
- Hirst GC, Aquino C, Birkemo L, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Henke B, James MK, Johnson MF, Momtahan T, Queen KL, Sherrill RG, Szcwyzk J, Willson TM and Sugg EE (1996) Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. II: Optimization of the C3 amino substituent. *J Med Chem* **39**:5236–5245.
- Holladay MW, Bennett MJ, Tufano MD, Lin CW, Asin KE, Witte DG, Miller TR, Bianchi BR, Nikkel AL, Bednarz L and Nadzan AM (1992) Synthesis and biological activity of CCK heptapeptide analogs: Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo. *J Med Chem* **35**:2919–2928.
- Honda T, Wada E, Battay JF and Wank SA (1993) Differential gene expression of CCK<sub>A</sub> and CCK<sub>B</sub> receptors in the rat brain. *Mol Cell Neurosci* **4**:143–154.
- Horwell DC (1991) Development of CCK-B antagonists. *Neuropeptides* **19** (Suppl): 57–64.
- Horwell DC, Hughes J, Hunter JC, Pritchard MC, Richardson RS, Roberts E and Woodruff GN (1991) Rationally designed "dipeptid" analogs of CCK:  $\alpha$ -Methyl-tryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. *J Med Chem* **34**:404–414.
- Horwell DC, Hunter JC, Kneen CO and Pritchard MC (1995) Synthesis of novel iodinated radioligands with high affinity and selectivity for CCK-B/gastrin receptors. *Bioorg Med Chem Lett* **5**:2501–2506.
- Hobert JJ, Lobb KL, Brown RF, Reel JK, Neel DA, Mason NR, Mendelsohn LG, Hodgkiss JP and Kelly JS (1992) A novel series of non-peptide CCK and gastrin antagonists: Medicinal chemistry and electrophysiological demonstration of antagonism, in *Multiple Cholecystokinin Receptors: Progress Toward CNS Therapeutic Targets* (Dourish CT and Cooper SJ eds) pp 28–37, Oxford University Press, London.
- Höcker M, Hughes JJ, Fölsch UR and Schmidt WE (1993) PD-135,158, a CCK-B/gastrin receptor antagonist stimulates rat pancreatic enzyme secretion as CCK-A receptor agonist. *Eur J Pharmacol* **242**:105–108.
- Hökfelt T, Skirboll LR, Rehfeld JH, Goldstein M, Markey K and Dann O (1980) A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: Evidence from immunohistochemistry combined with retrograde tracing. *Neuroscience* **5**:2093–2142.
- Huang SC, Fortune KP, Wank SA, Kopin AS and Gardner JD (1994) Multiple affinity states of different cholecystokinin receptors. *J Biol Chem* **269**:26121–26126.
- Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD and Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. *Proc Natl Acad Sci USA* **87**:6728–6732.
- Hull RAD, Shankley NP, Harper EA, Gerskowitz VP and Black JW (1993) 2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP): A selective cholecystokinin CCK-A receptor antagonist. *Br J Pharmacol* **108**:734–740.
- Hunter JC, Suman-Chauhan N, Meecham KG, Dissanayake VUK, Hill DR, Pritchard MC, Kneen CO, Horwell DC, Hughes J and Woodruff GN (1993) [<sup>3</sup>H]PD 140376: A novel and highly selective antagonist radioligand for the cholecystokinin<sub>B</sub>/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. *Mol Pharmacol* **43**:595–602.
- Huppi K, Siwarski D, Pisegna JR and Wank S (1995) Chromosomal localization of the gastric and brain receptors for cholecystokinin (CCK-AR and CCK-BR) in human and mouse. *Genomics* **25**:727–729.
- Hyde TM and Peroutka SJ (1989) Distribution of cholecystokinin receptors in the dorsal vagal complex and other selected nuclei in the human medulla. *Brain Res* **495**:198–202.
- Innis RB, Bunney BS, Charney DS, Price LH, Glazer WM, Sternberg DE, Rubin AL and Heninger GR (1986) Does the cholecystokinin antagonist proglumide possess antipsychotic activity? *Psychiatry Res* **18**:1–7.
- Innis RB and Snyder SH (1980a) Cholecystokinin receptor binding in brain and pancreas: Regulation of pancreatic binding by cyclic and acyclic guanine nucleotides. *Eur J Pharmacol* **65**:123–124.
- Innis RB and Snyder SH (1980b) Distinct cholecystokinin receptors in brain and pancreas. *Proc Natl Acad Sci USA* **77**:6917–6921.
- Inoue H, Iannotti CA, Welling CM, Veile R, Donis-Keller H and Permutt MA (1997) Human cholecystokinin type A receptor gene: Cytogenetic localization, physical mapping, and identification of two missense variants in patients with obesity and non-insulin-dependent diabetes mellitus (NIDDM). *Genomics* **42**:331–335.
- Ito H, Sogabe H, Nakarai T, Sato Y, Tomoi M, Kadowaki M, Matsuo M, Tokoro K and Yoshida K (1994a) Pharmacological profile of FK-480, a novel cholecystokinin type-A receptor antagonist: Comparison to loxiglumide. *J Pharmacol Exp Ther* **268**:571–575.
- Ito M, Iwata N, Taniguchi T, Murayama T, Chihara K and Matsui T (1994b) Functional characterization of two cholecystokinin-B/gastrin receptor isoforms: A preferential splice donor site in the human receptor gene. *Cell Growth Differ* **5**:1127–1135.
- Ito M, Matsui T, Taniguchi T, Tsukamoto T, Murayama T, Arima N, Nakata H, Chiba T and Chihara K (1993) Functional characterization of human brain cholecystokinin-B receptor: A trophic effect of cholecystokinin and gastrin. *J Biol Chem* **268**:18300–18305.
- Ivy AC and Oldberg E (1928) A hormone mechanism for gallbladder contraction and evacuation. *Am J Physiol* **86**:599–613.
- Jagerschmidt A, Guillaume N, Goudreau N, Maigret B and Roques BP (1995) Mutation of Asp<sup>100</sup> in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction. *Mol Pharmacol* **48**:783–789.
- Jagerschmidt A, Guillaume N, Roques BP and Noble F (1998) Binding sites and transduction process of the cholecystokinin B receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis. *Mol Pharmacol* **53**:878–885.
- Jagerschmidt A, Guillaume-Rousselot N, Vickland ML, Goudreau N, Maigret B and Roques BP (1996) His<sup>381</sup> of the rat CCK<sub>B</sub> receptor is essential for CCK<sub>B</sub> versus CCK<sub>A</sub> receptor antagonist selectivity. *Eur J Pharmacol* **296**:97–106.
- Jagerschmidt A, Popovici T, O'Donohue M and Roques BP (1994) Identification and characterization of various cholecystokinin B receptor mRNA forms in rat brain tissue and partial determination of the cholecystokinin B receptor gene structure. *J Neurochem* **63**:1199–1206.
- Jensen RT, Qian JM, Lin JT, Mantey SA, Pisegna JR and Wank SA (1994) Distinguishing multiple CCK receptor subtypes: Studies with guinea pig chief cells and transfected human CCK receptors. *Ann NY Acad Sci* **713**:88–106.
- Jensen RT, Wank SA, Rowley WH, Sato S and Gardner JD (1989) Interaction of CCK with pancreatic acinar cells. *Trends Pharmacol Sci* **10**:418–423.
- Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP and Miller LJ (1997) Direct identification between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. *J Biol Chem* **272**:24393–24401.
- Jorpes JE and Mutt V (1966) Cholecystokinin and pancreozymin: One single hormone? *Acta Physiol Scand* **66**:196.
- Katsuura G and Itoh S (1986) Passive avoidance deficit following intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats. *Peptides* **7**:809–814.
- Katzman M, Bradwejn J, Koszycki D, Vaccarino F and Richter M (1997) The effect of CCK-4 in social phobia and OCD. American Psychiatry Association's 150th Annual Meeting, May 17–22, 1997, San Diego, Washington, DC: American Psychiatry Association;105 p.
- Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosuni M and Natori T (1992) Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. *Diabetes* **41**:1422–1428.
- Kellner M, Yassouridis A, Jahn H and Wiedemann K (1997) Influence of clonidine on

- psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. *Psychopharmacology* **133**:55–61.
- Kenakin T (1995) Agonist-receptor efficacy. II: Agonist trafficking of receptor signals. *Trends Pharmacol Sci* **16**:232–238.
- Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, Vincent J and Fourie O (1999) Investigation of cholecystokinin system genes in panic disorder. *Mol Psychiatry* **4**:284–285.
- Kennedy K, Gigoux G, Escriveau C, Mairret B, Martinez J, Moroder L, Frehel D, Gully D, Vaysse N and Fourmy D (1997) Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin. *J Biol Chem* **272**:2920–2926.
- Kiraly I and Van Ree JM (1987) Behavioral evidence for the involvement of endogenous opioids in the interaction between cholecystokinin and brain dopamine systems. *Neurosci Lett* **74**:343–347.
- Klueppelberg UG, Molero X, Barrett RW and Miller LJ (1990) Biochemical characterization of the cholecystokinin receptor on CHP212 human neuroblastoma cells. *Mol Pharmacol* **38**:159–163.
- Knapp RJ, Vaughn LK, Fang SN, Bogert CL, Yamamura MS, Hruby VJ and Yamamura HI (1990) A new, highly selective CCK-B receptor radioligand ( $^3\text{H}$ )[N-methyl-Nle $^{28,31}$ ]CCK $_{26-33}$ ): Evidence for CCK-B receptor heterogeneity. *J Pharmacol Exp Ther* **255**:1278–1286.
- Kobayashi S, Ohta M, Miyasaka K and Funakoshi A (1996) Decrease in exploratory behavior in naturally occurring cholecystokinin (CCK)-A receptor gene knockout rats. *Neurosci Lett* **214**:61–64.
- Koks S, Vasar E, Soosaar A, Lang A, Volke V, Voikar V, Bourin M and Mannisto PT (1997) Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. *Eur Neuropsychopharmacol* **7**:289–294.
- Kolodziej SA, Nikiforovich GV, Skeeam R, Lignon MF, Martinez J and Marshall GR (1995) Ac-[3- and 4-alkylthioproline $^{31}$ ]-CCK $_4$  analogs: Synthesis, and implication for the CCK-B receptor-bound conformation. *J Med Chem* **38**:137–149.
- Kopin AS, Lee YM, McBride EW, Miller LJ, Lu M, Lin HY, Kolakowski LF and Beinborn M (1992) Expression, cloning and characterization of the canine parietal cell gastrin receptor. *Proc Natl Acad Sci USA* **89**:3605–3609.
- Kopin AS, McBride EW, Quinn SM, Kolakowski LF and Beinborn M (1995) The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands. *J Biol Chem* **270**:5019–5023.
- Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, Shrivastava R, Matsuura-Wolfe D, Lines C and Reines S (1995) A placebo-controlled trial of L-365,260, a CCK-B antagonist, in panic disorder. *Biol Psychiatry* **37**:462–466.
- Kritzer MF, Innis RB and Goldman-Rakic PS (1988) Regional distribution of cholecystokinin receptors in primate cerebral cortex determined by in vitro receptor autoradiography. *J Comp Neurol* **263**:418–435.
- Kritzer MF, Innis RB and Goldman-Rakic PS (1990) Regional distribution of cholecystokinin binding sites in macaque basal ganglia determined by in vitro receptor autoradiography. *Neuroscience* **38**:81–92.
- Kuehl-Kovarik MC, Ross LR, Elmquist JK and Jacobson CD (1993) Localization of cholecystokinin binding sites in the adult and developing Brazilian opossum brain. *J Comp Neurol* **336**:40–52.
- Lacourse KA, Lay JM, Swanberg LJ, Jenkins C and Samuelson LC (1997) Molecular structure of the mouse CCK-A receptor gene. *Biochem Biophys Res Commun* **236**:630–635.
- Ladurelle N, Keller G, Blommaert A, Roques BP and Daugé V (1997) The CCK-B agonist, BC 264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after peripheral intraperitoneal injection in rats. *Eur J Neurosci* **9**:1804–1814.
- Ladurelle N, Keller G, Roques BP and Daugé V (1993) Effects of CCK $_8$  and of the CCK-B selective agonist BC 264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: A microdialysis study in freely moving rats. *Brain Res* **628**:254–262.
- Lallement JC, Oiry C, Lima-Leite AC, Lignon MF, Fulcrand P, Galleyrand JC and Martinez J (1995) Cholecystokinin and gastrin are not equally sensitive to GTPyS at CCK-B receptors: Importance of the sulphated tyrosine. *Eur J Pharmacol* **290**:61–67.
- Langhans N, Rindi G, Chiu M, Rehfeld JF, Ardman B, Beinborn M and Kopin AS (1997) Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. *Gastroenterology* **112**:280–286.
- Lavigne GJ, Millington WR and Mueller GP (1992) The CCK-A and CCK-B receptors antagonists devazepide and L-365,260 enhance morphine antinociception only in non-acclimated rats exposed to novel environment. *Neuropeptides* **21**:119–129.
- Le Melleo JM, Bradwejn J, Koszycki D and Bichet D (1995) Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. *Arch Gen Psychiatry* **52**:605–606.
- Le Melleo JM, Bradwejn J, Koszycki D, Bichet F and Bellavance F (1998) The role of beta adrenergic system in CCK-4 induced panic symptoms. *Biol Psychiatry* **23**:298–304.
- Lee YM, Beinborn M, McBride EW, Lu M, Kolakowski LF and Kopin AS (1993) The human brain cholecystokinin-B/gastrin receptor: Cloning and characterization. *J Biol Chem* **268**:8164–8169.
- Lemaire M, Barneoud P, Böhme GA, Piot O, Haun F, Roques BP and Blanchard JC (1994) CCK-A and CCK-B receptor agonists and antagonists modulate olfactory recognition in male rats. *Psychopharmacology* **115**:435–440.
- Lemaire M, Piot O, Roques BP, Böhme AG and Blanchard JC (1992) Evidence for an endogenous cholecystokininergic balance in social memory. *Neuroreport* **3**:925–932.
- Liddle RA, Goldfine ID and Williams JA (1984) Bioassay of plasma cholecystokinin in rats: Effects of food, trypsin inhibitor, and alcohol. *Gastroenterology* **87**:542–549.
- Lignon MF, Galas MC, Rodriguez M, Laur J, Aumelas A and Martinez J (1987) A synthetic peptide derivative that is a cholecystokinin receptor antagonist. *J Biol Chem* **262**:7226–7231.
- Lin CW and Miller T (1985) Characterization of cholecystokinin receptor sites in guinea pig cortical membranes using [ $^{125}\text{I}$ ]Bolton Hunter-cholecystokinin octapeptide. *J Pharmacol Exp Ther* **232**:775–780.
- Lin CW, Shiosaki K, Miller TR, Witte DG, Bianchi BR, Wolfram CA, Kopecka H, Craig R, Wagenaar F and Nadzan AM (1991) Characterization of two novel cholecystokinin tetrapeptide (30-33) analogs, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. *Mol Pharmacol* **39**:346–351.
- Lines C, Challenor J and Traub M (1995) Cholecystokinin and anxiety in normal volunteers: An investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype CCK-B antagonist, L-365,260. *Br J Pharmacol* **39**:235–242.
- Lo WWY and Hughes J (1988) Differential regulation of cholecystokinin- and muscarinic-receptor-mediated phosphoinositide turnover in flow 900 cells. *Biochem J* **251**:625–630.
- Löfberg C, Agren H, Harro J and Oreland L (1998) Cholecystokinin in CSF from depressed patients: Possible relations to severity of depression and suicidal behaviour. *Eur Neuropsychopharmacol* **8**:153–157.
- Logsdon CD (1986) Glucocorticoids increase cholecystokinin receptors and amylase secretion in pancreatic acinar AR42J cells. *J Biol Chem* **261**:2096–2101.
- Lopez Y, Fioramonti J and Bueno L (1991) Central and peripheral control of post-prandial pyloric motility by endogenous opiates and CCK in dogs. *Gastroenterology* **101**:1249–1255.
- Lotti VJ and Chang RSL (1989) A new potent and selective non peptide gastrin antagonist and brain CCK-B ligand: L-365,260. *Eur J Pharmacol* **162**:273–280.
- Lowe JA, Drozda SE, McLean S, Bryce DK, Crawford RT, Zorn S, Morrone J, Appleton TA and Lombardo FA (1995) Water soluble benzodiazepine cholecystokinin-B receptor antagonist. *Bioorg Med Chem Lett* **5**:1933–1936.
- Maddes PCJ and King JS (1994) Distribution of cholecystokinin binding sites in the North American opossum cerebellum. *J Chem Neuroanat* **7**:105–112.
- Magnuson DSK, Sullivan AF, Simonnet G, Roques BP and Dickenson AH (1990) Differential interactions of cholecystokinin and FLFQPQR-NH $_2$  with  $\mu$  and  $\delta$  opioid antinociception in the rat spinal cord. *Neuropeptides* **16**:213–218.
- Makovec F, Chiste R, Bani M, Pacini MA, Setnikar I and Rovati LA (1985) New glutamic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity. *Arzneimittelforschung* **35**:1048–1051.
- Makovec F and D'Amato M (1997) CCK-B/gastrin receptor antagonists as potential drugs for peptic ulcer therapy. *Drug Discov Today* **2**:283–293.
- Maldonado R, Valverde O, Ducos B, Blommaert AG, Fournié-Zaluski MC and Roques BP (1995) Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCK-B antagonist PD-134,308. *Br J Pharmacol* **114**:1031–1039.
- Mantamadiotis T and Baldwin GS (1994) The seventh trans-membrane domain of gastrin/CCK receptors contributes to non-peptide antagonist binding. *Biochem Biophys Res Commun* **201**:1382–1389.
- Mantyh CR and Mantyh PW (1985) Differential localization of cholecystokinin-8 binding sites in the rat vs. the guinea pig brain. *Eur J Pharmacol* **113**:137–139.
- Mantyh CR, Pappas TN and Vigna SR (1994) Localization of cholecystokinin A and cholecystokinin B/gastrin receptors in the canine upper gastrointestinal tract. *Gastroenterology* **107**:1019–1030.
- Marino CR, Leach SD, Schaefer JF, Miller LJ and Gorelick FS (1993) Characterization of cAMP-dependent protein kinase activation by CCK in rat pancreas. *FEBS Lett* **316**:48–52.
- Marseigne I, Dor A, Bégué D, Reibaud M, Zundel JL, Blanchard JC, Pélaprat D and Roques BP (1988) Synthesis and biological activity of CCK $_{26-33}$ -related analogs modified in position 31. *J Med Chem* **31**:966–970.
- Marseigne I, Roy P, Dor A, Durieux C, Pélaprat D, Reibaud M, Blanchard JC and Roques BP (1989) Full agonists of CCK-8 containing a nonhydrolyzable sulfated tyrosine residue. *J Med Chem* **32**:445–449.
- Martin-Martinez M, Bartolomé-Nebreda JM, Gomez-Monterrey I, Gonzalez-Muniz R, Garcia-Lopez MT, Ballaz S, Barber A, Fortuno A, Del Rio J and Herranz R (1997) Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydroprido[1,2-c]pyrimidine derivatives: Potent and selective cholecystokinin-A receptor antagonists. *J Med Chem* **40**:3402–3407.
- McCann UD, Slate SO, Geraci M and Uhde TW (1994) Peptides and anxiety: A dose-response evaluation of pentagastrin in healthy volunteers. *Anxiety* **1**:258–267.
- Meister B, Broberger C, Villar MJ and Hökfelt T (1994) Cholecystokinin B receptor gene expression in hypothalamic neurosecretory neurons after experimental manipulations. *Neuroendocrinology* **60**:458–469.
- Menozi D, Gardner JD and Maton PN (1989) Properties of receptors for gastrin and CCK on gastric smooth muscle cells. *Am J Physiol* **257**:G73–G79.
- Mercer JG and Lawrence CB (1992) Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve. *Neurosci Lett* **137**:229–231.
- Mercer LD and Beart PM (1997) Histochemistry in rat brain and spinal cord with an antibody directed at the cholecystokinin $_A$  receptor. *Neurosci Lett* **225**:97–100.
- Mercer LD, Beart PM, Horne MK, Finkelstein DI, Carrive P and Paxinos G (1996) On the distribution of cholecystokinin B receptors in monkey brain. *Brain Res* **738**:313–318.
- Miceli MO and Steiner M (1989) Novel localizations of central- and peripheral-type cholecystokinin binding sites in Syrian hamster brain as determined by autoradiography. *Eur J Pharmacol* **169**:215–224.
- Migaud M, Durieux C, Viereck J, Soroca-Lucas E, Fournié-Zaluski MC and Roques BP (1996) The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A. *Peptides* **17**:601–607.
- Migaud M, Roques BP and Durieux C (1995) Evidence for a high affinity uptake system for cholecystokinin octapeptide (CCK8) in rat cortical synaptosomes. *Eur J Neurosci* **7**:1074–1079.
- Miller LJ (1984) Characterization of cholecystokinin receptors on human gastric smooth muscle tumors. *Am J Physiol* **247**:G402–G410.

- Miller LJ, Holicky E, Ulrich CD and Wieben ED (1995) Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. *Gastroenterology* **109**:1375–1380.
- Million ME, Léna I, Da Nascimento S, Noble F, Daugé V, Garbay C and Roques BP (1997) Development of new potent agonists able to interact with two postulated subtypes of the cholecystokinin CCK-B receptor. *Lett Peptide Sci* **4**:407–410.
- Miyake A (1995) A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon. *Biochem Biophys Res Commun* **208**:230–237.
- Montgomery SA and Green MC (1988) The use of cholecystokinin in schizophrenia: a review. *Psychol Med* **18**:593–603.
- Moons L, Batten TF and Vandesande F (1992) Comparative distribution of substance P (SP) and cholecystokinin (CCK) binding sites and immunoreactivity in the brain of the sea bass (*Dicentrarchus labrax*). *Peptides* **13**:37–46.
- Moran TH, Ameglio PJ, Peyton HJ, Schwartz GJ and McHugh PR (1993) Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys. *Am J Physiol* **265**:R620–R624.
- Moran TH, Ameglio PJ, Schwartz GJ and McHugh PR (1992) Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK. *Am J Physiol* **262**:R46–R50.
- Moran TH and McHugh PR (1988) Anatomical and pharmacological differentiation of pyloric, vagal and brainstem cholecystokinin receptors, in *Cholecystokinin Antagonists* (Wang RY and Schoenfeld R eds) pp 117–132. Alan R. Liss, New York.
- Moran TH, Norgren R, Crosby RJ and McHugh PR (1990) Central and peripheral transport of vagal cholecystokinin binding sites occurs in afferent fibers. *Brain Res* **362**:175–179.
- Moran TH, Robinson PH, Goldrich MS and McHugh PR (1986) Two brain cholecystokinin receptors: Implications for behavioral actions. *Brain Res* **362**:175–179.
- Moran TH, Smith GP, Hostetler AM and McHugh PR (1987) Transport of cholecystokinin (CCK) binding sites in subdiaphragmatic vagal branches. *Brain Res* **415**:149–152.
- Morency MA, Quirion R and Mishra RK (1994) Distribution of cholecystokinin receptors in the bovine brain: A quantitative autoradiographic study. *Neuroscience* **62**:307–316.
- Mueller K and Whiteside DA (1990) Enkephalin prevents CCK-induced enhancement of amphetamine-induced locomotor stereotypy. *Brain Res* **513**:119–124.
- Müller S and Lohse MJ (1995) The role of G-protein beta gamma subunits in signal transduction. *Biochem Soc Trans* **23**:141–148.
- Munro G, Pumford KM and Russell JA (1998) Altered cholecystokinin binding density in the supraoptic nucleus of morphine-tolerant and -dependent rats. *Brain Res* **780**:190–198.
- Nadzan AM, Garvey DS, Holladay MW, Shiosaki K, Tufano MD, Shue YK, Chung JYL, May PD, May GS, Lin CW, Miller TR, Witte DG, Bianchi BR, Wolfram CAW, Burt S and Hutchins GW (1991) Design of cholecystokinin analogs with high affinity and selectivity for brain receptors, in *Peptides: Chemistry and Biology. Proceedings of the 12th American Peptide Symposium June 16–21, 1991, Cambridge, MA* (Smith JA and Rivier JE eds) pp 101–102, ESCOM, Leiden.
- Nagata A, Ito M, Iwata N, Kuno J, Takano H, Minowa O, Chihara K, Matsui T and Noda T (1996) G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. *Proc Natl Acad Sci USA* **93**:11825–11830.
- Nakata H, Matsui T, Ito M, Taniguchi T, Naribayashi Y, Arima N, Nakamura A, Kinoshita Y, Chihara K, Hosoda S and Chiba T (1992) Cloning and characterization of gastrin receptor from ECL carcinoid tumor of *Mastomys natalensis*. *Biochem Biophys Res Commun* **187**:1151–1157.
- Niehoff DL (1989) Quantitative autoradiographic localization of cholecystokinin receptors in rat and guinea pig brain using <sup>125</sup>I-Bolton-Hunter CCK8. *Peptides* **10**:265–274.
- Nishida A, Miyata K, Tsutsumi R, Yuki H, Akuzawa S, Kobayashi A, Kamato T, Ito H, Yamano M, Katuyama Y, Satoh M, Ohta M and Honda K (1994) Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methyl-phenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. *J Pharmacol Exp Ther* **269**:725–731.
- Noble F, Derrien M and Roques BP (1993) Modulation of opioid analgesia by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. *Br J Pharmacol* **109**:1064–1070.
- O'Dowd B, Hnatowich M, Caron MG, Lefkowitz RJ and Bouvier M (1988) Site-directed mutagenesis of the cytoplasmic domains of the human  $\beta$ -2 adrenergic receptor: Localization of regions involved in G-protein-receptor coupling. *J Biol Chem* **264**:7564–7569.
- O'Neill MF, Dourish CT and Iversen SD (1991) Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCK-A receptor antagonist devazepide but not by the CCK-B receptor antagonist L-365,260. *Eur J Pharmacol* **193**:203–208.
- O'Shea RD and Gundlach AL (1995) Activity-linked alterations in cholecystokinin-B receptor messenger RNA levels in magnocellular hypothalamic neurones by food and water deprivation in the rat. *Neurosci Lett* **194**:189–192.
- Oliver AS and Vigna SR (1996) CCK-X receptors in the endothermic mako shark (*Isurus oxyrinchus*). *Gen Comp Endocrinol* **102**:61–73.
- Ondetti MA, Rubin B, Engel SL, Plusec J and Sheehan JT (1970) Cholecystokinin-pancreozymin. Recent developments. *Am J Dig Dis* **15**:149–156.
- Ovchinnikov YA, Ablulajew NG and Bogachuk AS (1988) Two adjacent cysteine residues in the C-terminal cytoplasmic fragment of bovine rhodopsin are palmitoylated. *FEBS Lett* **230**:1–5.
- Ozelebi F and Miller LJ (1995) Phosphopeptide mapping of cholecystokinin receptors on agonist-stimulated native pancreatic acinar cells. *J Biol Chem* **270**:3435–3441.
- Padia JK, Chilvers H, Daum P, Pinnock R, Suman-Chauhan N, Webdale L and Trivedi BK (1997) Design and synthesis of novel nonpeptide CCK-B receptor antagonists. *Bioorg Med Chem Lett* **7**:805–810.
- Padia JK, Field M, Hinton J, Meecham K, Pablo J, Pinnock R, Roth BD, Singh L, Suman-Chauhan N, Trivedi BK and Webdale L (1998) Novel nonpeptide CCK-B antagonists: Design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists. *J Med Chem* **41**:1042–1049.
- Palmour RM, Durieux C, Roques BP, Bertrand P, Capet M, Dubroeuq MC, Howbert JJ, Woodruff G, Bradwejn J and Ervin FR (1993) Anxiogenic effects of CCK agonists in a non-human primate model: Central or peripheral. CCK 1993: International Symposium; 1993 May 19–22; Chatham, Massachusetts.
- Pandolfi SJ, Hsu Y, Kondratenko NF, Schoeffield-Payne MS and Steinbach JH (1991) Dual pathways for agonist-stimulated arachidonic acid release in pancreatic acini: Roles in secretion. *Am J Physiol* **260**:G423–G433.
- Pandolfi SJ, Schoeffield MS, Sachs G and Muallem S (1985) Role of free cytosolic calcium in secretagogue-stimulated amylase release from dispersed acini from guinea pig pancreas. *J Biol Chem* **260**:10081–10086.
- Pang IK and Sternweiss PC (1990) Purification of unique  $\alpha$  subunits of GTP-binding regulatory proteins (G proteins) by affinity chromatography with immobilized  $\beta$  subunits. *J Biol Chem* **265**:18707–18712.
- Patel S, Smith AJ, Chapman KL, Fletcher AE, Kemp JA, Marshall GR, Hargreaves RJ, Rycroft W, Iversen LL, Iversen SD, Baker R, Showell GA, Bourrain S, Neduvetil JG, Matassa VG and Freedman SB (1994) Biological properties of the benzodiazepine amide derivative L-740,093, a cholecystokinin- $\beta$ /gastrin receptor antagonist with high affinity in vitro and high potency in vivo. *Mol Pharmacol* **46**:943–948.
- Payeur R, Nixon MK, Bourin M, Bradwejn J and Legrand JM (1993) The potential role of cholecystokinin in schizophrenia: Review and update. *Eur Psychiatry* **8**:67–78.
- Pearson RK and Miller LJ (1987) Affinity labeling of a novel cholecystokinin-binding protein in rat pancreatic plasmalemma using new short probes for the receptor. *J Biol Chem* **262**:869–876.
- Pearson RK, Miller LJ, Hadac EM and Powers SP (1987a) Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor. *J Biol Chem* **262**:13850–13856.
- Pearson RK, Miller LJ, Powers SP and Hadac EM (1987b) Biochemical characterization of the pancreatic cholecystokinin receptor using monofunctional photoactivatable probes. *Pancreas* **2**:79–84.
- Pendley CE, Fitzpatrick LR, Capolino AJ, Davis MA, Esterline NJ, Jakubowska A, Bertrand P, Guyon C, Dubroeuq MC and Martin GE (1995) RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat. *J Pharmacol Exp Ther* **273**:1015–1022.
- Pélaprat D, Broer Y, Studler JM, Peschanski M, Tassin JP, Glowinski J, Rostène W and Roques BP (1987) Autoradiography of CCK receptors in the rat brain using [<sup>3</sup>H]Boc[Nle<sub>28,31</sub>]CCK<sub>27-33</sub> and [<sup>125</sup>I]Bolton-Hunter CCK<sub>8</sub>. *Neurochem Int* **10**:495–508.
- Pi-Sunyer X, Kissileff HR, Thornton J and Smith GP (1982) C-terminal octapeptide of cholecystokinin decreases food intake in obese men. *Physiol Behav* **29**:627–630.
- Pierson ME, Comstock JM, Simmons RD, Kaiser F, Julien R, Zongrone J and Rosamond JD (1997) Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents. *J Med Chem* **40**:4302–4307.
- Piiper A, Stryjek-Kaminska D, Klengel R and Zeuzem S (1997) CCK, carbachol, and bombesin activate distinct PLC-beta isoenzymes via Gq/11 in rat pancreatic acinar membranes. *Am J Physiol* **272**:G135–G140.
- Pisegna JR, de Weerth A and Wank SA (1992) Molecular cloning of the human brain and gastric cholecystokinin receptor: Structure, functional expression and chromosomal localization. *Biochem Biophys Res Commun* **189**:296–303.
- Ploeger GE, Spruijt BM and Cools AR (1994) Spatial localization in the Morris water maze in rats: Acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol. *Behav Neurosci* **108**:927–934.
- Pohl M, Benoliel JJ, Bourgoin S, Lombard MC, Mauborgne A, Taquet H, Carayon A, Besson JM, Cesselin F and Hamon M (1990) Regional distribution of calcitonin gene-related peptide-, substance P-, cholecystokinin-, Met<sup>5</sup>-enkephalin-, and dynorphin A (1–8)-like materials in the spinal cord and dorsal root ganglia of adult rats: Effects of dorsal rhizotomy and neonatal capsaicin. *J Neurochem* **55**:1122–1130.
- Pohl M, Silvente-Poirot S, Pisegna JR, Tarasova NI and Wank SA (1997) Ligand-induced internalization of cholecystokinin receptors. *J Biol Chem* **272**:18179–18184.
- Pommier B, Da Nascimento S, Dumont S, Bellier B, Million E, Garbay C, Roques BP and Noble F (1999) The CCK-B receptor is coupled to two effector pathways through pertussis toxin sensitive and insensitive G proteins. *J Neurochem* **73**:281–288.
- Powers SP, Foo I, Pinon D, Klueppelberg UG, Hedstrom JF and Miller LJ (1991) Use of photoaffinity probes containing polyethyleneglycol spacers for topographical mapping of the cholecystokinin receptor complex. *Biochemistry* **30**:676–682.
- Praissman M, Martinez PA, Saladino CF, Berkowitz JM, Stegless AW and Finkelshtajn JA (1983) Characterization of cholecystokinin binding sites in rat cerebral cortex using a <sup>125</sup>I-CCK-8 probe resistant to degradation. *J Neurochem* **40**:1406–1413.
- Qian M, Johnson AE, Kallstrom L, Carrer H and Sodersten P (1997) Cholecystokinin, dopamine D2 and N-methyl-D-aspartate binding sites in the nucleus of the solitary tract of the rat: Possible relationship to ingestive behavior. *Neuroscience* **77**:1077–1089.
- Rao RV, Roettger BF, Hadac EM and Miller LJ (1997) Roles of cholecystokinin receptor phosphorylation in agonist-stimulated desensitization of pancreatic acinar cells and receptor-bearing Chinese hamster ovary cholecystokinin receptor cells. *Mol Pharmacol* **51**:185–192.
- Ratray M and De Belleruche J (1987) Morphine action on cholecystokinin octapeptide release from rat periaqueductal grey slices: Sensitization by naloxone. *Neuropeptides* **10**:189–200.
- Rehfeld JH and Nielsen FC (1995) Molecular forms and regional distribution of cholecystokinin in the central nervous system, in *Cholecystokinin and Anxiety* (Bradwejn J and Vasar E eds) pp 33–56, RG Landes Company, Austin.
- Reidelberger RD, Varga G and Solomon TE (1991) Effects of selective cholecysto-

- nin antagonists L364,718 and L365,260 on food intake in rats. *Peptides* **12**:1215–1221.
- Reuben M, Rising L, Prinz C, Hersey S and Sachs G (1994) Cloning and expression of the rabbit gastric CCK-A receptor. *Biochim Biophys Acta* **1219**:321–327.
- Reubi JC, Schaefer JC and Waser B (1997a) Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. *Cancer Res* **57**:1377–1386.
- Reubi JC and Waser B (1996) Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. *Int J Cancer* **67**:644–647.
- Reubi JC, Waser B, Laderach U, Stettler C, Friess H, Halter F and Schmassmann A (1997b) Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. *Gastroenterology* **112**:1197–1205.
- Roche S, Bali JP and Magous R (1990) Involvement of a pertussis toxin-sensitive G protein in the action of gastrin on gastric parietal cells. *Biochim Biophys Acta* **1055**:287–294.
- Rodriguez M, Lignon MF, Galas MC, Amblard M and Martinez J (1990) Cyclic cholecystokinin analogs that are highly selective for rat and guinea pig central cholecystokinin receptors. *Mol Pharmacol* **38**:333–341.
- Rodriguez RE and Sacristan MP (1989) In vivo release of CCK-8 from the dorsal horn of the rat: Inhibition by DAGOL. *FEBS Lett* **250**:215–217.
- Roques BP and Noble F (1996) Association of enkephalin catabolism inhibitors and CCK-B antagonists: A potential use in the management of pain and opioid addiction. *Neurochem Res* **21**:1395–1409.
- Roques BP, Noble F, Daugé V, Fournié-Zaluski MC and Beaumont A (1993) Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. *Pharmacol Rev* **45**:87–146.
- Rose C, Vargas F, Facchinetti P, Bourgeat P, Bambal RB, Bishop PB, Chan SMT, Moore ANJ, Ganellin CR and Schwartz JC (1996) Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. *Nature (Lond)* **380**:403–409.
- Rosenzweig SA, Miller LJ and Jamieson JD (1983) Identification and localization of cholecystokinin-binding sites on rat pancreatic plasma membranes and acinar cells: A biochemical and autoradiographic study. *J Cell Biol* **96**:1288–1297.
- Ruiz-Gayo M, Daugé V, Menant I, Bégué D, Gacel G and Roques BP (1985) Synthesis and biological activity of Boc(Nle28,Nle31)CCK27-33 a highly potent CCK8 analog. *Peptides* **6**:415–420.
- Ruiz-Gayo M, Delay-Goyet P, Durieux C, Corringier PJ, Baamonde A, Gacel G and Roques BP (1990) Investigation of opioid and cholecystokinin central receptors after peripheral injection of selective and enzyme-resistant peptides. *J Control Release* **13**:147–155.
- Ruiz-Gayo M, Durieux C, Fournié-Zaluski MC and Roques BP (1992) Stimulation of  $\delta$  opioid receptors reduces the in vivo binding of the CCK-B selective agonist [ $^3$ H]BC264: Evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. *J Neurochem* **59**:1805–1811.
- Sacerdote P, Wiedermann CJ, Wahl LM, Pert CB and Ruff MR (1991) Visualization of cholecystokinin receptors on a subset of human monocytes and in rat spleen. *Peptides* **12**:167–176.
- Saito AH, Sankaran H, Goldfine ID and Williams JA (1980) Cholecystokinin receptors in the brain: Characterization and distribution. *Science (Wash DC)* **208**:1155–1156.
- Sandvik AK and Waldum HL (1991) CCK-B (gastrin) receptor regulates gastric histamine release and acid secretion. *Am J Physiol* **260**:G925–G928.
- Sankaran H, Deveney CW, Godfine ID and Williams JA (1979) Preparation of biologically active radioiodinated cholecystokinin for radioreceptor assay and radioimmunoassay. *J Biol Chem* **254**:9349–9351.
- Sankaran H, Goldfine ID, Deveney CW, Wong KY and Williams JA (1980) Binding of cholecystokinin to high affinity receptors on isolated rat pancreatic acini. *J Biol Chem* **255**:11849–11853.
- Satoh Y, Matsuo T, Sogabe H, Itoh H, Tada T, Kinoshita T, Yoshida K and Takaya T (1994) Studies on a novel, potent and orally effective cholecystokinin A antagonist, FK480: Synthesis and structure-activity relationships of FK480 and related compounds. *Chem Pharm Bull (Tokyo)* **42**:2071–2083.
- Schalling M, Friberg K, Seroogy K, Riederer P, Bird E, Schiffmann SN, Mailleux P, Vanderhaeghen JJ, Kuga S and Goldstein M (1990) Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. *Proc Natl Acad Sci USA* **87**:8427–8431.
- Schiffmann SN, Goldman S, Heyman P, De Vuyst M, De Roy G and Vanderhaeghen JJ (1992) Ontogeny of cholecystokinin receptors in the human striatum. *Neurosci Lett* **141**:39–42.
- Schjoldager B, Shaw MJ, Powers SA, Schmalz PH, Szurszewski J and Miller LJ (1988) Bovine gallbladder muscularis: Source of a myogenic receptor for cholecystokinin. *Am J Physiol* **254**:G294–G299.
- Schmitz F, Pratt DS, Wu M-J, Kolakowski LF, Beinborn M and Kopin AS (1996) Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: Utilization of a novel *Xenopus laevis* cholecystokinin receptor. *Mol Pharmacol* **50**:436–441.
- Schreiber H, Stolz-Born G, Pietrowsky R, Kornhuber HH, Fehm HL and Born J (1995) Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons. *Biol Psychiatry* **37**:702–712.
- Schubert ML and Shamburek RD (1990) Control of acid secretion. *Gastroenterol Clin North Am* **19**:1–25.
- Sebret A, Léna I, Crété D, Matsui T, Roques BP and Daugé V (1999) Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation. *J Neurosci* **19**:7230–7237.
- Sekiguchi R and Moroji T (1986) A comparative study on characterization and distribution of cholecystokinin binding sites among the rat, mouse and guinea pig brain. *Brain Res* **399**:271–281.
- Semple G, Ryder H, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S and Miyata K (1996a) Synthesis and biological activity of 1-alkylcarbonyl methyl analogs of YM 022. *Bioorg Med Chem Lett* **6**:51–54.
- Semple G, Ryder H, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S and Miyata K (1996b) Synthesis and biological activity of 5-heteroaryl benzodiazepines: Analogues of YM 022. *Bioorg Med Chem Lett* **6**:55–59.
- Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S and Miyata K (1997) (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist. *J Med Chem* **40**:331–341.
- Sethi T, Herget T, Wu SV, Walsh JH and Rozengurt E (1993) CCKA and CCKB receptors are expressed in small cell lung cancer lines and mediate Ca<sup>2+</sup> mobilization and clonal growth. *Cancer Res* **53**:5208–5213.
- Shaw MJ, Madac EM and Miller LJ (1987) Preparation of enriched plasma membranes from bovine gallbladder muscularis for characterization of cholecystokinin receptors. *J Biol Chem* **262**:14313–14318.
- Sherrington R, Mankoo B, Attwood J, Kalsi G, Curtis D, Buetow K, Povey S and Gurling H (1993) Cloning of the human dopamine D5 receptor gene and identification of a highly polymorphic microsatellite for the DRD5 locus that shows tight linkage to the chromosome 4p reference marker RAF1P1. *Genomics* **18**:423–425.
- Shigeyoshi Y, Okamura H, Inatomi T, Matsui T, Ito M, Kaji H, Abe H, Nakata H, Chiba T and Chihara K (1994) Distribution of mRNA for CCK-B receptor in the brain of *Mastomys natalensis*: Abundant expression in telencephalic neurons. *Brain Res* **640**:81–92.
- Shiosaki K, Graig R, Lin CW, Barrett R, Miller T, Witte D, Wolfram CAM and Nadzan AM (1990) Toward development of peptidomimetics: Diketopiperazine templates for the Trp-Met segment of CCK<sub>4</sub>. In *Peptides: Chemistry, Structure and Biology. Proceedings of the 11th American Peptide Symposium, July 9–14, 1989, La Jolla, CA* (Rivier JE and Marshall GR eds) pp 978–980, ESCOM, Leiden.
- Shlik J, Aluoja A, Vasar V, Vasar E, Podar T and Bradwejn J (1997a) Effects of citalopram treatment on behavioural, cardiovascular, and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. *J Psychiatry Neurosci* **22**:332–340.
- Shlik J, Koszycki D and Bradwejn J (1998) Decrease in short-term memory function induced by CCK-4 in healthy volunteers. *Peptides* **19**:969–975.
- Shlik J, Vasar E and Bradwejn J (1997b) Cholecystokinin and psychiatric disorders: Role in aetiology and potential of receptor antagonists in therapy. *CNS Drugs* **8**:134–152.
- Showell GA, Bourrain S, Neduvell JG, Fletcher SR, Baker R, Watt AP, Fletcher AE, Freedman SB, Kemp JA, Marshall GR, Patel S, Smith GR and Matassa VG (1994) High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCK-B/gastrin receptor antagonists containing a cationic solubilizing group. *J Med Chem* **37**:719–721.
- Silvente-Poirot S, Dufresne M, Vaysse N and Fourmy D (1993a) The peripheral cholecystokinin receptors. *Eur J Biochem* **215**:513–529.
- Silvente-Poirot S, Hadjiivanova C, Escrieut C, Dufresne M, Martinez J, Vaysse N and Fourmy D (1993b) Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179. *Eur J Biochem* **212**:529–538.
- Silvente-Poirot S and Wank SA (1996) A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin. *J Biol Chem* **271**:14698–14706.
- Silvente-Poirot SS, Escrieut C and Wank SA (1998) Role of the extracellular domains of the cholecystokinin receptor in agonist binding. *Mol Pharmacol* **54**:364–371.
- Simmons RD, Blosser JC and Rosamond JR (1994) FPL 14294: A novel CCK-8 agonist with potent intranasal anorectic activity in the rat. *Pharmacol Biochem Behav* **47**:701–708.
- Smadja C, Maldonado R, Turcaud S, Fournié-Zaluski MC and Roques BP (1995) Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalin antidepressant-like effects. *Psychopharmacology* **120**:400–408.
- Smadja C, Ruiz F, Coric P, Fournié-Zaluski MC, Roques BP and Maldonado R (1997) CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins. *Psychopharmacology* **132**:227–236.
- Smith GP and Gibbs J (1992) The development and proof of the CCK hypothesis of satiety, in *Multiple Cholecystokinin Receptors in the CNS* (Dourish CT, Cooper SJ, Iversen SD and Iversen LL eds) pp 166–182, Oxford University Press, Oxford.
- Smith GP, Jerome C, Cushin BJ, Eterno R and Simansky KJ (1981) Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. *Science (Wash DC)* **213**:1036–1037.
- Smith GP, Moran TH, Coyle JT, Kuhar MJ, O'Donahue TL and McHugh PR (1984) Anatomical localization of cholecystokinin receptors to the pyloric sphincter. *Am J Physiol* **246**:R127–R130.
- Song I, Brown DR, Wiltshire RN, Gantz I, Trent JM and Yamada T (1993) The human gastrin/cholecystokinin type B receptor gene: Alternative splice donor site in exon 4 generates two variant mRNAs. *Proc Natl Acad Sci USA* **90**:9085–9089.
- Song M, Wong H, Ohning G and Walsh JH (1996) Immunohistochemical localization of the gastrin/CCK-B receptor in the rat stomach. *Gastroenterology* **110**:A1120.
- South EH and Ritter RC (1988) Capsaicin application to central or peripheral vagal fibers attenuates CCK satiety. *Peptides* **9**:601–612.
- Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH and Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. *Nature (Lond)* **365**:170–174.
- Stacher G, Steinringer H, Schmierer G, Schneider C and Winkler S (1982) Cholecystokinin octapeptide decreases intake of solid food in man. *Peptides* **3**:133–136.
- Suman-Chauhan N, Meecham KG, Webdale L, Hunter JC, Pritchard MC, Woodruff GN and Hill DR (1996) The influence of guanylyl nucleotide on agonist and antagonist affinity at guinea pig CCK-B/gastrin receptors: Binding studies using [ $^3$ H]PD 140376. *Regul Pept* **65**:37–43.
- Svoboda M, Lambert M, Furnelle J and Christophe J (1982) Specific photoaffinity crosslinking of [ $^{125}$ I]-cholecystokinin to pancreatic plasma membranes: Evidence for a disulfide-linked Mr 76000 peptide in cholecystokinin receptors. *Peptides* **4**:163–172.

- Szczowka J, Hallden G, Goldfine ID and Williams JA (1989) Purification of the pancreatic cholecystokinin receptor. *Regul Pept* **24**:215–224.
- Taghzouti K, Léna I, Dellu F, Roques BP, Daugé V and Simon H (1999) Cognitive enhancing effects in young and old rats of pBC 264, a selective CCK-B receptor agonist. *Psychopharmacology* **143**:141–149.
- Taghzouti K, Louilot A, Herman JP, LeMoal M and Simon H (1985) Alternation behaviour, spatial discrimination and reversal disturbances following 6-OHDA lesions in the nucleus accumbens of the rat. *Behav Neural Biol* **44**:354–363.
- Takata Y, Takiguchi S, Funakoshi A, Kono S and Aono A (1995) Gene structure of rat cholecystokinin type-A receptor. *Biochem Biophys Res Commun* **213**:958–966.
- Takiguchi S, Takata Y, Funakoshi A, Miyasaka K, Kataoka K, Fujimura Y, Goto T and Kono A (1997) A disrupted cholecystokinin type-A receptor (CCKAR) gene in OLETF rats. *Gene* **197**:169–175.
- Talkad VD, Fortune KP, Pollo DA, Shah GN, Wank SA and Gardner JD (1994) Direct demonstration of three different states of the pancreatic cholecystokinin receptor. *Proc Natl Acad Sci USA* **91**:1868–1872.
- Taniguchi H, Yazaki N, Yomota E, Shikano T, Endo T and Nagasaki M (1996) Pharmacological profile of T-0632, a novel potent and selective CCK-A receptor antagonist, in vivo. *Eur J Pharmacol* **312**:227–233.
- Taniguchi T, Matsui T, Ito M, Murayama T, Tsukamoto T, Katakami Y, Chiba T and Chihara K (1994) Cholecystokinin-B/gastrin receptor signaling pathway involves tyrosine phosphorylations of p125<sup>FAK</sup> and p42<sup>MAP</sup>. *Oncogene* **9**:861–867.
- Tarasova NI, Romanov VI, Da Silva PP and Michejda CJ (1996) Numerous cell targets for gastrin in the guinea pig stomach revealed by gastrin/CCKB receptor localization. *Cell Tissue Res* **283**:1–6.
- Tarasova NI, Stauber RH, Choi JK, Hudson EA, Czerwinski G, Miller JL, Pavlakis GN, Michejda CJ and Wank SA (1997) Visualization of G protein-coupled receptor trafficking with the aid of the green fluorescent protein. *J Biol Chem* **272**:14817–14824.
- Tateishi K, Funakoshi A, Misumi Y and Matsuoka Y (1998) Jun and MAP kinases are activated by cholecystokinin in the pancreatic carcinoma cell line KP-1N. *Pancreas* **16**:499–504.
- Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, Hinton JP, Prithard MC, Eden JM, Kneen C, Webdale L, Suman-Chauhan N, Boden P, Singh L, Field MJ and Hill D (1998) Second generation "peptoid" CCK-B receptor antagonists: Identification and development of N-(adamantylloxycarbonyl)- $\alpha$ -methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. *J Med Chem* **41**:38–45.
- Tsunoda Y, Song I, Taylor LP and Owyang C (1997) Molecular interaction between CCK ligands and the CCKA receptor. *Gastroenterology* **112**:A-3403.
- Tsunoda Y, Takeda H, Asaka M, Nakagaki I and Sasaki S (1988a) Initial and sustained calcium mobilizations in the parietal cell during stimulations with gastrin, inositol triphosphate, phorbol ester and exogenous diacylglycerol. *FEBS Lett* **232**:83–90.
- Tsunoda Y, Takeda H, Otaki T, Asaka M, Nakagaki I and Sasaki S (1988b) Intracellular Ca<sup>2+</sup> shift and signal transduction from the tubulovesicular portion of gastric parietal cells during gastrin stimulation or Ca<sup>2+</sup> ionophore treatment: Comparison between luminescent and fluorescent probes and electron probe X-ray microanalyzer. *Biochem Cell Biol* **66**:279–287.
- Tsunoda Y, Yodozawa S and Tashiro Y (1989) Heterogeneous distribution of free calcium and propagation of calcium transient in gastric parietal cells revealed by digital imaging microscopy. *J Histochem Cytochem* **37**:999–1005.
- Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G and Miller LJ (1993) Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. *Biochem Biophys Res Commun* **193**:204–211.
- Valverde O, Maldonado R, Fournié-Zaluski MC and Roques BP (1994) Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. *J Pharmacol Exp Ther* **270**:77–88.
- Van Bree L, Zhang F, Schiffmann SN, Halleux P, Maillieux P and Vanderhaeghen JJ (1995) Homolateral cerebrocortical changes in neuropeptide and receptor expression after minimal cortical infarction. *Neuroscience* **69**:847–858.
- Van Dijk A, Richard JG, Trzeciak A, Gillessen D and Möhler H (1984) Cholecystokinin receptors: Biochemical demonstration and autoradiographic localization in rat brain and pancreas using [<sup>3</sup>H]cholecystokinin-8 as radioligand. *J Neurosci* **4**:1021–1031.
- van Megen HG, Westenberg HG, den Boer JA, Haigh JR and Traub M (1994) Pentagastrin induced panic attacks: Enhanced sensitivity in panic disorder patients. *Psychopharmacology* **114**:449–455.
- van Megen HG, Westenberg MG, den Boer JA, Slaap B and Scheepmakers A (1997) Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4-induced panic attacks. *Psychopharmacology* **129**:357–364.
- van Vliet IM, Westenberg HG, Slaap BR, den Boer JA and Ho Pian KL (1997) Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls. *Biol Psychiatry* **42**:76–78.
- Vanderhaeghen JJ, Signeau JC and Gepts W (1975) New peptide in vertebrate CNS reacting with antigastrin antibodies. *Nature (Lond)* **257**:601–605.
- Vanhoutte PM, Humphrey PPA and Spedding M (1996) XI. International Union of Pharmacology. Recommendations for nomenclature of new receptor subtypes. *Pharmacol Rev* **48**:1–2.
- Vigna S, Steigerwalt RW and Williams JA (1984) Characterization of cholecystokinin receptors in bullfrog (*Rana catesbeiana*) brain and pancreas. *Regul Pept* **9**:199–212.
- Vigna SR, Thorndyke MC and Williams JA (1986) Evidence for a common evolutionary origin of brain and pancreas cholecystokinin receptors. *Proc Natl Acad Sci USA* **83**:4355–4359.
- Virgo L, Humphries C, Mortimer A, Barnes T, Hirsch S and de Belleruche J (1995) Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia. *Biol Psychiatry* **37**:694–701.
- Wang H-L (1997) Basic amino acids at the C-terminus of the third intracellular loop are required for the activation of phospholipase C by cholecystokinin-B receptors. *J Neurochem* **68**:1728–1735.
- Wang Z, Valdes J, Noyes R, Zoega T and Crowe RR (1998) Possible association of a cholecystokinin promoter polymorphism (CCK-36CT) with panic disorder. *Am J Med Genet* **81**:228–234.
- Wank SA (1995) Cholecystokinin receptors. *Am J Physiol* **269**:G628–G646.
- Wank SA, Harkins RT, Jensen RT, Shapira H, de Weerth A and Slattery T (1992a) Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. *Proc Natl Acad Sci USA* **89**:3125–3129.
- Wank SA, Pisegna JR and de Weerth A (1992b) Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. *Proc Natl Acad Sci USA* **89**:8691–8695.
- Wank SA, Pisegna JR and de Weerth A (1994a) Cholecystokinin receptor family: Molecular cloning, structure, and functional expression in rat, guinea pig, and human. *Ann NY Acad Sci* **713**:49–66.
- Wank SA, Pisegna JR and Poirat SS (1994b) Functional significance of potential splice variants of the human cholecystokinin (CCK) B receptor. *Gastroenterology* **106**:A570.
- Weinberg DS, Ruggeri B, Barber MT, Biswas S, Miknyocki S and Waldman SA (1997) Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. *J Clin Invest* **100**:597–603.
- Weng JH, Bado A, Garbay C and Roques BP (1996a) Novel CCK-B receptor agonists: Diketopiperazine analogs derived from CCK<sub>4</sub> bioactive conformation. *Regul Pept* **65**:3–9.
- Weng JH, Blommaert AGS, Moizo L, Bado A, Ducos B, Böhme A, Garbay C and Roques BP (1996b) Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phe-Asp-Nal-NH<sub>2</sub> derivatives. *Bioorg Med Chem* **4**:563–573.
- Wennogle L, Wysowskyj H, Steel DJ and Petrack B (1988) Regulation of central cholecystokinin recognition sites by guanyl nucleotides. *J Neurochem* **50**:954–963.
- Wettstein JG, Bueno L and Junien JL (1994) CCK antagonists: Pharmacology and therapeutic interest. *Pharmacol Ther* **62**:267–282.
- Whiteford HA, Stedman TJ, Welham J, Csernansky JG and Pond SM (1992) Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia. *J Clin Psychopharmacol* **12**:337–340.
- Widdop RE, Krstew E, Mercer LD, Carlberg M, Beart PM and Jarrott B (1994) Electrophysiological and autoradiographical evidence for cholecystokinin A receptors on rat isolated nodose ganglia. *J Auton Nerv Syst* **46**:65–73.
- Williams JA, Gryson KA and McChesney DJ (1986) Brain CCK receptors: species differences in regional distribution and selectivity. *Peptides* **7**:293–296.
- Willner P (1990) Animal models of depression: An overview. *Pharmacol Ther* **45**:425–455.
- Willson TM, Henke BR, Momtahan TM, Myers PL, Sugg EE, Unwalla RJ, Croom DK, Dougherty RW, Grizzle MK, Johnson MF, Queen KL, Rimele TJ, Yingling JD and James MK (1996) 3-[2-(N-phenylacetamide)]-1,5-Benzodiazepines: Orally active, binding selective CCK-A agonists. *J Med Chem* **39**:3030–3034.
- Wolkowitz OM, Gertz B, Weingartner H, Beccaria L, Thompson K and Liddle RA (1990) Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist. *Biol Psychiatry* **28**:169–173.
- Woodruff GN, Hill DR, Boden P, Pinnock R, Singh L and Hughes J (1991) Functional role of brain CCK receptors. *Neuropeptides* **19** (Suppl):45–56.
- Wu V, Yang M, McRoberts JA, Ren J, Seensalu R, Zeng N, Dagra M, Birnbaumer M and Walsh JH (1997) First intracellular loop of the human cholecystokinin-A receptor is essential for cyclic AMP signaling in transfected HEK-293 cells. *J Biol Chem* **272**:9037–9042.
- Yoshida H, Tsunoda Y and Owyang C (1997) Cholecystokinin peptides stimulate pancreatic secretion by multiple signal transduction pathways. *Am J Physiol* **273**:G735–G747.
- Yu MJ, Trasher KJ, McCowan JR, Mason NR and Mendelsohn LG (1991) Quinazolinone cholecystokinin-B receptor ligands. *J Med Chem* **34**:1505–1508.
- Yule DI, Tseng MJ, Williams JA and Logsdon CD (1993) A cloned CCK-A receptor transduces multiple signals in response to full and partial agonists. *Am J Physiol* **265**:G999–G1004.
- Zacharko RM, Koszycki D, Mendella PD and Bradwejn J (1995) Behavioral, neurochemical, anatomical and electrophysiological correlates of panic disorder: Multiple transmitter interaction and neuropeptide colocalization. *Prog Neurobiol* **47**:371–423.
- Zajac JM, Gully D and Maffrand JP (1996) [<sup>3</sup>H]-SR 27897B: A selective probe for autoradiographic labelling of CCK-A receptors in the brain. *J Recept Signal Transduct Res* **16**:93–113.
- Zarbin MA, Innis RB, Wamsley JK, Snyder SH and Kuhar MJ (1983) Autoradiographic localization of cholecystokinin receptors in rodent brain. *J Neurosci* **3**:877–906.
- Zhang LJ, Lu XY and Han JS (1992) Influences of cholecystokinin octapeptide on phosphoinositide turnover in neonatal-rat brain cells. *Biochem J* **285**:847–850.
- Zhang X, Dagerlind Å, Elde RP, Castel MN, Broberger C, Wiesenfeld-Hallin Z and Hökfelt T (1993) Marked increase in cholecystokinin B receptor messenger RNA levels in rat dorsal root ganglia after peripheral axotomy. *Neuroscience* **57**:227–233.
- Zimonjic DB, Popescu NC, Matsui T, Ito M and Chihara K (1994) Localization of the human cholecystokinin-B/gastrin receptor gene (CCKBR) to chromosome 11p15.5→p15.4 by fluorescence in situ hybridization. *Cytogenet Cell Genet* **65**:184–185.